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ABSTRACT 
 
 
INTRODUCTION 
The risk of cardiovascular disease in patients with end stage renal disease (ESRD) is far 
greater than in the general population. Amongst patients with ESRD, the prevalence of 
coronary artery disease (CAD) and congestive heart failure is approximately 40% 
compared with 5-12% in the general population. The excess risk is caused by multiple 
traditional and non-traditional risk factors for ischaemic heart disease present in these 
patients. There is little information on CAD and its risk factors in black haemodialysis 
patients as most of these studies were carried out in the white population. This study is
therefore aimed at determining the risk factors for atherosclerosis in Black and non-black 
(White and Indian) South African patients on haemodialysis.  
 
METHODS 
Fifty-eight black patients and twenty-six non-black patients on haemodialysis were 
recruited. Sixty-three age and sex matched controls (staff, students and kidney donors) 
were also recruited. Fasting venous blood samples were drawn for measurement of C-
reactive protein, homocysteine, Lp (a), serum lipids and adiponectin. Carotid intima-media 
thickness and plaque occurrence was measured by B-mode ultrasonography. 
Echocardiography was used to determine LVH. 
 
 
 vi 
RESULTS 
Haemodialysis (HD) patients had significantly lower total cholesterol, LDL cholesterol and 
triglycerides compared with controls (p<0.001; p= 0.042). Hs-CRP, adiponectin and 
homocysteine levels were significantly higher in patients compared with controls (p< 
0.001). The prevalence of plaques was significantly higher among HD patients (32%) 
compared with controls (7%) X2 = 60.72 p< 0.001. LVMI was significantly higher among 
HD patients (194.25± 7.69gm/m2) compared with controls (93.21 ± 3.27 gm/m2) p < 0.001. 
No significant difference between patients (Black or Asian/White) and controls with respect to 
CIMT was found. CVD risk factors in black haemodialysis patients and black controls showed a 
similar pattern to the whole study population combined. Risk factors associated with CIMT on 
regression analysis were total cholesterol, LDL-cholesterol, age, Hs-CRP, family history of 
CKD. Risk factors associated with plaque occurrence on logistic regression analysis were 
age, systolic blood pressure, male gender, smoking, calcium phosphate product and serum 
phosphate. 
 
CONCLUSION 
HD patients have a high prevalence of traditional and non-traditional risk factors for 
atherosclerosis and this is independent of race. Traditional risk factors like lipids were 
much lower in ESRD patients. HD patients showed a high prevalence of atherosclerosis as 
measured by increased carotid intima-media thickness and plaque occurrence in carotid 
arteries. Hs-CRP correlated significantly with a surrogate marker of atherosclerosis 
(CIMT).  
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CHAPTER 1 
1.0   INTRODUCTION AND  LITERATURE REVIEW                                                                                                                                
The risk of cardiovascular disease in patients with end stage renal disease (ESRD) is far greater than in 
the general population [1]. Several studies from the early 1970s to date have shown that the prevalence of 
cardiovascular diseases was significantly higher in uraemic patients treated by haemodialysis or 
peritoneal dialysis compared with other populations of a similar age [1-3]. Amongst patients with ESRD, 
the prevalence of coronary artery disease (CAD) and congestive heart failure (CHF) is approximately 
40% compared with 5-12% in the general population [1]. Even after stratification by age, sex, race and 
diabetes, the cardiovascular mortality in dialysis patients is 10-20 times higher than in the general 
population [1, 3, 4]. Atherosclerotic cardiovascular disease (ASCVD) accounts for approximately half of 
deaths in end stage renal disease (ESRD) and contributes to the extraordinarily high annual mortality of 
23% observed in such patients [1, 4]. The incidence of myocardial infarction (MI) and stroke in the 
dialysis population is 5 to15-folds higher in ESRD [1, 5]. Similarly, about one-third of hospitalizations in 
dialysis patients are due to cardiovascular diseases (CVD) [4]. Patients with ESRD should therefore be 
considered in the highest risk group for subsequent CVD. It therefore follows that this patient population 
should be carefully assessed and treated for CV risk factors early in the course of the disease. The Special 
Report from the National Kidney Foundation Task Force on Cardiovascular Disease [6] called for studies 
of ASCVD and its risk factors in ESRD patients.  
 
Coronary artery disease was found to be rare in black subjects in the general population, but the incidence 
is increasing with changes in socio-economic status [7]. A study carried out in Soweto in the 1960s 
showed that coronary atherosclerosis accounted for less than 1% of deaths [7]. Cheung et al [8] using 
data from the Hemodialysis (HEMO) Study reported that black race was associated with a 36% reduction 
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in CAD and a 46% reduction in peripheral vascular disease (PVD) but was not associated with a 
reduction in cerebrovascular  disease . Most studies of ASCVD risk factors in ESRD patients were 
carried out in the white population in the United States and Europe. There is limited data on ASCVD in 
South African patients with ESRD. Therefore this study is aimed at determining the prevalence of 
traditional and some non-traditional risk factors for ASCVD in the black South African patients on 
haemodialysis and to determine the relationship of these risk factors to sub-clinical atherosclerotic 
cardiovascular disease in this population. The study will provide baseline data base of CVD in this high 
risk population.    
 
1.1   Epidemiology of cardiovascular disease in chronic renal disease 
The initial enthusiasm for dialysis as a survival measure for patients with chronic renal failure (CRF) was 
tempered in 1974 when Linder and colleagues noted the extraordinarily high frequency of coronary heart 
disease and cardiac death in the first patients who underwent dialysis in Seattle at that time [2].  This 
observation lead to the hypothesis of accelerated atherosclerosis in CRF, which has remained disputed to 
date. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among patients with 
chronic kidney disease, accounting for 44% of overall mortality in patients receiving long-term dialysis 
[1, 4, 6]. The report of the Task Force on CVD convened by the National Kidney Foundation (NKF) 
showed that the annual mortality rates in dialysis patients ( 50 000 deaths) are much greater than in the 
general population ( 2 million deaths) despite stratification by age, sex, race and diabetes [1, 4, 6]. The 
high CVD mortality in ESRD is due to a high prevalence of CVD and also a high case fatality rate in 
those who already have CVD. Numerous data have shown that the prevalence of ischaemic heart disease 
and congestive heart failure is much higher in dialysis patients compared to the general population [1, 3, 
6] table 1.1. Herzog et al [9]  using data from the United States Renal Data System (USRDS), looked at 
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outcomes in 34,189 patients on long term dialysis who were hospitalized between 1977 and 1995 with 
acute MI and found that mortality rates at 2 years and 5 years after MI were 73% and 90% respectively. 
These figures are much higher than the rate after MI in the general population, even in patients with co 
morbid conditions. In the Worcester Heart Attack Study [10], mortality rates at 2 years after MI in 
diabetic men and women were 25% and 34% respectively. Cardiac failure is also associated with high 
case fatality in dialysis patients. In one study cardiac failure at the inception of dialysis was associated 
with a 2-fold increase in mortality rate [11]. Recent evidence has shown that the processes contributing to 
CVD commence early in the course of kidney disease and vascular and kidney diseases tend to progress 
together [1, 3 12]. The prevalence of CVD is increased in all the stages of CKD and also in renal 
transplant recipients who are also at high risk for CVD. 
 
Table 1.1   Approximate prevalence (%) of CVD in the General Population and Dialysis Patients 
Population       CAD (clinical)     LVH (echo)                      CHF (clinical) 
General population  5-12      20                     5 
Chronic renal insufficiency NA      25-50 (varies with renal function) NA 
Haemodialysis  42      75     40 
Peritoneal dialysis  40      75     40 
Renal transplant recipient 15      50     NA 
From [1].  Abbreviation: NA, Not available. Echo, echocardiography 
 
1.2   Spectrum of CVD in patients with CKD 
There are three distinct types of CVD that are highly prevalent in patients with CKD, all of which lead to 
poor outcome. These include alterations in cardiac geometry, atherosclerosis and arteriosclerosis. 
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1.2.1   Alterations in cardiac geometry 
The alteration in cardiac geometry includes concentric left ventricular hypertrophy (LVH) and eccentric 
LVH (left ventricular dilatation plus hypertrophy). Concentric LVH is associated with pressure overload, 
as in hypertension, arteriosclerosis or occasionally aortic stenosis [1, 5, 12]. It is characterized by 
increased wall thickness (increased myocyte thickness) and normal or decreased left ventricular chamber 
size [5, 12]. Concentric LVH is common among patients with CKD with a prevalence of approximately 
40% in those starting dialysis [1, 12]. The prevalence of LVH is inversely related to glomerular filtration 
rate (GFR). In a study by Levin et al [13], the prevalence of LVH as measured by echocardiography was 
45%, 31%, and 27% in patients with creatinine clearance  of < 25, 25 to 50, and >50ml/L respectively. 
Concentric LVH results in increased ventricular stiffness or diastolic dysfunction [5]. Eccentric LVH is 
characterized by an increase in wall thickness (increase in myocyte length) that is proportional to the 
increase in left ventricular (LV) diameter [1, 5, 12]. Risk factors for eccentric LVH include volume 
overload secondary to salt and water retention, anaemia and arteriovenous fistulae [1, 5, 12]. Eccentric 
LVH leads to systolic dysfunction. In a Canadian prospective cohort study of 432 patients who had 
echocardiography done within one year of starting dialysis, only 16% had normal cardiac function and 
dimensions, 42% had concentric LVH, 27% LV dilatation and 16% had systolic dysfunction [14]. LV 
mass index is strongly associated with cardiovascular mortality in the general population; this association 
is also found in dialysis patients [14]. 
 
 1.2.2   Atherosclerosis 
Atherosclerosis is the main cause of ischaemic heart disease in dialysis patients. Atherosclerosis is focal 
and primarily involves the intima causing narrowing or occlusion of the arteries with restriction of blood 
flow [12, 15]. In comparison with the general population, the atherosclerotic lesions in kidney failure 
tend to be more advanced and are frequently calcified [12, 15]. Surrogates of atherosclerosis include 
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carotid intima-media thickness (IMT) which is measured by high resolution B-mode ultrasonography and 
inducible myocardial ischaemia which is detectable by coronary stress test [5, 12, 15].  The gold standard 
for the diagnosis of CAD is coronary angiography. Stress imaging is an important modality for testing for 
myocardial ischaemia; however it may not be sensitive in dialysis patients [12, 16]. Dobutamine 
echocardiography and combined dypyridamole-exercise thallium imaging have been shown to be 
accurate in detecting CAD and predicting future coronary events [16]. Atherosclerosis presents clinically 
as IHD, MI, CHF, PVD, sudden death and stroke [1, 12, 15].  The prevalence of IHD and cardiac failure 
is approximately 50% among patients starting renal replacement therapy in the United States [1, 5].   
 
1.2.3 Arteriosclerosis 
Arteriosclerosis is a disease of large vessels, such as the carotid and the aorta, in which there is diffuse 
involvement of the media resulting in increased arterial stiffness and decreased distensibility or 
compliance [12, 15]. Arterial stiffness is measured by pulse wave velocity. Increased arterial stiffness 
often results in increased pulse pressure causing increased LV after load and concentric LVH [12, 15, 
17]. Arteriosclerosis also predisposes to IHD by decreasing subendocardial coronary perfusion [12, 15]. 
Higher systolic BP and pulse pressure, lower diastolic BP and LVH have been identified as independent 
risk factors for CV morbidity and mortality in ESRD [15].  
 
1.3   Risk factors for CVD in chronic kidney disease 
Several studies have shown that the high prevalence of CVD in ESRD patients can only be partly 
explained by the traditional risk factors [3, 8, 18]. The excess risk of CVD in ESRD is caused by multiple 
traditional and non-traditional risk factors for ischaemic heart disease present in these patients. The 
traditional risk factors are those variables that were defined in the general population in the Framingham 
study [19]. The traditional risk factors include older age, male gender, white race, hypertension, elevated 
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low-density lipoprotein cholesterol level (LDL Cholesterol), low levels of high density lipoprotein 
cholesterol (HDL cholesterol), diabetes mellitus, obesity, family history of CVD, cigarette smoking and 
psychosocial stress [12,19].  ESRD patients often have a high prevalence of these traditional risk factors 
[1, 3, 12]. The non traditional risk factors that are frequently observed in ESRD include: 
hyperhomocysteinaemia, increased levels of lipoprotein (a), enhanced oxidative stress, inflammation, 
abnormal calcium phosphate metabolism, disturbances of nitric oxide system, anaemia, malnutrition, and 
alterations in the thrombotic system  (table 1.2). This latter group of risk factors may be related to 
uraemia and the dialysis procedure, and can actively contribute to the accelerated development and 
progression of CVD. Colorado et al [18], using data from the Modification of Diet in Renal Disease 
(MDRD) study examined traditional risk factors in 1,795 patients with CKD. They computed the 
coronary point score, which is an aggregate of traditional risk factors derived from the Framingham 
study, which predicts the probability of developing CAD over 5 to 10 years in individuals who do not 
have CAD. The results showed that the coronary point score in patients with CKD was no different from 
those in the general population thus suggesting that the traditional risk factors could not sufficiently 
account for the burden of CVD in CKD. 
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Table 1.2 Risk factors for cardiovascular disease in CKD  
Traditional         Non-traditional 
 
Hypertension                   Inflammation 
Diabetes         Oxidant stress 
Smoking        Hyperhomocysteinaemia 
Older Age        Anaemia 
Male sex                                                 Abnormal calcium/phosphate metabolism 
Higher LDL Cholesterol     Lipoprotein (a) and apolipoprotein(a)  isoforms 
Lower HDL Cholesterol     Advanced glycation end products (AGES) 
Family History of CVD     Asymmetric dimethylarginine (ADMA) 
Menopause        Malnutrition 
Physical inactivity                             Aetiology of Chronic Kidney Disease (CKD) 
LVH         Proteinuria 
         Extracellular fluid volume overload 
         Renin angiotensin system activity 
         Decrease in glomerular filtration rate (GFR) 
         Endothelial dysfunction 
        Thrombogenic factors 
______________________________________________________________________ 
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1.3.1   Traditional risk factors  
1.3.1.1   Hypertension 
The prevalence of hypertension in chronic renal disease (CRD) is approximately 60% to 100% depending 
on the target population, cause of renal disease and residual renal function [20]. In the Choices for 
Healthy Outcomes in Caring for ESRD (CHOICE) study, the prevalence of hypertension was 96% in the 
study participants [21]. Hypertension contributes to the development of left ventricular hypertrophy 
(LVH), coronary artery disease and congestive heart failure [20]. LVH, coronary artery disease and 
congestive heart failure are associated with subsequent mortality [14, 20]. Patients with ESRD have a 
high prevalence of non-dipping and are also likely to have isolated systolic hypertension with an 
increased pulse pressure, which in turn has been associated with CVD and early death [22].  The 
aetiology of hypertension in ESRD is multifactorial and includes expanded extracellular volume, sodium 
retention, over activity of the sympathetic nervous system, activation of the renin angiotensin aldosterone 
system, endothelial dysfunction, use of erythropoietin and secondary hyperparathyroidism [20, 22]. Apart 
from causing hypertension, many of these factors probably cause damage to the kidney and the 
cardiovascular system. The association between blood pressure (BP) and mortality in haemodialysis 
shows a U- shaped relationship with both high as well as low BP carrying a high mortality [23]. Port et al 
[24] analyzed data from 4839 chronic haemodialysis patients in the Case Mix Adequacy Study of the 
U.S. Renal Data System: they found that a higher systolic BP (from 150 to > 180 mmHg) was associated 
with a lower mortality risk. When the predialysis systolic BP decreased below 110mmHg, the relative 
mortality rate increased significantly. The association between low blood pressure and mortality reflects 
the high frequency of advanced cardiomyopathy in dialysis patients. The BP level that minimizes death 
risk in dialysis patients has not been determined. There are conflicting views about the level of BP 
recommended in haemodialysis patients.  Schomig et al [25] believe that the same principles and goals 
established for the general population should apply to the haemodialysis population (BP<120/80); others 
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feel that these guidelines do not apply to the majority of haemodialysis patients. The National Kidney 
Foundation Task Force on Cardiovascular Disease recommend that a target predialysis BP of 
140/90mmHg or less appears reasonable in haemodialysis population [6].  Antihypertensive medications 
are effective in decreasing BP in patients with ESRD and the commonly used drugs are calcium channel 
blockers, angiotensin converting enzyme (ACE) inhibitors, and alpha and beta-adrenergic blockers 
[20,22]. These drugs have been shown to be beneficial in high-risk patient groups [20, 22]. Angiotensin 
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are recommended in 
patients with CKD prior to ESRD [20, 22]. This is based on evidence of renoprotection. ACE inhibitors 
may also have a role in CVD management and are recommended in patients with ESRD with increased 
left ventricular mass index [20, 22]. 
 
1.3.1.2   Dyslipidaemia  
1.3.1.2.1  Metabolism of lipids  
Lipids are transported in the blood stream as macromolecular complexes [26, 27]. These complexes are 
known as lipoproteins and are composed of a core of lipids (mainly triglyceride, cholesterol and 
cholesterol esters), which are surrounded by a stabilizing coat of phospholipids. Embedded on the surface 
of these lipoproteins are proteins called apoproteins (Apo) which allow these particles to be recognized 
by receptors in the liver and peripheral tissues. Five principal types of lipoprotein particles are found in 
the blood based on their density and electrophoretic mobility.  Chylomicrons are synthesized in the small 
intestine postprandially and contain mainly triglyceride (TG) with small amounts of cholesterol. They are 
the main mechanism for transporting products of dietary fat digestion to the liver and the peripheral 
tissues [26, 27]. Chylomicrons contain apoproteins B-48, A-1, AII and acquire Apo C-II and Apo E by 
transfer from HDL particles in the blood stream. Apo C-II binds to specific receptors in the adipose 
tissue, skeletal muscle and the liver and allows the endothelial enzyme lipoprotein lipase to remove most 
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of the triglyceride leaving a remnant chylomicron particle that contains the bulk of the original dietary 
cholesterol. The remnant particle is taken up by the liver and metabolized. Very- low- density- 
lipoprotein (VLDL) contains endogenously synthesized TG and a small amount of cholesterol. VLDL 
contains Apo B-100 and acquires Apo C-II and E by transfer from HDL particles. TG is removed from 
VLDL by the enzyme lipoprotein lipase through binding with Apo C-II, leaving an intermediate density 
lipoprotein (IDL) that contains cholesterol. IDL have Apo B-100 and Apo E molecules on their particle 
surface. Most IDL particles bind to liver LDL receptors through Apo E molecule and are catabolised. 
Some IDL particles have further TG removed by the enzyme hepatic lipase producing low-density 
lipoprotein particles (LDL) [27].  
 
LDL is the main carrier of cholesterol and delivers it to the liver and peripheral tissues. Peripheral cells 
utilize LDL cholesterol for cell membrane structure and also the production of hormones.   LDL particles 
contain Apo B-100 and Apo E.  Apo B-100 is the principal ligand for the LDL clearance receptor [27]. 
Once bound to the receptor, the coated pit invaginates and fuses with liposomes that destroy the LDL 
particle. The number of hepatic LDL clearance receptors and the activity of the rate-limiting enzyme in 
the cholesterol synthetic pathway, hydroxy methylglutaryl coenzyme A (HMG-CoA) reductase, regulate 
the concentration of LDL in the blood. LDL particles are heterogeneous with respect to size, density, and 
lipid compositions [28, 29]. LDL particles have been divided into 2 distinct phenotypes: pattern A, with a 
higher proportion of large buoyant LDL particles, and pattern B, with a predominance of small dense 
LDL (sd-LDL) particles [26, 29]. The subclass pattern B is frequently associated with a more atherogenic 
lipoprotein profile.  LDL subclass pattern B consists of higher levels of triglyceride, apolipoprotein B, 
intermediate density lipoprotein (IDL), very low-density lipoprotein (VLDL) and a lower level of high-
density lipoprotein (HDL) [26,27].  It has been suggested that sd-LDL are highly atherogenic as a result 
of their higher penetration into the arterial wall, decreased affinity for the LDL receptor, their prolonged 
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plasma half-life, and increased susceptibility  to oxidative stress compared to buoyant LDL [28, 29].   
LDL is an atherogenic lipoprotein particle, and it is established that higher levels of LDL are associated 
with increased cardiovascular disease risk [29, 30]. In addition, the heterogeneity of LDL particle 
composition, due to differences in the amount of cholesterol per particle, suggests that particle size is an 
important consideration in the atherogenic potential of the LDL. High-density lipoprotein particles are 
produced in the liver and the intestine. They contain Apo A-1 and are transformed into mature HDL 
particles by acquisition of phospholipids, Apo E and Apo C. Mature HDL particles take up cholesterol 
from cells in the peripheral tissues aided by cholesterol-efflux regulatory protein - a product of the ATP-
binding cassette transporter 1 gene (ABC1 gene). Apo A-1 is important for the activation of the enzyme 
lecithin- cholesterol acyl-transferase (LCAT), which transfers acetyl group from phosphatidylcholine to 
cholesterol to form cholesterol esters [26, 30]. HDL Cholesterol has an important role to play in the 
mechanism against atherosclerosis. First, it is a component of the reverse cholesterol transport system 
that is, HDL particles transport cholesterol away from the periphery and may transfer it indirectly to other 
particles such as VLDL in the circulation or deliver its cholesterol directly to the liver (reverse 
cholesterol transport). The direct delivery takes place through scavenger-receptor B1. Second, it has some 
anti- oxidant effects thereby reducing the oxidation of LDL [30]. It also decreases the cytokine-induced 
expression of adhesion molecules by the vascular endothelium [30].  
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Table 1.3 Lipoprotein classification 
LIPOPROTEIN         MAJOR LIPID      MAJOR              SOURCE 
                                   COMPONENT     APOLIPOPROTEINS 
Chylomicrons  TG       Apo A-1, A-II, A-IV        Intestine 
          Apo C-I, C-II, C-III;  
     ApoB-48, ApoE   
 
VLDL   TG                  ApoB-100            Liver 
          ApoC-I, C-II, C-III;  
     ApoE 
 
IDL CE                  ApoB-100; ApoE,          Catabolism of  VLDL 
     ApoC     
 
LDL CE       ApoB-100          Catabolism of IDL    
 
 
HDL   CE, PL       ApoA-I, A-II, A-IV        Liver, intestine  
          ApoC-I, C-II, C-III;  
     ApoE  
 
 
TG = Triglyceride; CE = Cholesterol ester; PL = Phospholipid; [From 26].    
 
 
 
 
Table 1.4 Enzymes in Lipoprotein metabolism 
ENZYME     FUNCTION 
 
Lipoprotein lipase Hydrolyses TG in chylomicrons and VLDL 
Lecithin-cholesterol acyltransferase  Esterifies free cholesterol on the HDL surface 
Hepatic-triglyceride lipase   Hydrolyses TG in IDL and HDL particles 
Cholesterol ester transfer protein Facilitates transfer between lipoprotein cholesterol esters 
and TG  
[From 26] 
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1.3.1.2.2 Dyslipidaemia in End-stage renal disease 
Dyslipidaemia remains a prominent feature of ESRD. Lipid abnormalities include hypertriglyceridaemia, 
increased levels of very low-density lipoproteins (VLDL), increased levels of intermediate density 
lipoproteins (IDL), apo B and low levels of high-density lipoproteins (HDL) [29, 30, 31, 32]. The 
dyslipidaemia is caused by a delayed catabolism of triglyceride rich apoB containing lipoproteins due to 
decreased activity of lipolytic enzymes such as lipoprotein lipase, hepatic triglyceride lipase and lecithin 
cholesterol acyl transferase (LCAT) [32].  There is also the presence of increased levels of oxidized low-
density lipoprotein (LDL) that provides a more atherogenic attack complex that damages endothelial 
cells. Oxidized LDL [33] can cause disruption of the endothelial cell surface, promote inflammatory and 
immune changes via cytokine release from macrophages and antibody production, and increase platelet 
aggregation. It may also play a role in plaque instability. In addition to ox-LDL, there is the 
predominance of small dense LDL (sd LDL) which in itself is highly atherogenic [28, 29, 32].  An 
increased prevalence of small dense LDL particles has been noted in patients with CAD [29].  Therefore, 
measurement of LDL particle density or diameter has been proposed as a technique for further risk 
stratification in patients with elevated LDL levels, or for patients with normal LDL levels who have other 
high risk factors for CAD, or to predict response to a particular therapy [29].    
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Figure 1.1 Schematic representation of sites of origin, interaction between and fate of the major 
lipoprotein particles. (From 27) 
 
Although hypercholesterolaemia is associated with increased risk of CVD in the general population, in 
haemodialysis patients (with the exception of diabetic ESRD patients), low serum cholesterol is 
associated with a high mortality [34, 35].  Yeun et al [35], in their study involving 91 patients, showed 
that patients who died had lower cholesterol levels. Lowrie and Lew [34] reported an increase in overall 
mortality in chronic haemodialysis patients when the serum cholesterol decreased from the range of 5.20 
to 6.50 mmol/l (200 to 250 mg/dl) to less than 2.60 mmol/l (100 mg/dl). The possible explanations for 
this reverse causality are: first, cholesterol may simply be a marker of inflammation or malnutrition both 
of which are powerful predictors of mortality in dialysis patients. Cytokines like tumour necrosis factor  
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(TNF ), interleukin 2 (IL-2) have been reported to have inhibitory effects on lipoprotein lipase activity 
[30]. Bologa et al reported that high IL-6 levels predicted low serum cholesterol levels, suggesting that 
cholesterol may be suppressed in response to inflammation. [36]. Second, since most patients on dialysis 
have dyslipidaemia, it may not be a discriminating factor. 
 
The role of hypertriglyceridaemia as a risk factor for atherosclerosis remains elusive. Although 
hypertriglyceridaemia is predictive of CVD risk in the general population, this association diminishes in 
multivariate analysis after adjusting for other risk factors like low HDL cholesterol and high LDL 
cholesterol. Triglycerides are physiologically linked to sdLDL and low HDL levels and it is postulated 
that the atherogenic risk for hypertriglyceridaemia is linked to the increased levels of sdLDL [28]. Serum 
triglyceride is used as a surrogate marker for sd-LDL and triglyceride levels of > 2mmol/l (180mg/dl) is 
associated with atherogenic levels of sd-LDL in ESRD patients [28, 29].  Apo C-III is a competitive 
inhibitor of lipoprotein lipase (LPL) and the levels are increased in renal failure [29, 30, 31]. LPL is the 
main enzyme necessary for the lipolysis of TG and for catabolism of VLDL and chylomicrons in the 
vascular endothelium.   Increased Apo C III levels correlate with increased TG levels in renal failure [30]. 
This may be accompanied by an increase in IDL remnants of VLDL and chylomicrons [29, 30, 31, 32].  
As renal function declines, HDL levels decrease due to many reasons. Firstly, there is decreased synthesis 
of HDL resulting from downregulation of the Apo A-1 gene expression by the liver [30]. Apo A-1 is an 
important activator of LCAT and levels are decreased. LCAT esterifies cholesterol and is necessary for 
the maturation of HDL; therefore HDL maturation is impaired [30]. Inflammation may alter the structure 
of HDL so that the Apo A-1 protein content of the particle is replaced by serum amyloid protein A 
(SAA). This new form of HDL has now acquired pro-inflammatory properties; it is chemoattractive to 
macrophages and has reduced capacity to reduce oxLDL and cannot suppress the effects of inflammatory 
cytokines on induction of adhesion molecules by the endothelial cells [30]. 
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Renal failure is associated with increased levels of remnant particles (IDL). IDL particles stimulate 
endothelium-dependent contraction and also induce greater uptake of cholesterol by macrophages than 
does oxLDL [37]. IDL is an independent risk factor for CVD in patients with CKD [37]. LDL also 
activates the RAA [30], inducing Angiotensin II levels and upregulating the angiotensin type I (AT1) 
receptor. Through this mechanism, LDL augments the synthesis of superoxide anion (O-2) thus providing 
a link between lipids and oxidative stress [30]. Despite the absence of data consistently linking 
hyperlipidaemia to CAD in patients receiving dialysis, it is recommended that the lipid abnormality in 
patients with CKD be treated to the same target levels as patients with known CAD [29].   
 
1.3.1.3   Diabetes mellitus 
Diabetes mellitus is the most common cause of ESRD in many parts of the world [38, 39].  In the United 
States, 40% of patients starting dialysis have diabetes [39]. In the CHOICE Study, the prevalence of 
diabetes was 54% among the participants [21]. In Canada and Europe, almost one third of new patients 
starting renal replacement therapy are diabetic [39]. The majority of these patients have type-2 diabetes. 
Diabetes is a well-established and important risk factor for coronary artery disease. Diabetic dialysis 
patients have the highest cardiovascular mortality with 11% (haemodialysis) and 13% (peritoneal 
dialysis) per year [40]. Based on the high risk for CAD associated with diabetes and the attendant high 
CV mortality in these patients, the current recommendation is that all diabetic patients should be treated 
for risk factors such as hyperlipidaemia even in the absence of clinical signs and symptoms [3, 29]. It 
follows that all patients with CKD caused by diabetes should be considered for secondary preventive 
measures [6]. In South Africa, diabetic patients with significant co-morbidity (including cardiac disease) 
are excluded from the chronic dialysis programme [42]. 
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1.3.1.4   Age 
Patients entering renal replacement therapy (RRT) are increasingly over the age of 60years [39]. The 
average age of a patient starting dialysis in the US is almost 60years [38]. In South Africa, patients over 
the age of 60 years are excluded from the chronic dialysis programme due to limited resources [42]. CAD 
is generally a disease of the middle aged and older populations; the majority of patients receiving dialysis 
are in the age in which CAD is common in the general population.  
 
Majority of the patients starting RRT are males, another known risk factor for CAD [39, 41]. Most 
women starting RRT are menopausal either by virtue of their age or because of their underlying disease 
or treatments [39]. Thus the demographics of patients in whom chronic renal dysfunction develops puts 
them at risk for CAD. 
 
1.3.1.5   Smoking and lifestyle 
Although incomplete data are available, a significant number of patients with CKD continue to smoke. 
Approximately 15-18% of ESRD patients are active smokers [43] and about 15-45% of them smoked 
before the onset of ESRD [43]. Smoking damages the kidneys and contributes to elevation of blood 
pressure. Data from USRDS showed that the relative risk for myocardial infarction in patients with type 1 
diabetes who smoke was approximately 2.6 compared to patients who did not smoke [43]. Similar results 
were obtained for patients with type-2 diabetes [29]. Other life issues like exercise and dietary habits 
have not been well studied in patients with CRF with regards to modifying CV risk. Smoking is a 
modifiable risk factor for CVD and should be addressed in each patient. 
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1.3.2   Non-traditional risk factors 
1.3.2.1   Inflammation 
Inflammation is now considered to play an essential role in the initiation of atherosclerosis as well as 
plaque erosion and rupture [44]. Inflammatory stimulus leads to the release of a number of acute phase 
reactants, both negative and positive. The positive acute phase reactants include an elevation of C-
reactive protein (CRP), fibrinogen, ferritin, interleukin-6 (IL-6) and lipoprotein (a). The negative acute 
phase reactants include cholesterol, albumin, prealbumin, transferrin and apolipoprotein B and 
apolipoprotein A1 and their levels fall during inflammation [45]. Patients receiving haemodialysis are 
exposed to a wide variety of events that may induce inflammation. These include their underlying 
diseases such as glomerulonephritis, repeated infection from dialysis access sites, use of bio-incompatible 
membranes, and water-borne toxins [46]. Many of these patients also suffer from intercurrent illnesses 
that would induce a state of inflammation. In view of the evidence implicating a key role to inflammation 
in atherosclerosis, several circulating markers of inflammation have been examined as potential tools for 
predicting the presence of vascular disease or the risk of vascular events. These markers include P-
selectin, interleukin-6 (IL-6), tumour necrosis factor  (TNF ), soluble intercellular adhesion molecule 1 
(ICAM) and C-reactive protein (CRP). CRP has emerged as the most powerful inflammatory marker of 
future cardiovascular risk in the general population and dialysis patients.  
 
1.3.2.2   C-reactive protein (CRP)  
CRP is a member of the pentraxin family of proteins and is considered the protypical acute phase reactant 
in man. CRP is produced in the liver in response to IL-6.  CRP levels rise rapidly within 6 hours after a 
cytokine-mediated response to most forms of tissue injury, infection and inflammation and peaks around 
48 hours [45]. CRP levels increase with age and females tend to have slightly higher levels [45]. The 
circulating level of CRP tends to reflect more the on-going inflammation than do other biochemical 
 19
markers of inflammation. This is because the half-life of CRP (about 19 hours) is the same under all 
conditions and the sole determinant of its plasma concentration is an increased rate of synthesis, which in 
turn reflects the intensity of the pathological processes stimulating its production. The liver is the site of 
clearance of CRP, thus production of CRP is impaired in liver failure [45, 46, 47]. The biologic functions 
of CRP include the ability to recognize pathogens and all damaged cells of the host (including nuclear 
antigens, lipoproteins and apoptotic cells) and to mediate their elimination by recruiting the complement 
system and phagocytic cells [48, 49]. Initially CRP was thought to be a bystander marker of vascular 
inflammation without playing a direct role in the inflammatory process. However recent evidence 
suggests that CRP may contribute directly to the pro-inflammatory state. CRP stimulates monocytes to 
release inflammatory cytokines like IL-1, IL-6 and TNF. It also induces the expression of adhesion 
molecules like E-selectin, ICAM-1, and VCAM-1 by the endothelial cells. CRP also opsonizes LDL and 
mediates LDL uptake by macrophages [48, 49]. CRP is produced in the liver, however recent data 
showed that arterial tissue can produce CRP as well as complement proteins [45, 47]. CRP has emerged 
as the most powerful inflammatory marker of future cardiovascular risk. In the general population, CRP 
has been shown to be predictive of cardiovascular events [50, 51]. CRP also carries important prognostic 
information in acute coronary syndromes. Subjects presenting with unstable angina or non ST- elevation 
myocardial infarction (MI) and elevated levels of high sensitivity CRP (Hs-CRP) are candidates for 
adverse events like recurrent angina, ST elevation, MI or coronary death [52]. In the Women Health 
Study [51], baseline levels of CRP were significantly higher among women who subsequently developed 
CV events compared with those who did not. CRP levels are known to be higher among patients with 
several traditional risk factors. Adipocytes are known to secrete IL-6 [47], the main hepatic stimulus for 
CRP production. Several studies in dialysis patients have shown an association between elevated CRP 
levels with the risk of cardiovascular events and death [35, 53, 54]. Zimmermann et al [53], in a 
prospective cohort study of 288 HD patients showed that all-cause and CV mortality was higher in 
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patients with elevated CRP being 31% and 16% respectively. Patients in the highest quartile of CRP had 
a 4.6 fold and 5.5 fold higher risks of all cause and CV mortality compared with patients in the lowest 
quartile [53]. In another study by Iseki et al [54] high CRP levels were associated with poorer survival 
compared with normal CRP levels. Five-year survival was 44.4% in the high CRP group compared with 
82.5% in the normal CRP group. Yeun et al [35] have also identified CRP as the most powerful predictor 
of all-cause and CV mortality in 91 HD patients who were followed up for 34 months. Patients with CRP 
levels in the highest quartile had the lowest survival compared with those in the lowest quartile. CRP 
levels have also been found to be associated with various classic markers of CVD such as Lp (a), 
fibrinogen and low HDL in ESRD populations [53]. Elevated CRP levels have significant association 
with hypoalbuminaemia, malnutrition, erythropoietin resistance and morbidity and mortality in both 
haemodialysis (HD) and peritoneal dialysis (PD) patients [55]. Several studies have demonstrated that 
elevated CRP levels are associated with surrogate markers of atherosclerotic vascular disease in both HD 
[53] and predialysis patients [56]. Stenvinkel et al [56] also showed a significantly increased carotid 
intima media thickness of pre-dialysis patients with elevated CRP levels. The Cardiovascular Risk 
Extended Evaluation in Dialysis (CREED) did show that CRP was an independent predictor of the 
number of atherosclerotic plaques in the carotid artery of 112 chronic HD patients [57]. 
 
Hs CRP is usually ordered as one of several tests in a CV risk profile, often along with tests for 
cholesterol and triglycerides. Ridker et al [58] demonstrated that the combination of increased Hs-CRP (> 
2.11mg/L) and increased total cholesterol is associated with a 5-fold increase risk of coronary events 
compared with a 1.5-fold and 2.3-fold increase respectively if only one parameter was elevated. The 
American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC) have studied 
the effectiveness of inflammatory markers in clinical cardiac care and prevention. CRP appears to have 
the strongest association with cardiovascular disease, especially when the high-sensitivity CRP assay is 
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used [59]. The conclusion of the AHA/CDC report is that high-sensitivity CRP is probably the best 
supported inflammatory marker and should be measured twice (optimally, two weeks apart). CRP testing 
should not be used for widespread screening of the general adult population. The focus should be on the 
major risk factors such as high BP, high cholesterol, smoking and diabetes. Second, CRP is useful as an 
independent marker of risk and as a discretionary tool in the evaluation of those with moderate risk of 
CVD to help determine treatment course. Third point is that CRP is not for tracking treatment efficacy 
due to lack of evidence that reducing Hs-CRP levels improves outcomes such as survival [59].  
 
 The AHA/CDC [59] defined risk groups as follows: 
• Low risk :          < 1.0mg/L 
• Average risk :       1.0 -3.0 mg/L 
• High risk :          > 3.0 mg/ L 
 
Results greater than 10 mg/L may represent a chronic inflammatory or infectious process. Only high-
sensitivity (Hs-CRP) or ultra-sensitive tests for CRP are useful for predicting heart attacks, since the 
elevation in the CRP level in those cases require CRP quantification in the sample in the concentrations 
below those traditionally measured by the majority of the commercially available assays. A recent 
publication by Danesh and colleagues [60] has questioned the usefulness of CRP as a predictor of 
coronary heart disease. In their study, CRP concentration was moderately predictive of coronary heart 
disease and added only marginally to the predictive value of established risk factors for coronary heart 
disease. As suggested by the CDC/AHA [59], further clarification of the utility of CRP in predicting 
future coronary heart disease in the general population is required. 
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1.3.2.3   Malnutrition 
The prevalence of malnutrition in dialysis patients varies between 18-75% depending on dialysis 
modality, the nutritional assessment tool used and the origin of the patient population [61]. The causes of 
malnutrition in dialysis patients are multifactorial and include: inadequate nutrient intake, dietary 
restrictions, nutrient losses during dialysis, hypercatabolism caused by comorbid conditions [61]. 
Stenvinkel at al [56] in their study which involved 109 predialysis patients reported that 44% of their 
patients were malnourished. Low serum albumin concentrations are usually used as an index of 
malnutrition. Albumin is a negative acute phase protein. Its level drops with inflammation. Low serum 
albumin levels are correlated with high CRP and lipoprotein (a) levels in malnourished CRF patients 
[56].      
                                                                                                                                                                                                                      
Malnutrition and hypoalbuminaemia have been shown to be important predictors of mortality in patients 
undergoing haemodialysis or peritoneal dialysis [34, 55, 61]. Some recent studies have also shown an 
association of between hypoalbuminaemia and cardiac disease in haemodialysis patients [61]. The 
association between malnutrition and cardiac disease has been described in the malnutrition inflammation 
atherosclerosis syndrome [61]. It has been found that CRF patients with malnutrition have on-going acute 
phase response and /or carotid plaques. Salvage et al [62] reported serum albumin to be related to carotid 
plaques and IMT in 24 CRF patients. Stenvinkel at al [56] reported that malnourished patients had higher 
CRP levels and elevated calculated intima media area and a higher prevalence of carotid plaques. 
 
1.3.2.4   Oxidative stress  
 Oxidative stress is defined as a disturbance in the balance between anti-oxidants and pro-oxidants, with 
increased levels of pro-oxidants leading to tissue damage. Oxidant by-products such as superoxide anion 
(O2 _) and hydrogen peroxide (H2O2), are produced in the body as a consequence of normal metabolism. 
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These molecules are highly reactive with other biologic molecules, and are referred to as reactive oxygen 
species (ROS). Under normal physiologic conditions, the production of oxygen free radicals and 
peroxides is balanced by an efficient system of antioxidants, which are molecules capable of scavenging 
ROS thereby preventing oxidative damage. Phagocytic cells produce ROS as part of their defense against 
invading microorganisms [63]. Oxidative stress results in the oxidation of proteins, lipids, carbohydrates 
and DNA present in the environment [63, 64]. Renal failure is associated with increased oxidative stress 
and this has been shown to contribute to the pathogenesis and progression of renal failure [64, 65].  There 
are a number of anti-oxidants present in the body and they can be divided into intracellular or 
extracellular anti-oxidants.  At the intracellular level, enzymatic anti-oxidants such as superoxide 
dismutase (SOD) or catalase and gluthathione peroxidase play an important role in the conversion of 
ROS to oxygen and water (figure1.2). Several non-enzymatic anti-oxidants also play important roles in 
scavenging free radicals. The main non-enzymatic intracellular anti oxidant is reduced gluthathione 
(GSH). There are several extracellular antioxidants, such as proteins like transferrin, lactoferrin, albumin, 
cerulopasmin and urate [66]. These compounds prevent free radical reaction by sequestering transition 
metal ions by chelation in plasma [66].  Albumin, bilirubin, urate and plasma ascorbic acid may also 
scavenge free radicals directly. Some anti-oxidants are located both intra and extracellularly, such as  
tocopherol (vitamin E),  carotene and the water soluble anti-oxidants ascorbic acid (vitamin C) and 
gluthathione. Vitamin E is the major lipid soluble antioxidant and is present in the membranes and in 
plasma lipoproteins [66].  ROS themselves have short half lives of just a few seconds [65, 66] therefore 
oxidative stress is usually measured by the detection of various modified macromolecules that are 
generated from ROS in the body tissues, plasma and other body fluids. These marker molecules usually 
have longer half lives and include molecules derived from lipid peroxidation such as malondialdehyde 
and F2 isoprostanes. Oxidative stress has detrimental effects on cellular and tissue function, contributing 
to the pathogenesis of a wide variety of disease states, including CHF, atherosclerosis, cancer, and the 
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normal process of aging. Oxidative stress has emerged as an important cofactor for the development of 
endothelial dysfunction and possibly atherogenesis [64, 65, 66]. An excess production of ROS may injure 
endothelial and smooth muscle cell membranes by diminishing levels of nitric oxide (NO), through 
increased synthesis of asymmetric dimethylarginine (ADMA) and also inhibits guanylyl cyclase, which 
leads to a decreased production of guanosine monophosphate, and activation of platelet aggregation and 
adhesion. ROS also exert their toxic activity on the vasculature by oxidation of LDL particles to form 
oxidized LDL (oxLDL). Oxidized LDL is one of the key mediators of atherosclerosis. Several studies 
have demonstrated increased oxidative stress in patients with CRF compared to healthy controls [63, 64]. 
Since renal failure is associated with increased oxidative stress, the issue is whether antioxidant treatment 
will be of particular benefit in these patients. Two studies recently reported beneficial effects of vitamin E 
on lipid metabolism, atherosclerosis and CVD in haemodialysis patients. Mune et al [67] used vitamin E 
coated dialyzers in ESRD patients for 2 years and then measured oxLDL, LDL- malondialdehyde, and 
aortic calcification as an index of progression of atherosclerosis. This treatment resulted in a significant 
reduction in LDL oxidation and reduced the progression of aortic calcification. In the Secondary 
Prevention with Antioxidants of CVD in ESRD (SPACE) trial, the effect of high dose vitamin E 
supplementation at a dose of 800IU/ day was investigated in haemodialysis patients with pre-existing 
CVD. The results showed a significant reduction in CVD end points like myocardial infarction but no 
significant effects on all-cause or CV mortality [68]. 
 
 25
   
Figure 1.2 Formation of reactive oxygen species. [From 65] 
 
1.3.2.5   Endothelial dysfunction 
 The endothelium is an active organ with endocrine and paracrine functions. It secretes relaxing and 
contractile factors and anti-aggregatory substances. The principal relaxing factors are NO and 
prostacyclin I, and those with contractile functions are thromboxane A2 and prostaglandin E2.  Endothelial 
dysfunction in the context of vascular disease means a reduced vasodilatory capacity due to reduced NO 
activity. Accumulating evidence suggests that CRF is associated with impaired endothelial function [48, 
69].  
 
The mechanisms of endothelial dysfunction in CRF are possibly due to elevated levels of asymmetric 
dimethyl arginine (ADMA), a competitive inhibitor of NO, increased oxidative stress and accumulation 
of oxLDL. Nitric oxide (NO) is a very active molecule that is released by the endothelial cells into the 
circulation.  It is synthesized from L-arginine by the action of the enzyme nitric oxide synthase (NOS).  It 
is a potent vasodilator that regulates vascular resistance and tissue blood flow. NO also inhibits key 
processes of atherosclerosis such as monocyte endothelial adhesion, platelet aggregation and vascular 
smooth muscle proliferation [48]. The synthesis of NO can be blocked by inhibition of nitric oxide 
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synthase by ADMA and N-monomethyl-L-arginine (NMA) [70]. ADMA and NMA are derived from 
proteins that have been post-translationally methylated and subsequently hydrolyzed. These proteins are 
largely found in the nucleolus and appear to be involved in RNA processing and transcriptional control 
[70, 71]. ADMA and NMA are formed from the methylation of arginine by the enzyme protein arginine 
methyl transferase type I (PRMT I), while PRMT II forms symmetric dimethyl arginine (SDMA). SDMA 
is a stereo isomer of ADMA which has no inhibitory effect on NOS [71]. The major source of the methyl 
groups needed for the various methylating reactions is S-adenosylmethionine, an intermediate in the 
conversion of methionine to homocysteine (figure 1.3). Endothelial cells and other cells in the body form 
ADMA. ADMA is metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH) to 
dimethylamine and L citrulline and excreted by the kidneys to some extent (figure1.3). 
 
 Both animal and human studies have shown that elevated ADMA blood levels are associated with 
increased blood pressure and increased monocyte adhesiveness [48]. Evidence from published clinical 
studies has shown a strong correlation between increased ADMA blood levels and cardiovascular 
morbidity and mortality [70, 71]. Vallance et al [72] were the first to report high plasma concentrations of 
ADMA and SDMA in patients with ESRD. They proposed that the high prevalence of hypertension and 
atherosclerosis in patients with ESRD might be partly caused by dysfunction of the L-arginine/NO 
pathway secondary to the accumulation of ADMA due to declining renal excretion [72].  They noted that 
infusion of ADMA into the brachial artery of normal subjects caused vasoconstriction. Several other 
studies have confirmed markedly increased plasma ADMA concentrations in patients with ESRD [73, 
74]. Decreased renal excretion and reduced degradation by DDAH are possible mechanisms responsible 
for the elevated plasma levels of ADMA in ESRD.  
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Evidence for the pathogenic role of ADMA in atherosclerosis includes the observation that ADMA levels 
are much higher in ESRD patients with atherosclerosis than in those with renal disease without 
atherosclerosis [73].  Zoccalli et al [74] showed that ADMA was a powerful independent predictor of 
CVD mortality in dialysis patients. In this study that involved 225 patients with ESRD, plasma ADMA 
levels were not only significantly related to the severity of carotid atherosclerosis but were the second 
strongest predictor of CV mortality after age [74]. Thus ADMA is an important factor for accelerated 
atherosclerosis through reduced NO availability. 
 
 
 
Figure 1.3 Biochemical pathways for the generation and degradation of asymmetric dimetylarginine 
(ADMA). The methionine/ homocysteine pathway is linked to the generation of ADMA 
[From 71] 
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1.3.2.6   Hyperhomocysteinaemia 
Homocysteine is an intermediate amino acid formed during the metabolism of methionine, a sulphur-
containing essential amino acid and is cleared by the kidneys. Homocysteine is metabolized either by 
remethylation to methionine or trans-sulfuration. Re-methylation is catalyzed by the enzyme methionine 
synthase, the methyl donor being 5-methyl–tetrahydrofolate or methylation can also occur by betaine-
homocysteine methyl transferase, the methyl donor in this case being betaine [75]. Vitamin B12 is an 
essential co-factor for methionine synthase. The enzyme cystathionine - synthase catalyzes the 
transsulfuration of homocysteine to cysteine (see figure 1.4). This process requires vitamin B6   
(pyridoxine) as a cofactor. Homocysteine is present in the plasma in four forms; as free homocysteine 
(1%), as homocysteine disulfide (10%), as homocysteine-cysteine mixed disulfide (10%) or as the protein 
bound form (80%) [75]. Total homocysteine refers to the sum of all the free and protein bound 
homocysteine species (t Hcy); normal value in the fasting state is 5 -15µmol/l. In renal failure, the 
concentration of both the free and protein bound homocysteine fractions increase but their ratio remains 
normal [76]. High levels of homocysteine occur in chronic renal failure and deficiency of folate, vitamin 
B12 or vitamin B6 [75, 76]. Homocysteine concentrations increase in a graded manner with the level of 
renal impairment [76]. Hyperhomocysteinaemia has been identified as an independent risk factor for 
cardiovascular morbidity and mortality in the general population [75, 77, 78] and in ESRD patients on 
dialysis [79, 80]. High homocysteine levels were reported in subjects with IHD and stroke in the general 
population [77]. The Homocysteine Studies Collaboration meta-analysis [77] was the results of 
prospective studies of apparently healthy populations which showed elevated homocysteine level to be an 
independent risk factor for cardiovascular disease. Delport et al [78] reported high levels of homocysteine 
among Caucasian men with vascular disease. The mechanisms by which homocysteine might contribute 
to atherogenesis include induction of endothelial dysfunction, promotion of platelet aggregation and 
enhanced coagulability, increased smooth muscle cell proliferation, cytotoxicity and stimulation of LDL 
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oxidation [75, 76]. In the general population, homocysteine levels can be readily lowered by treatment 
with folic acid and vitamin B12 [81]. Folic acid is converted to 5-methyl tetrahydrofolate, which donates a 
methyl group to homocysteine and reconstitutes methionine from which homocysteine has been derived. 
In most normal subjects or in patients with cardiovascular disease, a dose of 400 to 600 µg produces a fall 
in the plasma concentration by 20-30% [81]. In contrast, patients with ESRD are resistant to this 
homocysteine lowering action of folic acid, even when given in pharmacological doses. Other 
alternatives have been tried with varying outcomes; none of them could normalize homocysteine levels. 
In one study [82] vitamin B12 when given orally lowered homocysteine levels by 17% and by 30% when 
administered subcutaneously. There are recent reports on the use of acetylcysteine in the reduction of 
plasma homocysteine levels. Acetylcysteine is a powerful antioxidant. It has some beneficial effects on 
gluthathione stores and adhesion molecules, and improves peripheral and coronary arterial function [83]. 
Scholze et al [83] used a 5g dose of acetylcysteine intravenously at the time of dialysis. They noted a 
significant fall in plasma homocyteine level. Homocysteine concentration fell from a mean of 20µmol/L 
before haemodialysis to 2.2µmol/L after; this is in contrast to a fall to a mean value of 12µmol/L in the 
absence acetylcysteine. The mechanism of action is probably related to improved endothelial function. 
Results of trials on the usefulness of high doses of folic acid in patients with renal disease, eg. 
Homocysteinemia in Kidney and End Stage Renal Disease Study (HOST) are being awaited. 
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Figure 1.4 Metabolism of Homocysteine (From 75) 
 
1.3.2.7   Anaemia 
Anaemia has many deleterious effects, both directly and indirectly on the cardiovascular system [84]. 
Anaemia results in decreased erythrocyte count, systemic arterial dilatation that leads to a decrease in 
systemic vascular resistance and reduced after load, which in turn may increase stroke volume [84]. 
Anaemia results in decreased blood viscosity, which leads to an increase in venous return, and thus, 
augments preload. Anaemia also results in decreased haemoglobin level and oxygen delivery and 
increased sympathetic activity, which results in an increase in heart rate and venous tone. Increased 
venous return, increased heart rate and increased venous tone with decreased afterload all act to raise 
cardiac output [84].  Anaemia is a risk factor both for the development of de novo and recurrent CHF, 
LVH, LV dilatation, higher cardiac morbidity and mortality, and lower quality of life [11]. 
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Many trials show that treatment of severe anaemia with recombinant human erythropoietin reduces left 
ventricular mass in patients on dialysis and in those with CKD. Hayashi et al [85] showed regression of 
LVH after anaemia was corrected to levels of 11-12g/dl. Accumulating evidence shows a variety of other 
beneficial effects such as improved quality of life, avoidance of the need for transfusion and 
cardiovascular benefits. The risks and benefits of normalizing haematocrit (Hct) in haemodialysis patients 
with cardiac disease have been recently evaluated. In the Normal Haematocrit Trial [86], in which 1200 
patients with ischaemic heart disease and congestive heart failure were randomized to Hct goal of either 
30% or 42%; the primary end points were time to first myocardial infarction or death. There was no 
evidence of benefit; instead there were more deaths and non-fatal myocardial infarction in the group with 
normal Hct. In addition patients with normalized Hct had increased arterio-venous access thrombosis, an 
apparently small decrease in dialytic urea clearance and increased use of iron [86]. In the Canadian 
Normalization of Haemoglobin Trial, [87] 146 patients with either asymptomatic concentric LVH or LV 
dilatation were randomly assigned to receive doses of recombinant human erythropoeitin designed to 
achieve a target haemoglobin level of either 10gm/dl or 13gm/dl. The result showed that there was no 
further decrease in LVMI when Hb increased from 10 to 13g/dl. However, patients in the higher 
haemoglobin group with concentric LVH were less likely to progress to dilatation. In addition the higher 
target haemoglobin group was associated with better quality of life.  The results of these trials suggest 
that normalization of Hb may not work well when cardiac disease is established. Additional trials should 
be conducted to determine the patient groups that are likely to benefit from higher Hb levels and the 
timing for these interventions. The current standard practice is partial correction of anaemia using 
erythropoietin and iron with target Hb in the 11-12g/dl range [88].   
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1.3.2.8   Calcium and phosphorus metabolism 
Alterations in calcium/phosphorus metabolism are directly related to decline in kidney function. As the 
level of kidney function declines, phosphate levels increase and calcium levels decrease and parathyroid 
hormone (PTH) levels increase.  Using USRDS data, Block et al [89] have shown that an elevated serum 
phosphate and a calcium / phosphate product in excess of 4.5-5 mmol/l  (72 when expressed in mg/dl) is 
associated with an increased risk of mortality in patients on haemodialysis. Serum phosphorus has been 
shown to be associated with increased IMT of the carotid artery [90]. Hyperphosphataemia is associated 
with increased blood pressure, hyperdynamic circulation, increased cardiac work and high arterial tensile 
stress [29]. Heavy calcification of the large vessels has long been observed as a feature of chronic 
uraemia. Goodman et al [91] demonstrated that coronary artery calcification occurred and was related to 
increased calcium/phosphate product in a group of young patients receiving dialysis. With the advent of 
electron beam computed tomography (EBCT), the calcium content of the heart, coronary vessels, the 
heart valves and the aorta can now be noninvasively assessed.   Braun et al [92] used EBCT to assess 
calcification in the coronary arteries and valves of 49 patients on haemodialysis; they showed that 
patients receiving dialysis had calcification scores that are much higher than those of non uraemic 
patients with established CAD. The coronary artery calcification scores were 2.5 to 5- fold higher in 
haemodialysis patients compared with non-haemodialysis patients regardless of the age group [92]. Other 
factors associated with calcification include longer duration of dialysis, high calcium intake and elevated 
PTH levels [15].  The possible mechanism by which abnormal calcium/phosphate product increases 
cardiovascular risk is via PTH. PTH is a growth factor for smooth muscle cells and may contribute to 
sclerosis of the major peripheral vessels causing increased afterload and subsequent LV dysfunction. 
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1.3.2.9   Lipoprotein a [Lp (a)] 
Lipoprotein (a) is similar to LDL cholesterol, with the addition of a large glycoprotein designated as 
apolipoprotein (a). The kidney catabolises Lp (a) therefore levels of Lp (a) increase as renal function 
progressively deteriorates [93].  Lp (a) levels are elevated in both haemodialysis and peritoneal dialysis 
patients although they are usually higher in the latter group [3]. Lipoprotein (a) is a strong risk factor for 
vascular disease in most populations [94]. Studies have shown that the apolipoprotein (a) [apo(a)] gene 
locus determines the risk for CVD through its allelic control of Lp (a). Subjects who express the low 
molecular weight (LMW) apo (a) phenotype show on average markedly higher Lp (a) concentrations than 
those with  higher molecular weight apo (a) phenotypes and these have been shown to be associated with 
increased cardiovascular risk [29, 93]. Kronenberg et al [93], in a cross sectional study involving 167 
patients found that the LMW phenotypes of apo (a) and higher serum Lp (a) levels were associated with 
carotid plaques as investigated by ultrasound. They demonstrated that haemodialysis patients with the 
LMW phenotypes of apo (a) had significantly more carotid sites affected by atherosclerotic plaques than 
those with other phenotypes. Delport et al [78] however reported that the high molecular weight apo (a) 
phenotype was associated with increased risk of vascular disease especially in the presence of 
hyperhomocysteinemia.  
 
1.3.2.10   Activation of the renin angiotensin system and sympathetic hyperactivity  
Studies have shown that patients with CRF have increased plasma catecholamine concentrations pointing 
to increased sympathetic activity [95, 96]. Sympathetic hyperactivity is very important because it may 
influence cardiovascular and renal prognosis. Renal ischaemia appears to be the main factor for causing 
sympathetic hyperactivity in patients with kidney disease. Experimental evidence shows that sympathetic 
activity contributes to the progression of renal failure. The exact mechanism by which sympathetic 
activity causes kidney damage is not fully known but the effects include vascular and glomerular injury. 
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Injury to the podocytes is postulated to be one of the mechanisms through which sympathetic activity 
causes kidney damage. The podocytes have adrenergic as well as angiotensin II (Ang II) receptors [97]. 
Cathecholamines also induce vasoconstriction, proliferation of smooth muscle cells and adventitial 
fibroblasts in the vascular wall. Sympathetic activity to the resistance vessels can be measured with 
microneurographic techniques in the sympathetic muscle nerve fibres i.e. muscle sympathetic nerve 
activity (MNSA). MNSA is increased in haemodialysis patients who still have their kidneys and also in 
hypertensive patients with moderate renal failure [95, 96]. Converse et al [98] reported that MNSA was 
increased in patients on haemodialysis. MSNA is also increased in many types of hypertension such as 
renovascular hypertension, malignant hypertension, pre-eclampsia, hypertension associated with obesity 
and hypercapnia, and also with age [95]. It is postulated that decreased NO availability may also 
contribute to sympathetic hyperactivity in CRF. NO levels are reduced in CRF either due to inhibition by 
asymmetric dimethylarginine (ADMA), or via NO scavenging by reactive oxygen species (ROS). The 
NO system is a natural inhibitor of catecholamines. Other factors that contribute to sympathetic 
hyperactivity include smoking, obesity and hypercapnia [96]. ACE inhibitors and Ang II receptor 
antagonist reduce MSNA whereas calcium channel blockers do not [99]. Beta blockers or a centrally 
acting sympatholytic agent might also be beneficial in reducing sympathetic hyperactivity [99]. 
Sympathetic hyperactivity contributes to hypertension and LVH in CKD patients [97]. Sympathetic 
activity also contributes to the development of organ damage independent of its effect on blood pressure 
[100]. It is associated with heart failure, arrhythmia and in experimental conditions, with atherogenesis.  
 
1.3.2.11    Advanced glycation end products (AGES) 
 Advanced glycation end products (AGES) are formed by a non enzymatic reaction of reducing 
carbohydrates with amino groups in proteins and subsequent rearrangements and oxidation reactions 
[101]. Their accumulation may cause macro and microangiopathy [101] and may lead to progression of 
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atherosclerosis by interaction with receptors that induce production of ROS followed by release of 
inflammatory cytokines such as IL-6. [102]. 
 
1.3.2.12   Thrombogenesis 
Fibrinogen is an acute-phase protein as well as a clotting factor and is synthesized by the liver in response 
to inflammatory cytokines [29]. Plasma fibrinogen levels increase with age and are greater in women 
than men [29]. Elevated fibrinogen levels are associated with CVD in patients with normal renal function. 
The odds ratio for CAD was 2.3 in subjects with the highest versus the lowest tertile of fibrinogen in a 
metanalysis [103]. Cross sectional studies have shown that fibrinogen levels are higher in haemodialysis 
and peritoneal dialysis patients compared with the general population [104]. Koch et al showed an 
association between fibrinogen levels and CAD in haemodialysis patients [104]. Fibrinogen has also been 
identified as a risk predictor for recurrent vascular events and myocardial infarction in longitudinal 
studies [105].  
 
1.3.2.13   Extracellular fluid volume overload and electrolyte imbalance 
Fluid and electrolyte abnormalities are common in patients on dialysis. However, little data is available 
on their role in the pathogenesis of CVD. Potassium shifts between the extracellular and intracellular 
compartments have been hypothesized to contribute to sudden deaths in dialysis patients [22]. Fluid 
overload is associated with eccentric LVH, non atherosclerotic hypertrophy of the large conduit arteries 
as well as occlusive atherosclerotic lesions of the small vessels. These changes are important in the 
pathogenesis of CVD in CKD [22].  
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1.3.2.14   Glomerular filtration rate 
Recently, renal dysfunction has been included among the strongest predictors of cardiovascular risk 
[106].  The increase in cardiovascular risks starts early in the course of renal disease at levels of serum 
creatinine (or endogenous creatinine clearance) and albumin excretion rates not thought to be previously 
associated with CV risk.  Reduced GFR is associated with a high prevalence of CV risk factors and this 
may be useful for risk stratification and clinical CVD in both low risk and high risk populations. The 
Framingham Heart Study [106] was the first longitudinal study to identify that minor renal dysfunction 
was associated with increased risk of cardiovascular disease. This study involved 6233 individuals drawn 
from the general population. The mean age was 54 years and subjects were followed up for a mean period 
of 15 years. Mild renal dysfunction was present in 8% of women and 9% of men at baseline. Mortality 
rates in men with serum creatinine levels of 124 to 265 mol/l (1.4-3mg/dl) were significantly higher 
than controls but not in women.  This observation was also confirmed in the 2nd National Health and 
Nutrition Examination Survey (NHANES   ) in which renal insufficiency emerged as a significant 
predictor of subsequent deaths resulting from CVD [107]. The Hope study also showed that the 
cardiovascular risk and mortality was higher in individuals with serum creatinine (Scr) above 124 mol/L 
(1.4mg/dl) than in those with lower values and there was a linear increase of risk with increasing quartiles 
of Scr [108]. Decreased GFR has been found to be an independent risk factor for CVD outcomes and all-
cause mortality in subjects with hypertension [109]. There are a number of possible explanations for the 
independent association of reduced GFR and CVD outcomes. First, reduced GFR is associated with an 
increased number of non-traditional CVD risk factors [12]. Second, reduced GFR may be a measure of 
residual confounding from traditional risk factors. Subjects with reduced GFR may have more severe 
hypertension or dyslipidaemia and therefore are more likely to suffer more vascular damage from 
hypertension or dyslipidaemia [12]. Third, reduced GFR could be a marker of undiagnosed vascular 
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disease or a marker of the severity of vascular disease, especially in high or the highest risk population 
[12]. 
 
1.3.2.15   Microalbuminuria 
Microalbuminuria can result from a specific renal abnormality such as altered haemodynamics or 
glomerular membrane abnormality or it may reflect a more generalized increase in vascular permeability 
secondary to endothelial dysfunction. The prevalence of microalbuminuria is raised among patients with 
type 1 and type 2 diabetes [110], and hypertension [111] and is a useful marker of the likelihood of 
progressive renal impairment. In type 2 diabetic patients, microalbuminuria at baseline is associated with 
an increased risk of CV events [110]. Microalbuminuria is also associated with an increased risk of CAD 
among non diabetic patients [112] and increased risk of LVH and myocardial ischaemia among patients 
with essential hypertension [111]. However since microalbuminuria is associated with risk factors for 
CAD, whether microalbuminuria is itself an independent cause of CVD remains uncertain. 
 
1.4  Adipocyte cytokines 
1.4.1  Adiponectin 
There is growing interest in adipose tissue as an endocrine organ. In addition to leptin, fat cells secrete a 
variety of biologically active molecules, which may influence the function, as well as the structural 
integrity of the cardiovascular system. Adiponectin (ADPN), a recently discovered collagen-like protein, 
is secreted exclusively by adipocytes and circulates in the blood. Adiponectin stimulates fatty acid 
oxidation, decreases plasma triglycerides, and improves glucose metabolism by increasing glucose 
sensitivity [113]. Interest in adiponectin derives from its potential protective role for the cardiovascular 
system. Adiponectin inhibits the inflammatory process and possibly atherogenesis by suppressing the 
migration of monocytes / macrophages and their transformation to foam cells [113]. ADPN also 
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modulates the endothelial response to inflammatory stimuli [114]. ADPN is inversely related to 
creatinine clearance [114,115]. ADPN is markedly increased in patients with ESRD [114, 115]. However, 
what is not known is whether this increase is just due to accumulation or whether it represents a counter-
regulatory response to several metabolic and haemodynamic risk factors of renal insufficiency. The 
multiple links of adiponectin to several metabolic risk factors like glucose, TG, insulin, and HDL 
cholesterol in uraemic patients are all consistently in line with the hypothesis that adiponectin is a 
protective factor [115].  Plasma adiponectin concentrations are reduced in patients with obesity, type 2 
diabetes mellitus and coronary artery disease [116]. ADPN in patients with ESRD is increased compared 
with healthy subjects, but within the uraemic milieu, low adiponectin is still a marker of high risk because 
it predicts a higher rate CV event [115]. Plasma adiponectin is an inverse predictor of CV events in 
dialysis patients, and this is independent of traditional and nontraditional risk factors [115]. However, 
adiponectin levels were found to be increased in both patients with low incidence of cardiovascular 
events (20.8 ± 6.8 µg/mL) and those with high CV events (9.3 ± 2.7µg/ mL) compared with healthy 
subjects (5.9 ± 2.6µg/mL) [115]. This observation suggests that the biological phenomena underlying the 
cardioprotective role of adiponectin must be down-regulated in ESRD, thus resetting the relationship 
between this protein and cardiovascular damage and clinical complications in these patients at a higher 
level [115]. Adiponectin levels inversely correlate with CRP and interleukin-6 levels [115].  
 
1.4.2  Leptin 
Leptin plays an important role in regulation of food intake and energy expenditure. Serum leptin 
concentrations in normal humans have been reported to correlate with body mass index (BMI) as well as 
body fat mass [117]. Leptin levels increase in renal failure due to reduced clearance and there is some 
suggestion that inflammation may also contribute to hyperleptinaemia [117]. Leptin is an independent 
predictor of adverse events in the general population.   
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1.5 Carotid intima-media thickness 
Epidemiological and clinical studies have shown that damage to large arteries is a major factor in the high 
cardiovascular morbidity and mortality in patients with ESRD [118]. There are two distinct types of large 
artery damage that occur in ESRD. The first is atherosclerosis, which is focal and primarily involves the 
intima causing narrowing or occlusion of the arteries with restriction of blood flow [12, 15]. This 
condition leads to IHD, CHF, PVD, sudden death and stroke. The second is arteriosclerosis in which 
there is diffuse involvement of the media resulting in increased arterial stiffness and decreased 
distensibility or compliance [12, 15]. The consequences of arterial stiffening are higher systolic blood 
pressure (SBP) and lower diastolic blood pressure (DBP), thereby causing increased left ventricular 
afterload and alteration of coronary perfusion [17]. The principal outcomes of these changes are LVH and 
aggravation of coronary ischaemia. Higher SBP and pulse pressure, lower DBP, and LVH have been 
identified as independent factors of cardiovascular morbidity and mortality in ESRD patients [118]. 
Subtle structural changes, such as increase in the intima media thickness (IMT), occur early in the course 
of atherosclerosis. Carotid intima-media thickness (CIMT) is usually measured by B-mode 
ultrasonography in which two echogenic lines representing the lumen-intima interface and the media-
adventitia interface can be identified [119]. Studies comparing ultrasound measurements of CIMT with 
histology showed that ultrasound far wall CIMT truly and accurately represents intima-media thickness 
(IMT), whereas the best estimate of the near wall CIMT measurement tends to underestimate the true 
IMT [119].  Increased IMT in the common carotid artery is related to generalized atherosclerosis and 
increase risk of future myocardial infarction and cerebrovascular disease [119,120]. Several studies in the 
general population have shown that increased CIMT was associated with increased risk of cardiovascular 
events like fatal and non fatal MI and strokes [120, 121]. In the Atherosclerosis Risk in Communities 
(ARIC) Study, 7289 women and 5552 men aged 45- 64 years were followed up for 4 to 7 years [121]. 
Analysis was based on 290 coronary heart disease events that occurred during the period. CIMT was 
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calculated as the mean of the far wall of the common carotid artery, the bifurcation and the internal 
carotid artery. The age adjusted risk of coronary heart disease increased gradually with increasing CIMT: 
the risk of coronary heart disease increased by 69% (95% CI 50-90%) in middle-aged women and 36% 
(23-51%) in middle-aged men per 0.19mm increase in mean maximum CIMT.  The IMT has also been 
shown to be directly associated with most of the risk factors for atherosclerosis [119]. Kawagishi et al 
showed that IMT was significantly higher in dialysis patients than age- and gender matched controls [90]. 
London et al did show that IMT was strongly associated with left ventricular mass index [122]. Studies 
have shown that the frequency of atherosclerotic plaques is far larger in the haemodialysis patients when 
compared to healthy subjects or patients without renal disease when matched for traditional risk factors 
[62, 90]. Calcified plaques are more common in dialysis patients [15, 62]. Benedetto et al in their study of 
138 patients who were receiving chronic dialysis showed that IMT was associated with concentric LVH 
and also an independent predictor of cardiovascular death [123].  IMT is non invasive, cheap, simple and 
reproducible and could be used in early diagnosis of coronary artery disease.  Stenvinkel et al 
demonstrated that coronary ultrasonography is a useful diagnostic tool and the results obtained were 
comparable to exercise test and variance electrocardiogram for the detection of coronary heart disease in 
a high prevalence population [56]. 
 
1.5.1   Methods of measurement of carotid intima-media thickness 
 There are several important differences in the B-mode measurement of carotid IMT between 
laboratories. These include the sites of measurement, which are the segments of the artery, the near/far 
wall, and the angles of interrogation, automated versus manual measurement [119, 124]. The argument in 
favour of the use of common carotid IMT rather than the mean maximum IMT is that the common 
carotid IMT can be assessed in a more reproducible manner than mean IMT, the data collection is nearly 
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always complete whereas the measurements for the bifurcation and internal segments have more missing 
values [119, 124]  
 
1.6   Pathogenesis of atherosclerosis 
In the past, atherosclerosis was mainly understood to be a consequence of cholesterol accumulation 
together with infiltration of macrophages and smooth muscle cells covered by a fibrous cap. However 
despite changes in life style and the use of drugs to lower cholesterol, many people still die from CVD in 
the US, Europe and Asia. New insights into disease pathology have shown it to be a disease of many 
ramifications. Inflammation as well as  impaired NO production are  now considered to play an essential 
role in each of the stages of atherogenesis from the initial recruitment of leucocytes to eventual rupture of 
the unstable atherosclerotic plaque [44]. 
 
The vascular endothelium plays a critical role in maintaining vascular integrity and homeostasis. 
Atherosclerosis starts with endothelial dysfunction which can result from mechanical shear stresses from 
morbid hypertension, biochemical abnormalities from elevated and modified LDL, diabetes, elevated 
plasma homocysteine, immunological factors like free radicals from cigarette smoking, inflammation 
(e.g. infections such as herpes virus, Chlamydia pneumonia and Helicobacter pylori) and genetic 
alterations [44]; figure 1.5. Endothelial dysfunction leads to alterations in the normal homeostatic 
properties of the endothelium [44, 48], thereby leading to increased adhesiveness of the endothelium to 
leucocytes and platelets as well as increased permeability to oxidized lipoproteins (ox LDL) and 
decreased NO production [44, 48]. The injured endothelium also releases vasoactive molecules, cytokines 
and growth factors [44] which lead to further recruitment of leucocytes and smooth muscle cell 
proliferation. The adherence and subsequent migration of leucocytes across the vascular endothelium are 
mediated by the expression of cellular adhesion molecules on the endothelial surface [125]. The selectins 
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are adhesion molecules that mediate the initial rolling of inflammatory cells along the endothelial surface. 
P-selectin is stored in the  granules of platelets and Weibel Palade bodies, while E-selectin is 
synthesized de-novo by endothelial cells when activated by interleukin-1 (IL-1) or TNF . Intercellular 
adhesion molecule 1 (ICAM-1) and vascular adhesion molecule 1 (VCAM-1) belong to the 
immunoglobulin superfamily of cellular adhesion molecules [125]. These adhesion molecules are thought 
to regulate attachment and transendothelial migration of leucocytes [125]. ICAM I is produced by 
macrophages and endothelial cells in response to inflammatory cytokines such as IL-1, TNF  and 
interferon , whereas VCAM-1 production is mainly restricted to endothelial cells.  
 
LDL, which may be modified by oxidation, glycation (in diabetes), aggregation, association with 
proteoglycans, or incorporation into immune complexes, is a major cause of injury to the endothelium 
and underlying smooth muscle [48, 125]. When LDL particles become trapped in an artery they undergo 
progressive oxidation. The oxidized LDL cannot be internalized by cells via the LDL receptor pathway. 
The oxLDL has to utilize the scavenger receptor pathway expressed only on tissue macrophages [125]. 
The internalization leads to the formation of lipid peroxides and facilitates the accumulation of 
cholesterol esters resulting in foam cells. Cholesterol accumulation in the foam cells leads to 
mitochondrial dysfunction, apoptosis and necrosis, with resultant release of cellular proteases, 
inflammatory cytokines and prothrombotic molecules [125]. In addition to causing disruption of the 
endothelial surface, oxLDL stimulates endothelial cells to produce pro-inflammatory molecules such as 
macrophage chemotactic protein-I (MCP-I) and monocyte colony stimulating factor (M-CSF). Mediators 
of inflammation such as TNF, IL-1, M-CSF increase the binding of LDL to endothelium and smooth 
muscle and also increase the transcription of the LDL receptor gene [44]. Thus a vicious circle of chronic 
inflammation, modification of LDL and further inflammation can be maintained in the artery by the 
presence of these lipids. 
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As the inflammatory process continues, lymphocytes, macrophages, foam cells and the resident vascular 
wall cells secrete cytokines and growth factors that can promote smooth muscle cell migration and 
proliferation [48]. Smooth muscle cell growth is a key event in the development of atherosclerosis. The 
smooth muscle cells before migrating undergo a change leading to the acquisition of a synthetic 
phenotype profile [48]. Collagen is produced in larger and larger quantities by the smooth muscle cells 
and the whole sequence of events cumulates as an 'advanced’ or raised fibro-lipid plaque (intermediate 
lesion). With continued inflammatory response, there is thickening of the arterial wall which compensates 
by gradual dilation (remodeling) [44, 48]. Continued inflammation results in increased number of 
macrophages and lymphocytes which emigrate from the blood and multiply within the lesion. Activation 
of these cells leads to the release of hydrolytic enzymes, cytokines, chemokines and growth factors [44], 
which can induce further damage and eventually lead to focal necrosis. Thus the cycle of accumulation of 
mononuclear cells and formation of fibrous tissue leads to further enlargement and restructuring of the 
lesion so that it becomes covered by a fibrous cap that overlies a core of lipid and necrotic tissue, a so-
called advanced complicated lesion. The 'advanced plaque' may grow slowly and encroach on the lumen 
or become unstable, undergo thrombosis and produce an obstruction (complicated plaque). Inflammation 
plays a key role in plaque instability [44]. Acute events depend on the composition of the plaque. 
Vulnerable lesions have an increased number of activated inflammatory cells with scarce amounts of 
smooth muscle cell content. The physical disruptions of the fibrous cap, together with the exposure of the 
plaque necrotic core are key events that lead to thrombotic complications. The integrity of the fibrous cap 
depends on the balance of matrix production (mainly due to smooth muscle cells) and enzymatic 
degradation [48]. These processes are influenced by inflammatory cytokines.  
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Figure 1.5 Development of atherosclerotic lesions [From 49]. 
 
1.7 Primary and secondary prevention of CVD in chronic kidney disease 
Most patients with CKD are excluded from randomized clinical trials that test for the efficacy of treatment 
interventions for the prevention of CVD.  Some of the recommendations given are based on extrapolation 
from the general population [126]. Strategies for risk factor reduction in CKD should take into account both 
traditional and uraemia related risk factors. Measures to prevent CVD in this group of patients should not be 
based on the presence or absence of previous CVD or other risk factors but rather the highest risk nature of 
these patients. 
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1.7.1   Hypertension 
 The preferred therapy is control of extracellular fluid volume and maintenance of dry weight through salt 
reduction, diuretics in patients with mild to moderate CKD, reduction in fluid intake and ultrafiltration in 
haemodialysis and peritoneal dialysis patients. It is reasonable to use the current guidelines of the Seventh 
Joint National Committee for Prevention, Detection, Evaluation, and Treatment of High Blood Pressure to 
define optimal BP control in haemodialysis patients.  Target BP for antihypertensive therapy is <140/90. 
Persistent low BP is indicative of CVD.  All classes of antihypertensive agents are effective in ESRD 
patients except diuretics. ACE inhibitors, angiotensin receptor blockers, beta blockers are suggested because 
of their effects in reducing sympathetic overactivity. ACEI also improve endothelial function and LVH 
[126]. 
 
1.7.2   Hyperlipidaemia 
 It may be reasonable to use the guidelines of the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel for the initial classification, treatment initiation, and target cholesterol level. The 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are effective in lowering 
cholesterol and are safe [126]. 
 
1.7.3   Hyperglycaemia 
The recommendation is for intensive glycaemic control in patients with type1 and type 2 diabetes with CKD 
to reduce adverse CVD outcomes [29,126]. 
 
1.7.4   Tobacco use  
The recommendation is counseling on smoking cessation. Nicotine replacement can be used and is safe in 
CKD [126]. 
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1.7.5   Physical inactivity   
The American Heart Association recommends a moderate level of physical activity for 30 minutes per day 
for most days of the week in the general population. This level of activity is feasible in patients with CKD 
and they should be encouraged to start exercise programmes [126]. 
 
1.7.6   Menopause   
Hormone replacement therapy may help with post menopausal hormone deficiency but there is need to 
monitor serum lipids [126]. 
 
1.7.7   Homocysteine 
Vitamin B supplements (Folate, Vitamin B6) have been administered; however the levels do not drop to 
normal and further research is required [126]. 
 
1.7.8   Thrombogenic factors   
Patients with CKD have decreased platelet function and increased procoagulant activity, and aspirin may 
worsen platelet function. It seems reasonable to prescribe low dose aspirin (75 to 150mg/d) to reduce the 
risk of CVD outcomes in patients with CAD or those at high risk for developing CAD [126]. 
 
1.7.9   Anaemia  
Anaemia is a risk factor for LVH and LVH is associated with worse CVD outcomes. Anaemia should be 
treated with iron supplementation to achieve serum ferritin concentration 100g/l and transferrin saturation 
> 20%. Epoietin should be used to maintain haemoglobin concentrations > 11g/dl (usual target is 11-
12.5g/dl) [88]. Treatment of anaemia causes LVH to regress in CKD [88]. 
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1.7.10   Calcium and phosphate 
Non- aluminium phosphate binders can be given if serum phosphate is > 1.5 mmol/l. Active vitamin D 
supplements should be used when parathyroid hormone is > 2.5 times normal and phosphate concentration 
is < 1.7 mmol/l. Dietary counseling and improving on dialyisis treatment is helpful. Aim for a normal 
calcium phosphate product (< 5mmol/l) [29, 126]. 
 
1.7.11   Left ventricular hypertrophy 
Treatment of hypertension and anaemia can cause regression of LVH in CKD 20, 22, 126].   
 
1.8   Rationale for the study   
Myocardial infarction is less frequent in black South Africans [7, 127]. Study of risk factors for CVD 
may identify the reasons for the difference. Patients with ESRD on dialysis are considered to be a high 
risk group for CVD and there have been several studies done in the white population. There is limited 
data on ASCVD in South African patients with ESRD. Therefore a study of this nature is necessary to 
determine the prevalence of risk factors for ASCVD in the South African patients on haemodialysis and 
to determine the relationship of these risk factors to sub-clinical atherosclerotic cardiovascular disease in 
this population. To determine if race has any effect on the differences in ASCVD prevalence we also 
studied a group with a high prevalence of ASCVD (whites and Indians) and compared risks factors in 
both groups. The study will provide baseline data base of CVD in this high risk dialysis population. 
    
1.9   Aim of study 
The aim of this study is to determine the risk factors for atherosclerosis in Black (low risk), and non-
black (high risk) South African patients on haemodialysis. 
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1.9.1   Objectives 
1.  To assess the levels of CRP, homocysteine, lipoprotein (a) and adiponectin in patients with ESRD on 
haemodialysis  
2. To measure carotid intima-media thickness (CIMT) as a non-invasive indicator of CAD in these 
patients.  
3. To determine the relationship of these cardiovascular risk factors to the degree of sub clinical 
atherosclerosis as determined by CIMT in the two dialysis groups, as well as a matched normal control 
group. 
4. Choice of cytokines 
Hs-CRP, homocysteine and Lp (a) have been extensively studied in both the general population and 
ESRD and are associated with increased risk of CVD. There is very little data in our population hence we 
decided to include these molecules in this study. ADPN is a recently discovered adipocyte cytokine with 
little information of its effect in ESRD patients hence we decided to include this in our study.  
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CHAPTER 2 
MATERIALS AND METHOD 
The protocol for this study was approved by the Human Ethics Committee of the University of the 
Witwatersrand; ethics clearance certificate number M03-08-02. 
 
2.1 Study population 
2.1.1 Sample size  
The sample size was calculated based on a 2 sample t-test to detect a difference of 4.32 in the level of 
inflammatory markers using data from a previous study [128] with a standard deviation of 0.99. A 
minimum sample size of 44 per group is adequate to detect this difference at 0.05 significance level with 
a power of 0.9. 
 
2.1.2 Inclusion criteria 
• Patients who have been on maintenance chronic haemodialysis for three months or more at the 
Johannesburg, Helen Joseph and Chris Hani Baragwanath dialysis units who agree to participate 
in the study. Consecutive patients who agreed to participate in the study were recruited.  
• Age between 18years and 60years 
There were fifty-eight black and twenty-six non black patients (from a population with high prevalence of 
CAD i.e. Indians and Whites). All patients were dialyzed thrice weekly with standard bicarbonate buffer.  
Fifty-one patients (60.7%) dialyzed through arteriovenous fistulae, 19 had temporary catheters in the 
internal jugular vein, 10 had permcaths and 4 had grafts.   
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2.1.3 Exclusion Criteria 
• Patients with active or chronic infections including vascular access related sepsis. 
• Patients with diabetes mellitus. 
• Patients who are seropositive for hepatitis B,  C and the human immunodeficiency virus 
• Patients with active inflammatory disease. 
 
2.1.4 Controls 
Thirty-five black and twenty-eight non-black, age and sex-matched “healthy” volunteers were recruited 
from: 
• Staff and students of Johannesburg and Chris Hani Baragwanath hospitals. 
• Donors from the transplant work-up clinic (prior to kidney donation).  
 
2.2 Methods 
This was a cross-sectional study. Enrollment of all eligible patients was initiated in January 2004 to 
October 2004. Using a structured interview form, information on age, race, gender, physical activity, and 
tobacco use was obtained. Current physical activity was evaluated by asking if the patients engaged in 
any regular exercises such as brisk walking, jogging, bicycling or swimming. Patients were classified into 
three groups based on smoking history. They were categorized as current smokers if they smoke, former 
smokers if they stopped smoking six months previously and non- smokers if they never smoked. ASCVD 
was defined as a history of angina, MI, coronary artery bypass graft surgery or angioplasty, stroke, 
peripheral by-pass, peripheral angioplasty, or amputation. The use of antihypertensive medications, 
statins, and calcium containing phosphate binders was noted. Height and weight were measured using the 
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Detecto scale (New York) and body mass index (BMI) was calculated as weight to height squared. The 
dry weight was used to calculate BMI in haemodialysis patients.  
 
2.2.1 Blood Pressure 
Blood pressure (BP) was recorded non-invasively in the arm without the A-V fistula with an acusson 
mercury syphygmomanometer in the sitting position. Blood pressure was estimated by averaging all pre 
dialysis and post dialysis blood pressure recordings taken during the month before the study (total of 12 
measurements; that is 3/wk). For the controls blood pressure was taken in the sitting position after resting 
for 5 minutes. The average of three readings taken 5 minutes apart was taken as the blood pressure. Pulse 
pressure was calculated as systolic blood pressure minus diastolic blood pressure. Mean arterial pressure 
(MAP) was calculated as diastolic blood pressure plus one third pulse pressure. 
 
2.2.1.1 Pre-dialysis or post-dialysis measurements? 
 Most studies of blood pressure in haemodialysis patients have used pre-dialysis blood pressure 
measurements[23, 24]. Predialysis pressure may not be the most appropriate to study.  Two recent large 
studies showed no increase in cardiovascular mortality with increasing pre-dialysis blood pressure, but 
did find increasing mortality at higher levels of post-dialysis blood pressure [24, 25]. There is a rapid rise 
in blood pressure a few hours before each haemodialysis session and several ambulatory blood pressure 
monitoring studies have shown a closer relationship between mean ambulatory blood pressure and post-
dialysis blood pressure than with pre-dialysis blood pressure.  The closest estimate of the ambulatory 
blood pressure may be obtained by measuring blood pressure 20 minutes after completion of dialysis but 
this is impractical in routine practice, and a measurement shortly after completion of dialysis has to be 
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acceptable, despite the concern that this may be influenced by haemodynamic instability caused by 
continued equilibration between the blood volume and the interstitial compartment.  Mean ambulatory 
systolic pressure may be more closely related to the pre-dialysis measurement and diastolic pressure to 
the post–dialysis measurement.   
 
2.2.2 Dialysis treatment 
Patients were asked questions about their dialysis treatment including date of commencement of 
treatment, previous treatments received including previous kidney transplants. The type of access and 
dialyzers used were also noted. The dose of erythropoietin received was noted. The monthly Kt/V was 
calculated using single pool urea kinetic modeling. The post dialysis blood urea sample was obtained by 
the slow stop technique. A Kt/V of 1.20 was considered adequate. Most patients were virtually anuric 
(24-hour urine volume <200 mL/day) and were being treated three times a week with standard 
bicarbonate dialysis (sodium 138 mmol/L, HCO3 35 mmol/L, potassium 1.5 mmol/L, calcium 1.50 
mmol/L, magnesium 0.75 mmol/L). Sixty-seven patients (79.76%) patients dialyzed with the Fresenius 
hollow fibre polysulfone dialyzers (F5 to F10HPS, surface area 1.0 to 2.2m2 (Fresenius Medical Care Bad 
Hamburg Germany) while 17 (20.24%) dialyzed with the Gambro hemophan dialyzers (GFS 16 surface 
area 1,2m2 Gambro Germany). 
 
2.2.3 Carotid intima- media thickness  
Carotid artery intima-media thickness (IMT) was measured by high resolution B-mode ultrasonography 
with a 7.5-MHz transducer (Toshiba Nemio 30, Toshiba Corporation Otawara-Shi Japan). Patients were 
examined in the supine position with the neck hyperextended and the head turned 45o from the side being 
scanned. Reference point for the measurement of intima-media thickness (IMT) was the beginning of the 
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dilatation of the carotid bulb (flow tip divider). IMT was taken as the distance from the leading edge of 
the first echogenic line to the leading edge of the second echogenic line. Where possible, measurements 
were taken at the near and far falls of all carotid segments. Measurement of the near wall of the 
bifurcation and the internal carotid artery was difficult especially some dialysis patients due to presence 
of temporary catheters in the neck. Hence in this study we focused on measurement at the far walls of the 
three segments on both sides.  
 
Measurements were taken on the longitudinal views of  the far walls of the common carotid artery 1cm 
proximal to the dilatation of the carotid bulb, carotid bifurcation (the 1cm-segment proximal to the flow 
divider), and internal carotid artery at about 1cm segment distal to the flow divider (figure 2.1).  The 
maximum IMT in the far wall of the various carotid segments was recorded.  For statistical analysis the 
mean of right and left common carotid IMT was considered. The presence of plaques was defined as 
localized echo structures encroaching into the vessel lumen for which the distance between the media-
adventitia interface and the internal side of the lesion was  1.2 mm [63, 119]. Plaques were classified as 
soft, mixed or calcified plaques according to their calcification. Soft plaques appeared as faint grey 
echoes which protruded into the lumen. Mixed plaques included small areas of calcification incorporated 
in a soft plaque. Highly echogenic lesions, often causing shadowing, represented calcified plaques [63]. 
The number and the thickness of carotid plaques were measured from both carotid systems.  Plaque 
thickness was measured in a suitable longitudinal view. Plaque score was calculated by summing up the 
thickness of all the plaques for both carotid systems [129]. IMT was measured in the plaque free areas 
and measurements were carried out on both sides by two trained Ultrasonographers from the Vascular 
Unit of the Johannesburg hospital.  The presence of atherosclerosis in this study was thus determined by 
measuring CIMT and occurrence of plaques. 
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       Figure 2.1 Carotid intima-media thickness measurement sites [From 121] 
 
 
2.2.4 Echocardiography  
Echocardiography is a non invasive test that gives information about cardiac dimensions of the heart 
assessing for cardiac geometry and wall motion abnormalities. Echocardiography was done in the 
Cardiology Unit using the Acuson Sequoia C256 machine (Acuson Corporation California USA) 
equipped with 2 to 4-MHz probes allowing M-mode, two dimensional, and pulsed doppler measurements. 
Echocardiography was performed by 3 Consultant Cardiologists under the supervision of a Professor. 
These studies were performed on a non-dialysis day where possible. Echocardiography was performed 
according to the standard guidelines [130]. All scans were performed with the head of the table inclined at 
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an angle of 15 degrees and the participant rotated 30–45 degrees in the left lateral decubitus position at 
end-expiration.  Left ventricular internal dimension measurements in end-diastole (LVEDD), and end-
systole (LVESD) were made at the level of the mitral valve leaflet tips in the parasternal long-axis view. 
The normal range for LVEDD is 3.5- 5.6cm, and 2.0-4.0cm for LVESD [130]. The interventricular wall 
thickness during diastole (IVSTd) and posterior wall thickness during diastole (PWTd) were measured by 
M-mode. From these measurements, the left ventricular mass (LVM) and left ventricular mass index 
(LVMI) were calculated according to Devereux and Reichek [131]. LV mass was divided by body 
surface area (BSA) to calculate the LV mass index (LVMI) [130, 131]. The cutoff points for LV 
hypertrophy using the LVM/BSA ratio were 136 g/m2 for males and 100 g/m2 for females [131].  
 
LVM = ([LVEDD/10 + IVSTd/10 + PWTd/10]3 x 1.04) - ([LVEDD/10]3 - 13.6)  
LVMI = LVM/  (weight x length  
   3600   
RWT = (2 x PWTd)/ LVEDD  
 
Relative wall thickness (RWT) was used to characterize LVH into eccentric and concentric LVH. [132]. 
RWT greater than 0.45 in the presence of LVH is indicative of concentric hypertrophy and eccentric 
hypertrophy if less than 0.45 in the presence of LVH.  LV diastolic function is complex and dependent on 
factors like age, preload, afterload, heart rate and the co-existence of other abnormalities like mitral valve 
disease [130]. Diastolic function was assessed using M-mode. The anterior mitral valve leaflet (AMVL) 
during diastole has a characteristic M- shaped (E-A) pattern assuming the individual is in sinus rhythm 
and no mitral stenosis. The E-wave is the result of passive early diastolic left ventricular filling. The A-
wave represents active late diastolic LV filling due to atrial contraction. The acceleration time (AT) and 
deceleration time (DT) of the E-wave can be measured. AT is the time from the onset of diastolic flow to 
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the peak of the E-wave. DT is the time from the E-wave peak to the point where the deceleration slope 
hits the baseline. The E-wave is often greater than the A-wave.  If the left ventricle is stiffer than usual, 
there may be diminished AMVL excursion (E-wave) and an increase in A-wave size (as the atrial 
contraction contributes to a greater extent to ventricular filling of the left ventricle); the E: A ratio is thus 
reduced.  The E-wave, E: A ratio and E-wave deceleration times tend to fall with increasing age [130]. 
The normal ranges are E:A ratio of 1.04 ± 0.38 for men and 1.03 ± 0.34 for women [130]. Systolic 
function was assessed by measuring the left ventricular ejection fraction and fractional shortening. 
Systolic dysfunction was defined as a shortening fraction less than 28% or ejection fraction less than 50% 
[130]. 
 
2.2.5 Biochemistry        
Blood samples for CRP, lipids, lipoprotein (a), and adiponectin were collected in anti-coagulant free 
tubes after an overnight fast on the mid-week day, predialysis. Samples for homocysteine were collected 
in EDTA tubes after overnight fast. Samples were kept on ice until the plasma was separated within 30 
minutes of blood collection. Samples were centrifuged at 3000 rpm for 10 minutes at room temperature 
and frozen at -70oC till ready for assay.  
 
2.2.5.1 Routine Tests 
 Serum albumin, cholesterol, triglyceride, HDL-Cholesterol, urea, creatinine, albumin, calcium, 
phosphate, and parathyroid hormone measurements were done in the National Health Laboratory (NHLS) 
as part of the routine monthly tests in the dialysis patients. All samples were analyzed using the 
Roche/Hitachi Modular ISE 900 automated analyzer (Roche Diagnostics Corporation, Mannheim 
Germany). The mean of three measurements taken over 3-months from the time of recruitment including 
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the month of entry into the study were used for analysis. All routine tests were measured with 
commercially available kits and carried out according to manufacturers instructions. 
 
2.2.5.1.1 Serum lipids 
Serum total cholesterol and triglycerides were determined using enzymatic colometric test High density 
lipoprotein (HDL) cholesterol was measured after precipitation of the non-HDL fraction with 
phosphotungstate-magnesium. The concentration of LDL cholesterol was estimated indirectly by use of 
the Friedewald formula [133].See appendix A for details.  
 
Friedewald LDL cholesterol = total cholesterol – (HDL cholesterol + triglyceride/5).  
 
2.2.5.1.2   Serum calcium 
Serum calcium was determined using the complexometric methods in addition to atomic absorption 
spectrometry. This method is based on the reaction of calcium with o-cresol-phthalein complexone in 
alkaline solution to form calcium-o-cresolphthalein complex. Magnesium is masked with 8-
hydroxyquinoline. The colour intensity of the purple complex formed is directly proportional to the 
calcium concentration and was measured spectrophotometrically. Normal values are 2.15 – 2.55mmol/L. 
 
2.2.5.1.3   Serum phosphate 
Serum phosphate was measured based on the reaction of phosphate with ammonium molybdate to form 
ammonium phosphomolybdate. Inorganic phosphate forms an ammonium phosphomolybdate complex 
with ammonium molybdate in the presence of sulphuric acid. The complex was determined 
spectrophotometrically in the ultraviolet region (340nm). See appendix B for details. Normal values are 
0.87 – 1.45mmol/L. 
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2.2.5.1.4   Serum parathyroid hormone 
The intact parathyroid hormone (PTH) peptide consists of 84 amino acids sequenced and designated 
according to reactivity. The N-terminal or amino terminal 1-34 region of the intact PTH molecule is 
biologically active. This region of the PTH molecule contains the amino acid sequence that enables the 
PTH to bind to the parathyroid hormone receptors in the target tissues and regulate the extracellular 
calcium. The middle and the carboxyl-terminal 35-84 region of the intact PTH molecule are biologically 
inert but possess immunological reactivity. PTH circulates in the blood as both intact PTH and PTH 
fragments. Intact PTH has a half-life of less than 4 minutes and is cleared by the kidney and the liver. The 
kupffer cells in the liver are responsible for cleaving the intact molecule into fragments and releasing 
them into circulation. The middle and the carboxyl- terminal PTH fragments vary in size and have longer 
half-lives and are cleared in the kidney by glomerular filtration. In renal insufficiency, the concentration 
of the middle and carboxyl- terminal PTH fragments is increased. The ratio of the circulating 
concentrations of intact PTH to middle and carbonyl-terminal PTH can vary between individuals, 
particularly in patients with CRF. Quantification of circulating intact PTH in conjunction with the 
measurement of ionized calcium assists in the differential diagnosis of hyperparathyroidism, 
hypoparathyroidism and hypercalcaemia. The measurement of intact PTH using two-site immunoassays 
provides a more accurate assessment of parathyroid secretory status especially with renal impairment 
(ADVIA Centaur Assay manual). Intact PTH was measured using the ADVIA Centaur Intact PTH assay 
(Bayer Diagnostics, United Kingdom). The ADVIA Centaur Intact PTH assay is a two-site sandwich 
immunoassay using direct chemiluminometric technology, which uses constant amounts of two anti-
human PTH antibodies. The first is a polyclonal goat anti-human PTH antibody labeled with acridinium 
ester directed at the N-terminal (N-terminal 1-34). The second antibody is a biotinylated polyclonal goat 
anti-human PTH (39-84 regions) antibody. Streptavidin in the Solid Phase is covalently coupled to the 
paramagnetic latex particles. The system performs a series of steps (for details of the methods see 
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appendix C). The amount of PTH in the patient’s sample is equivalent to the amount of relative light units 
(RLU) detected by the system. Normal values are 7– 53ng/L 
 
2.2.5.1.5   Serum creatinine    
Serum creatinine was measured by the modified Jaffe method. Creatinine in alkaline solution forms a 
yellow-orange complex with picrate. The colour intensity is directly proportional to the creatinine 
concentration and was measured spectrophotometrically at 510nm. Normal range in men is 62 –106 
mol/L and 44 – 80mol/L in women. 
 
2.2.5.1.6   Serum albumin 
Serum albumin was measured by a colorimetric assay with end point method. Albumin binds with 
bromocresol green (an ionic dye stuff) at a pH value of 4.1 to form a blue-green complex. The colour 
intensity of the blue-green colour is directly proportional to the albumin concentration and was 
determined spectrophotometrically at 510nm.  Normal values are 34– 48g/L. 
 
2.2.5.2 Special biochemical tests 
2.2.5.2.1   Hs-CRP  
CRP is a member of the pentraxin family of protein and is considered the protypical acute phase reactant 
in man. CRP is produced in the liver in response to IL-6 its concentration increases rapidly during 
inflammatory reactions [45].  CRP was measured using an immunoturbidimetric assay (CRP latex high 
sensitive assay, Roche Diagnostics, Manmheim Germany). The Roche CRP assay is based on the 
principle of particle-enhanced immunological agglutination. The kit was used on the Roche/Hitachi 911 
Modular machine and assay performed according to the manufacturer’s instructions. The test principle is 
based on the reaction of anti-CRP antibodies coated with latex reacting with antigen in the sample to 
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form an antigen-antibody complex. The agglutination was measured by immunoturbidimetry.  Briefly, 
10L of serum was mixed with 125L of R1 (buffer).  
 
After which 125L of R2 solution which is an anti-CRP antibody-latex solution was added. Following 
the reaction, agglutination was measured turbidimetrically. The measurement ranged is from 0.1- 
20.0mg/L with an expected value of < 5mg/L.  
 
2.2.5.2.2 Adiponectin 
Serum adiponectin was measured by ELISA immunoassay technique using the Quantikine human 
adiponectin kit by R and D systems (Abingdon Oxon United Kingdom). The assay uses the quantitative 
sandwich enzyme immunoassay technique with a microplate pre-coated with a monoclonal antibody 
specific for adiponectin. Standards and samples were pipetted into the wells and any adiponectin present 
was bound by the immobilized antibody. After washing away any unbound substances, an enzyme- 
linked monoclonal antibody specific for adiponectin was added to the wells. Following washing to 
remove any unbound antibody – an enzyme reagent (adiponectin conjugated to horseradish peroxidase), 
and a substrate solution (tetramethylbenzidine) were added to the wells for colour development (in 
proportion to the amount of adiponectin bound in the initial step). Colour development was stopped by 
the addition of sulfuric acid and the intensity of the colour was measured at 450nm. 
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Table 2.1 Assay procedure for adiponectin 
 
         Sample and Reagents 
 
       Volume   
 
                    Remarks 
Assay Diluent RD1 W 
         100µl  
Diluted Sample  / Standard/ 
Saline diluent (blank) 
           50µl Plate was incubated at room 
temperature for 2 hrs 
Washing solution         
         400µl         
        
Wells were washed four (4) 
times 
Adiponectin conjugate 
         200µl 
 
Plate was covered with adhesive 
tape and incubated for 2hrs at 
room temperature 
Washing solution 
         400µl Wells were washed four (4) 
times 
 
Substrate solution 
         200µl Plate was protected from bright 
light and incubated for 30min at 
room temperature 
Stop solution 
          50µl  The absorbance was read at 
450nm. 
 
The lowest level of human adiponectin detected by this assay by is 1ng/ml in a 100L sample size. 
Adiponectin measurements were done in the laboratory of the Nephrology Unit. The expected values are 
5 – 30g/mL.  
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2.2.5.2.3 Homocysteine  
Homocysteine (Hcy) was measured by Fluorescence Polarization Immunoassay (FPIA) technique using 
the AXSYM kit (Abbott Laboratories, USA) on the Abbott IMx autoanalyzer. Homocysteine assay was 
done according to manufacturers instructions. Briefly, bound homocysteine (oxidized form) is reduced to 
free homocysteine that is enzymatically converted to S-adenosyl-L-homocysteine (SAH). Homocysteine, 
mixed disulfide, and protein bound forms of Hcy in the sample are reduced to free Hcy by the use of 
dithiothreltol (DDT). Free Hcy is converted to SAH by the use of SAH hydrolase and excess adenosine. 
Under physiological conditions, SAH hydrolase converts SAH to homocysteine. Excess adenosine in the 
pretreatment solution drives the conversion of Hcy to SAH by the bovine SAH Hydrolase. 
 
The AXSYM Kit was made-up of the following: 
- Pretreatment solution containing dithiothreitol (DTT) 
- 8-adenosyl-L-homocystein Hydrolase (bovine) in phosphate buffer with protein (bovine) 
stabilizer 
- Anti-S-adenosyl-L-homocystein Antibody (mouse monoclonal) in phosphate buffer with 
protein (porcine) stabilizer 
- 8-adenosyl-L-cystein Fluorescein Tracer in phosphate buffer protein (bovine) stabilizer. 
 
Samples and all AxSYM reagents required for test were pipetted by the sampling probe into the various 
wells of the reaction vessel (RV). The sample, pretreatment solution, the line diluent, and SAH were 
pipetted into the one of the wells to make up the predilution mixture. The RV was immediately 
transferred into the processing centre by the processing probe. An aliquot of the predilution mixture, 
antibody, and solution 4 (line diluent) were transferred into the cuvette of the RV. Tracer, solution 4 and 
a second aliquot of the predilution mixture were transferred to the cuvette. SAH and labeled fluorescein 
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tracer compete for the sites on the monoclonal antibody molecule. The intensity of polarized fluorescent 
light was measured by the FPIA optical assembly. Further information can be obtained from the AxSYM 
System Operation Manual Section 3. 
 
2.2.5.2.4   Lipoprotein (a) 
Lipoprotein (a) was measured by a monoclonal anti-Lp (a) antibody technique using the human 
Gesellschak kit (Biochemica and Diagnostica Wiesbaden Germany). Assay was performed according to 
the manufacturer’s instructions. Lp (a) in the serum sample causes agglutination of latex particles coated 
with anti-Lp (a) antibodies. The agglutination is proportional to the Lp (a) concentration in the sample 
and can be measured by turbidimetry. The samples and controls were diluted 1:10 with normal saline. 
Dilutions of the Lp (a) standards were prepared using normal saline as the diluent and these were used 
directly for the assay. Normal saline was used as reagent blank. The concentration of Lp (a) standard was 
multiplied by the corresponding factor indicated in the table below to obtain the Lp (a) concentration of 
the dilution. The factor allows for the 1:10 dilution of the sample. 
 
                                  Table 2.2 Dilution factor for Lp (a) standards 
Dilution 1 2 3 4 5 6 
STD 
(µl) 
0 10 10 10 20 40 
Saline 
(µl) 
200 790 390 190 180 160 
Factor 0.0 0.125 0.25 0.5 1 2 
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Table 2.3 Lp (a) assay procedure  
 
          Sample and Reagents 
 
       Volume   
 
                    Remarks 
Diluted Sample  / Standard/ 
Saline diluent (blank) 
          30µl  
Buffer Solution         
        800µl         
        
Solution were mixed well and 
initial absorbance A1 (at 37oC) 
read after 10sec at 570nm 
 
Latex reagent 
        
         60µl 
 
 
This   was well mixed, and incubated at 37oC for 10 min before final absorbance 
A2 was read at 570nm.  
 
  
  
 
The absorbance difference ( A= A2– A1) of each standard dilution was calculated and the values plotted 
(Y-axis) against the respective Lp (a) concentrations (X- axis) lin-lin paper. The Lp (a) concentration in 
the undiluted sample was calculated by interpolation of its absorbance (A) on the calibration curve.  If 
the absorbance of the sample exceeded the absorbance of the highest standard, the sample was diluted 
1:20 with normal saline and the assay repeated using this diluted sample. The result obtained was 
multiplied by the dilution factor of 2. The normal range is up to 30 mg/L.  
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2.3 Statistics 
Data are reported as mean ± SEM.  Differences in means for continuous variables were compared using 
Student t-test while for categorical variables the Chi-squared (X2) test was used. Results are reported at 
95% Confidence Interval. The relationship between CIMT and CVD risk factors was tested by the 
generalized linear regression model using stepwise selection method. The generalized linear regression 
model was used because the variables entered into the models were a combination of both continuous and 
categorical variables.  
 
The generalized linear model can be used to predict responses both for dependent variables with discrete 
distributions and for dependent variables which are nonlinearly related to the predictors. This analysis 
was based on established risk factors for atherosclerosis in patients on dialysis like age, gender, smoking, 
systolic pressure, diastolic blood pressure, cholesterol, TG, HDL- Cholesterol, LDL- cholesterol, calcium 
phosphate product, albumin, Hs- CRP, Lp (a), and homocysteine.  
 
Significant independent variables were ordered according to their standardized effect, defined as 
regression coefficient (). Logistic regression analysis was used to determine risk factors associated with 
plaque occurrence.  All analysis was done using Stata version 8.0 statistical software (Stata Corporation 
2003). 
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CHAPTER 3 
RESULTS 
3.1 Demographic data of the study group 
In this cross-sectional study, 90 patients who had been on haemodialyisis for at least three months were 
recruited. Six died during the course of the study, two out of the six patients that died completed the 
study. Two patients were transplanted and two were transferred to another dialysis facility. Only 84 
patients were able to complete all aspects of the study and were thus included in the analysis. There were 
58 (69%) black patients and 26 (31%) non-black patients. There were 44 (52.4%) male and 40 (47.6%) 
female patients. The mean age for the male patients was 40.3 ± 1.68 years and 39.8 ± 1.53 years for the 
female patients. Table 3.1 shows the age distribution by gender and race. The black patients were older 
than the non-black patients, mean age for the black patients was 41.6 ± 1.25 years and 36.6 ± 2.27 years 
for the non-black patients p = 0.042. The mean age for the black female patients was 42.3 ± 1.63 years, 
and 35.7 ± 2.83 for the non-black female patients while for the black male patients mean age was 41.1 ± 
1.84 and 37.8 ± 3.88 years for non-black male patients. The mean duration of dialysis was 45.95 ± 4.92 
months (range 3 months to 192 months). Seventy-nine (94.05%) patients received erythropoietin therapy. 
The dose ranged from 2000IU weekly to 16,000IU per week. Twenty-seven patients (31.1%) had 
received a previous kidney transplant and 44.1% had peritoneal dialysis before being moved to 
haemodialysis. 
 
The controls were matched for age, sex and race. There were 30 (47.62%) male and 33 (52.38%) female 
subjects. The mean age for male controls was 40.5 ± 2.02 years; while for female controls was 39.4 ± 
1.84 years.  
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Table 3.1 Age distribution by gender and race 
 Age (years) 
  
Patients 
Mean ±SEM 
Controls 
Mean ± SEM 
t value 
 
p value 
 
N 84 63   
Black females 42.28 ± 1.63 42.00 ±2.30   0.10 NS 
Non-black females 35.73 ± 2.83 36.56 ± 2.80 −0.21 NS 
Black males 41.09± 1.84 41.67 ± 2.41 −0.19 NS 
Non-black males 37.82± 3.88 38.75 ± 3.61 −0.18 NS 
 
 
3.2 Aetiology of End-stage renal disease 
The causes of end-stage renal failure were hypertension in 43 (51.2%) patients, glomerulonephritis in 17 
(20.2%), chronic pyelonephritis/reflux nephropathy in 7 (8.33%), Lupus nephritis in 4(4.76%) patients, 
congenital abnormalities of the kidneys in 4 (4.76%) patients, polycystic kidney disease  in 2 (2.38%), 
miscellaneous causes like trauma in 1(1.19%), obstructive uropathy in 1 (1.19%), and unknown in 5 
patients (5.96%) Figure3.1. The congenital anomalies of the kidneys varied from horse-shoe shaped 
kidneys to dysplastic kidneys. When aetiology was analysed by race, 37 (63.8%) black patients had 
essential hypertension while only 6 (23.1%) non-black patients had essential hypertension. 
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Figure 3.1 Aetiology of ESRD in the study patients 
Abbreviations are: HTN, hypertension; GN, Glomerulonephritis; CP, Chronic pyelonephritis /reflux 
nephropathy; UKM, unknown; Lupus, Lupus Nephritis; CON ABN, Congenital anomalies; APKD, Adult 
polycystic kidney disease; MISC, Miscellaneous causes. 
 
3.3 Traditional Cardiovascular disease risk factors  
3.3.1 History of Cardiovascular disease  
Three white patients had a history of ischaemic heart disease. There was no history of cerebrovascular 
disease or peripheral vascular disease in the study population. Family history of myocardial infarction, 
diabetes mellitus, hypertension and chronic kidney disease were similar in both patients and controls 
(table 3.2). Almost half of the study participants (45.58%) reported a family history of hypertension in the 
first degree relatives, 21.77% reported history of diabetes, 16.33% reported history of myocardial 
infarction, 16.33% reported family history of CKD and only 6.8% did not report any history of these 
CVD risk factors in the family. 
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Table 3.2 Family history of CVD in the study population 
Positive family history Patients Controls Pearson X2 p value 
  N=84 N=63   
Myocardial infarction 11 (13.1%) 13 (20.63%) 1.50 0.221 
Hypertension  41 (48.81%) 26 (41.27%) 0.83 0.364 
Diabetes Mellitus 18 (21.43%) 14 (22.22%) 0.01 0.908 
Chronic kidney disease 5 (5.95%) 9 (14.29%) 2.90 0.089 
 
 
3.3.2 Hypertension  
Systolic blood pressure, diastolic blood pressure, pulse pressure and mean arterial pressure were 
significantly higher among patients compared to controls. Mean systolic blood pressure for the patients 
was 147.1 ± 1.98 mmHg versus 120 ± 1.68 mmHg for controls p< 0.001. Diastolic blood pressure was 
83.9 ± 1.44 mmHg in patients and 74.3 ± 1.30 mmHg in controls p< 0.001. Pulse pressure was 63.12 ± 
1.25 mmHg in patients and 45.79 ± 1.28 mmHg in controls p < 0.001 and the mean arterial pressure 
(MAP) was 105 ± 1.53 mmHg in patients compared with 89.6 ± 1.28 mmHg in controls p <0.001 (table 
3.3). Fifty-seven patients (79.76%) were being treated with various combinations of antihypertensive 
medications: angiotensin-converting enzyme (ACE) inhibitors N=46; calcium channel blockers N= 61;  
blockers N= 28;  blockers 14; [15 on monotherapy with either angiotensin-converting enzyme (ACE) 
inhibitors, calcium channel blockers, and beta blockers, 24 on double, 19 on triple, 8 on quadruple 
therapy and 1 patient on 5 drug-therapy with various combinations of these drugs). In addition most of 
the patients were on commonly used medications in ESRD such as phosphate binders, vitamin B, and D 
supplementation. Only one patient was on HMG-Co A – reductase inhibitor. 
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Table 3.3 Cardiovascular disease risk factors of the study population 
Risk factors Patients Controls t value p value 
  
 Mean ± SEM or %   Mean ± SEM or %  or X2   
  N = 84 N = 63   
Current smokers 18 (21.43%) 12 (19.05%) 4.48 NS 
Exercise 24 (28.57%) 30 (47.62%) 5.62 0.018 
BMI (kg/m2 24.45 ± 0.55 25.48 ± 0.58 − 1.28 NS 
Systolic BP (mmHg) 147.1 ± 1.98 119.9 ± 1.69 10.01 < 0.001 
Diastolic BP (mmHg) 83.9 ± 1.45 74.3 ± 1.26 4.84 <0.001 
Pulse pressure (mmHg) 63.12 ± 1.25 45.79 ± 1.28 9.50 <0.001 
MAP (mmHg) 105 ± 1.53 89.6 ± 1.28 7.37 <0.001 
Total Cholesterol (mmol/L) 3.73 ± 0.08 4.97 ± 0.16 −7.25 < 0.001 
Triglyceride (mmol/L) 1.25 ± 0.08 1.57 ± 0.13 −2.11 0.04 
HDL-Cholesterol (mmol/L 1.18 ± 0.04 1.28 ± 0.05 −1.72 NS 
LDL- Cholesterol (mmol/L) 1.98 ± 0.07 2.94 ± 0.15 − 6.39  < 0.001 
Carotid IMT (mm) 0.65± 0.02 0.61 ± 0.02 1.50 NS 
Hs-CRP (mg/L) 8.06 ± 1.31 2.27 ± 0.34 3.73 < 0.001 
Homocysteine mol/L 20.22± 0.70 9.16 ± 0.48 12.38 < 0.001 
Adiponectin (g/L) 22.19 ± 0.98 9.93 ± 0.68 9.63 < 0.001 
Lipoprotein(a) (mg/dl) 43.31 ± 4.13 42.1 ± 4.77 0.19 NS 
LVH 69(82.14%) 11 (17.5%) 60.72 <0.001 
Plaques 32 (38.1%) 5 (7.93%) 17.39 <0.001 
 
3.3.3 Body Mass Index  
BMI was similar in both patients and controls with a mean BMI of 24.45 ± 0.55 kg/m2 in patients 
compared with 25.48 ± 0.58 kg/m2 in controls; p = 0. 204. (Table 3.3)  
 
3.3.4 Smoking and Physical activity  
There was no difference in the number of smokers between patients and controls. Eighteen patients 
(21.43%) reported as current smokers while 25 (29.76%) had smoked before. Among the controls, 12 
subjects (19.05%) are current smokers while 35 (23.81%) had smoked before. In terms of physical 
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activity, more controls did exercise compared with patients, 30 (47.62%), versus 24 (28.57%) Pearson X2 
5.62; p =0.018.  
 
3.3.5 Serum Lipids 
The patients had significantly lower serum total cholesterol, LDL cholesterol level and triglyceride levels 
compared with controls p < 0.001 and p= 0.04 respectively (table 3.3). Although the haemodialyisis 
patients had lower HDL–cholesterol compared to controls, this was not statistically significant.  
 
3.3.6 Left Ventricular Hypertrophy 
The prevalence of left ventricular hypertrophy was significantly higher in the patients compared with the 
controls (82.14 % versus 17.5% X2 = 60.72, P < 0.001) table 3.3 and figure 4.2. Of these patients, 86.5% 
(64 patients) had concentric LVH, 6.75% eccentric LVH and 6.75% had dilated cardiomyopathy 
(DCMO) figure 4.3. Seventeen patients (20.24%) had systolic dysfunction, 54 (65.06%) diastolic 
dysfunction; while none of the control subjects had systolic dysfunction and only 7 (11.48%) had 
diastolic dysfunction. This difference was statistically significant Pearson X2 = 14.42; p< 0.001: X2 = 
41.35; p <0.001 respectively). The LVMI was significantly higher in haemodialyisis patients compared to 
controls mean LVMI was 194.25 ± 7.69 gm/m2 in patients versus 93.21± 3.27 gm/ m2   in the controls p< 
0.001.  Ejection fraction was significantly lower in haemodialyisis patients compared with controls 
(60.88 ± 1.28 versus 67.36 ± 0.81 p< 0.001 (table 3.4). Risk factors associated with LVMI in the study 
population were male gender, diastolic blood pressure (BP), presence of CKD, smoking, adiponectin and 
presence of plaques R2= 0.67 (table3.5). Male subjects had higher LVMI by 25.58gm/m2 while adjusting 
for the other risk factors.  Haemodialyisis patients had higher LVMI by 56.14gm/m2 compared with 
controls when all other risk factors are adjusted for. Patients with plaques also had higher LVMI by 45.64 
gm/m2. Smoking was also associated with a higher LVMI. When the control subjects were taken out of 
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the model (that is looking at the haemodialyisis patients alone), the risk factors retained their significance. 
However in a model which looked at only the control subjects, the factors associated with LVMI were 
age and male gender. Seven patients (8.33%) had calcification of their heart valves. 
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                              Figure 3.2 Prevalence of LVH in the study population 
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Figure 3.3 Distribution of the different types of LVH in haemodialysis patients  
Abbreviation: DCMO, Dilated cardiomyopathy. 
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   Table 3.4 Echocardiographic values for the study population 
Variables Patients Controls t value p value 
  
 Mean ± SEM or 
%  
 Mean ± SEM or 
%  or X2   
  N = 84 N = 63   
IVSd (cm) 1.41 ± 0.33 1.07 ± 0.20 4.475 <0.001 
PWTd (cm) 1.28 ±0.03 0.92 ± 0.02 9.49 <0.001 
LVIDd (cm) 4.90 ± 0.09 4.31 ± 0.06 5.12 <0.001 
LVM (gm) 334.48 ± 14.57 168.15 ± 7.11 9.28 < 0.001 
LVMI (gm/m2) 194.25 ± 7.69 93.21± 3.27 10.93 <0.001 
FS (%) 33.09 ± 0.87 37.45 ± 0.68 −3.73 <0.001 
EF (%) 60.87± 1.28 67.36 ± 0.81 − 3.96 <0.001 
Diastolic 
dysfunction 54 (65.06%) 7 (11.48%) 41.35 < 0.001 
Systolic 
dysfunction 17 (20.24%) 0 (0%) 14.42 <0.001 
 
 
  Table 3.5 Risk factors associated with LVMI in the study population (Patients and controls) (R2 = 
0.67) 
LVMI 
  
Coefficient 
 
 
t value 
 
p value 
 
95%Confidence interval 
 
Plaque/no plaques 45.642 4.96 <0.001 25.433        63.851 
Male/Female − 25.577 −3.22 0.002     − 41.302       − 9.852 
Diastolic BP 1.640 5.28 <0.001 1.025          2.254 
Patients/controls −56.137 −5.54 <0.001 −76.176       −36.099 
Adiponectin 1.468 3.01 0.003 0.504           2.433 
Smoker/non smoker − 34.421 −3.73 <0.001 − 52.668      −16.174 
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  Table 3.6 Risk factors associated with LVMI in haemodialysis patients (R2 = 0.48) 
LVMI 
  
Coefficient  
 
t value 
 
p value 
 
95%Confidence interval 
 
Smoker/Non 
smoker −50.140 −3.57 0.001 −78.100      −22.180 
Male/female − 39.951 −3.05 0.003 − 66.067     − 13.836 
Plaque/No plaques 50.72 4.09 <0.001 25.997        75.444 
Adiponectin 1.463 2.21 0.030 0.146          2.780 
Diastolic BP 1.835 4.08 <0.001 0.941          2.730 
 
 
 Table 3.7 Regression model of risk factors for LVMI in the control group 
(R2 = 0.30) 
LVMI Coefficient  t value p value 95%Confidence interval 
  
        
Age 1.146 4.38 <0.001        0.622       1.669 
Male/female −13.104 −2.35 0.022    −24.259    −1.949 
 
 
3.4 Non-traditional Cardiovascular disease risk factors 
3.4.1 Inflammatory markers 
The serum Hs-CRP levels were much higher in haemodialysis patients compared to controls with a mean 
level of 8.06 ± 1.31 mg/L in patients and 2.27 ± 0.34 mg/L in controls. Patients were divided into two 
groups according to Hs-CRP levels: CRP < 5 mg/L (N = 49), CRP  5 mg/L (N= 35). The patients who 
had abnormal Hs- CRP levels had significantly higher total cholesterol and LDL-Cholesterol levels; and 
lower serum albumin and haemoglobin levels (table 3.8). Seventeen patients (48.57%) with Hs-CRP > 5 
mg/L had plaques while 15 (30.61%) of patients with Hs-CRP < 5mg/L had plaques this difference was 
of borderline significance X2 =3.71, p = 0.054. CIMT was similar in both groups. Only 8 controls had 
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Hs-CRP levels > 5mg/L. None of them had plaques and 4 of these patients had LVH. In a linear 
regression model, Hs-CRP was associated with higher CIMT and high homocysteine levels.  
 
Table 3.8 CVD risk factors in patients with normal and abnormal Hs-CRP 
Risk factors 
Patients with N 
CRP Patients with Abn CRP t value p value 
  Mean ± SEM or % Mean ± SEM or % or X2   
  N = 49 N = 35   
Gender M/F 26/23 22/13 0.80 NS 
Age (years) 40.14 ± 1.47 39.94 ± 1.81 0.87 NS 
BMI (kg/m2 23.88 ± 0.59 25.24 ± 0.89 −1.22 NS 
S BP (mmHg) 146.43 ± 2.89 147.94 ± 2.51 0.38 NS 
DBP (mmHg) 83.86 ± 1.98 84.06 ± 2.12 −0.07 NS 
Total Cholesterol (mmol/L) 3.52 ± 0.11 4.03 ± 0.65 −3.13 0.002 
Triglyceride (mmol/L) 1.24 ±0.12 1.27 ± 0.11 − 0.17 NS 
HDL-Cholesterol (mmol/L 1.16± 0.04 1.20 ± 0.06 −0.37 NS 
LDL- Cholesterol (mmol/L) 1.79 ± 0.09 2.25 ± 0.10 − 3.13 0.002 
Albumin gm/L 40.67±0.51 38.37± 0.69 2.68 0.009 
Calcium mmol/L 2.26 ± 0.03 2.39 ± 0.05 − 2.37 0.020 
Phosphate mmol/L 1.50±0.07 1.62 ± 0.09 −1.04 NS 
Calcium x Phosphate 3.39± 0.16 3.88 ± 0.24 −1.79 NS 
Parathyroid hormone 579.31 ± 65.49 523.67 ± 87.70 −0.54 NS 
Haemoglobin 9.89 ± 0.19 8.89± 0.26 3.18 0.002 
Carotid IMT (mm) 0.65± 0.12 0.66 ± 0.03 −0.37 NS 
Homocysteine mol/L 19.44 ± 0.73 21.29 ± 1.30 −1.21 NS 
Adiponectin (mol/L) 22.63 ± 1.29 21.57 ± 1.52 0.53 NS 
Lipoprotein(a) (mg/dl) 43.26 ± 5.30 43.37 ± 6.65 −0.01 NS 
Abbreviation: N CRP, normal CRP. Abn CRP, abnormal CRP. 
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3.4.2 Adiponectin 
Serum adiponectin levels were significantly higher in patients compared with controls. Mean level of 
22.19 ± 0.98 g/mL in patients and 9.93 ± 0.68 g/mL in control subjects p< 0.001. Patients who were 
completely anuric had the highest levels of serum adiponectin. On multivariate analysis, risk factors 
found to be associated with serum adiponectin levels in the study population were total cholesterol, 
triglycerides, and LDL- cholesterol (table 3.9). Adiponectin had a significant inverse relationship with 
serum triglyceride (figure 3.4) and LDL levels. Adjusting for these, adiponectin was significantly higher 
in patients by an average of 13.1g/mL P< 0.001. Among the haemodialysis patients, risk factors found 
to be associated with adiponectin were total cholesterol, triglycerides, LDL-Cholesterol and LV 
dysfunction. Serum triglyceride and LDL-Cholesterol were inversely associated with adiponectin table 
3.10.  When race was fixed into the model, these factors still remained significant with no evidence of a 
race effect. Serum adiponectin was higher in female subjects compared with the male subjects but this 
difference was not significant. Mean level was 23.09 ± 1.37g/ml for female patients and 21.37 ± 1.39 
g/mL for male patients p = 0.383. Among the controls, the female controls had a mean level of 11.15 ± 
0.86 g/ml while for the male controls the mean was 8.60 ± 1.02 g/ml p = 0.059. 
 
 
Table 3.9 Risk factors found to be significantly associated with Adiponectin  
in the study population (generalized linear regression model) (R2 = 0.47) 
Adiponectin Coefficient  t value p value 95%Confidence interval 
  
    
Triglyceride −4.872 −4.68 <0.001 −6.929            − 2.815 
LDL cholesterol −4.617 −2.68 0.008 −8.020            − 1.214 
Patients/controls −13.145 −9.21 <0.001 −15.967          −10.323 
Total cholesterol 5.186 3.06 0.003 1.838                8.534 
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Table 3.10 Factors associated with adiponectin in haemodialysis patients  
(R 2 = 0.32) 
Adiponectin Coefficient  t value p value 95%Confidence interval 
  
    
Total cholesterol 7.564 2.9 0.005    2.359         12.768 
LDL cholesterol −8.939 −3.09 0.003 −14.697     − 3.181 
Triglyceride −7.107 −4.93 <0.001 −9.978       − 4.235 
Diastolic dysfunction 5.357 2.8 0.007 1.543          9.171 
Systolic dysfunction 5.781 2.5 0.001 1.165         10.396 
 
 
 
Figure 3.4 Regression of serum adiponectin and triglyceride in the study population. 
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3.4.3 Homocysteine  
Plasma homocysteine levels were higher in patients compared to controls P < 0.001 Table 3.3. Using 
stepwise regression model, risk factors found to be associated with plasma homocysteine levels in both 
patients and controls were: high levels of Hs-CRP, increasing age, and increase in total cholesterol. 
Adjusting for these, homocysteine was higher in haemodialysis patients (P< 0.001) by an average of 11.6 
mol/L table 3.11. In another regression model, looking at haemodialyisis patients alone, homocysteine 
was associated with Hs-CRP and age and inversely associated with adiponectin levels however this was a 
poor model as adjudged by the R2 of 0.19. When race was fixed into the model, these factors remained 
significant with no evidence of a race effect table 3.12. 
 
Table 3.11 Risk factors found to be significantly associated with plasma homocysteine levels in the 
study population (R2 = 0.57) 
Homocysteine Coefficient  t value p value 95%Confidence interval 
  
    
Hs-CRP 0.117 2.53 0.013 0.026         0.209 
patients/controls −11.629 −10.98 <0.001    − 13.725      − 9.534 
Age 0.898 2.2 0.029 0.009          0.170 
Total cholesterol 1.096 2.45 0.015 0.213         1.978 
 
Table 3.12 Factors associated with homocysteine in haemodialyisis patients 
 (R2 = 0.19) 
Homocysteine Coefficient  t value p value 95%Confidence interval 
  
    
Blacks/non Blacks 0.626 0.41 0.684 −2.429       3.682 
Hs-CRP 0.119 2.21 0.030 0.012       0.226 
Adiponectin − 0.195 −2.56 0.012 −0.346    −0.043 
Age 0.160 5.21 0.021 −0.025      0.295 
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Figure 3.5 Regression of homocysteine with age 
 
 
 
3.4.4 Lipoprotein (a) 
 
 Serum lipoprotein (a) levels showed marked variability among patients and controls. Mean levels were 
similar in both haemodialyisis patients and controls p= 0.848 (Table 3.3). Elevated Lp (a) concentrations 
(>30mg/dl) were observed in 52.4% of patients and 49.2% of controls. On regression analysis, Lp (a) 
concentration was significantly associated with serum adiponectin levels, total cholesterol and inversely 
associated with age. The R2 indicates that only 19% of the variability in lipoprotein can be explained by 
this model. Black subjects had significantly higher Lp (a) by an average of 26.01mg/dl. 
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Table 3.13 Risk factors associated with serum Lp (a) levels (R2 = 0.19) 
Lipoprotein (a) Coefficient  t value p value 95%Confidence interval 
  
    
Total cholesterol 9.733 3.44 0.001    4.141        15.326 
Age −0.795 −2.79  0.006 −1.359      − 0.231 
Blacks/non blacks −26.011 −3.98 <0.001 −38.933   − 13.090 
Adiponectin 1.137 3.61 <0.001  0.515        1.759 
 
 
3.5     Carotid-intima media thickness 
The mean carotid intima media thickness (CIMT) was higher in haemodialysis patients compared with 
controls. Mean CIMT was 0.65 ± 0.02 mm in patients and 0.61± 0.02mm in controls, however this 
difference was not statistically significant (p = 0.137) Table 3.3. Complete measurements of the far wall 
for all the segments were available. Measurements were not complete for the near wall in 34.69% of the 
study population. The highest CIMT measurements were at the birfurcation in both groups. The 
haemodialysis patients had significantly higher CIMT measurements at this segment on both sides (table 
3.14). Risk factors found to be associated with CIMT in a regression model in both subjects and controls 
were total cholesterol, LDL cholesterol, Hs-CRP, age, and family history of CKD (table 3.15). CIMT was 
positively associated with age, serum LDL-Cholesterol, Hs-CRP and family history of CKD. Adjusting 
for all these, controls had slightly lower CIMT (0.02mm) but insignificant (p=0.42). There was an inverse 
relationship between total cholesterol and CIMT. 
 
On univariate analysis looking at some dialysis related factors in haemodialysis patients alone, there was 
no relationship between CIMT and the length of time patient has been on dialysis, serum calcium or 
calcium/phosphate product (r = 0.05; p = 0.542). On multivariate analysis risk factors found to be 
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associated with CIMT in haemodialyisis patients were Hs-CRP and family history of CKD. After 
adjusting for these, there was no significant difference between the races Table 3.16. 
 
Table 3.14 The IMT measurements at the various carotid segments 
Carotid segment  Patients Controls t value p value 
 (far wall only) 
Mean ± SEM or 
% 
Mean ± SEM or 
% or X2  
  N = 84 N = 63   
CIMT (mm) 0.65 ± 0.02 0.61 ± 0.02 1.50 NS 
LCCA (mm) 0.65 ± 0.02 0.61 ± 0.02 1.50 NS 
RCCA (mm) 0.65 ± 0.02 0.61 ± 0.02 1.50 NS 
LBIF (mm) 0.78 ± 0.04 0.67 ± 0.03 2.26 0.025 
RBIF (mm) 0.77 ± 0.03 0.68 ± 0.03 1.94 0.053 
RICA (mm) 0.61 ± 0.02 0.57 ± 0.02 1.42 NS 
LICA (mm) 0.58 ± 0.02 0.60 ± 0.03 − 0.56 NS 
 
Table 3.15 Risk factors associated with CIMT in both patients and controls 
CIMT 
  
Coefficient  
 
t value 
 
p value 
 
95%Confidence interval 
 
Cases/controls −0.023 −0.80 0.424     −0.079             0.033 
Total cholesterol 0.050   −1.97 0.051     −0.101             0.000 
LDL cholesterol 0.053 1.92 0.057     −0.002             0.107 
Age 0.006 5.46 0.001  0.004               0.008 
Hs-CRP 0.003 2.41 0.017 0.000              0.005 
Family history of CKD 0.131 3.37 0.001 0.054              0.209 
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Figure 3.6 Regression of CIMT and age in the study population 
 
 
Table 3.16 Risk factors associated with CIMT in haemodialysis patients only 
CIMT 
 
 
Coefficient  
 
t value 
 
p value 
 
95%Confidence interval 
 
Blacks/non-blacks      −0.380  −1.11 0.273   −0.106              0.030 
Hs-CRP 0.003 2.44 0.017 0.000             0.006 
Family history of CKD 0.231 3.62 0.001 0.104             0.358 
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3.6 Carotid artery plaques 
 The prevalence of plaques in the carotid arteries was significantly higher in haemodialysis patients 
(38.1%) compared with controls (7.93%). Majority of the patients (90.48%) had plaques at more than one 
site. Most of the plaques (> 85%) were found at the bifurcation and internal carotid arteries. As expected 
most of the dialysis patients, (29) had calcified plaques, 2 had soft plaques and 1 had mixed plaque while 
all control subjects had soft plaques and all occurring at only 1 site. The plaque score ranged from 1.1mm 
to 18.8mm with a median score of 5.13mm in patients and median score of 1.3 mm in controls (1.2-
2.0mm). When we compared patients who had plaques with those who did not have plaques, 
haemodialyisis (HD) patients who had plaques were older, there were more male patients, and they had 
been on haemodialyisis for a much longer duration. They had significantly higher systolic BP (154 .38 ± 
2.86 mmHg versus 142.56 ± 2.49 mmHg p= 0.003), and MAP but diastolic blood pressure was similar 
(DBP) (85.97 ± 2.19 versus 82.69 ± 1.90 mmHg; p = 0.274) table 3.17. The lipid parameters were similar 
in the two groups. As expected the CIMT in those patients with plaques was significantly higher than in 
those patients with out plaques. There were more smokers among patients with plaques compared with 
those without plaques. The prevalence of LVH was similar in both groups. The HD patients with plaques 
had higher Hs-CRP levels although this was not statistically significant (p= 0.381). The mean Kt/V was 
similar in both groups mean level of 1.33 ± 0.04 in patients without plaques and 1.28 ± 0.04 in patients 
with plaques. Logistic regression analysis showed that age, male gender, smoking, systolic blood 
pressure, serum phosphate and calcium phosphate product were significantly associated with plaque 
occurrence table 3.18.  
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Table 3.17  CVD risk factors in haemodialyisis patients with and without plaques 
 
Risk factors 
Patients with 
plaques Patients without plaques t value p value 
  Mean ± SEM or % Mean ± SEM or % or X2  
  N =32 N = 52   
Gender M/F 22/10 (68.75%) 22/30 (42.31%) 5.55 0.018 
Current smokers 11 (34.38%) 7 (13.46%) 5.15 0.023 
Exercise 8 (25%) 16 (30.77%) 0.57 NS 
Age (years) 45.8 ± 1.56 36.6 ± 1.36 4.33 <0.001 
BMI (kg/m2 24.24± 0.59 24.58 ± 0.81 −0. 29 NS 
HD Duration (months) 59.38± 7.85 37.69± 6.08 2.19 0.031 
S BP (mmHg) 154.4±2.86 116.1 ± 2.66 3.04 0.003 
DBP (mmHg) 86 ± 2.19 71.8 ± 1.68 1.1 NS 
PP (mmHg) 68.41±2.08 59.87 ± 1.38 3.56 <0.001 
MAP (mmHg) 108.8 ± 2.23 102.7± 2.01 1.97 0.052 
Cholesterol (mmol/L) 3.72 ± 0.17 3.74 ± 0.09 −0.11 NS 
Triglyceride (mmol/L) 1.15 ±0.14 1.32 ± 0.10 − 0.96 NS 
HDL (mmol/L) 1.18 ± 0.06 1.18 ± 0.05 0.07 NS 
LDL (mmol/L) 2.01 ± 0.14 1.98 ± 0.08 0.21 NS 
Albumin gm/L 39.22±0.55 39.98± 0.62 − 0.85 NS 
Calcium mmol/L 2.37± 0.05 2.28 ±0.03 1.44 NS 
Phosphate mmol/L 1.54±0.10 1.55 ± 0.07 −0.06 NS 
Calcium x Phosphate 3.67 ± 0.25 3.55 ± 0.17 0.43 NS 
Parathyroid hormone 457.85 ±79.49 616.6 ± 65.36 −1.53 NS 
Haemoglobin 9.40±0.25 9.54 ± 0.22 − 0.42 NS 
Carotid IMT (mm) 0.70± 0.04 0.62 ± 0.01 2.42 0.018 
Hs-CRP (mg/L) 9.53 ± 1.90 7.15 ± 1.76 0.88 NS 
Homocysteine mol/L 20.43± 1.02 20.09 ± 0.94 0.14 NS 
Adiponectin (mol/L) 22.86 ± 1.61 21.78 ± 1.24 0.54 NS 
Lipoprotein(a) (mg/dl) 39.88 ± 6.01 45.42 ± 5.57 0.65 NS 
LVH 22(68.75%) 42 (80.77%) 2.79 NS 
 
Abbreviation: SBP is systolic blood pressure, DBP is diastolic blood pressure, PP is pulse pressure, MAP 
is mean arterial pressure, and HD duration is duration on dialysis,  
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Table 3.18 Risk factors associated with plaque occurrence 
 
Plaque Odds Ratio z p value 95%Confidence interval 
  
    
Age 1.167 3.64 0 1.073           1.267 
Systolic BP 1.036 1.98 0.048 1.000           1.072 
Male/female 0.259 −1.95 0.051 0.067           1.005 
Phosphate 0.009 −1.92 0.055 0.000           1.116 
Calcium x phosphate 8.248 2.17 0.03 1.224           55.568 
Smoker/non smoker 8.097 2.53 0.011 1.606           40.805 
 
 
 
3.7 Cardiovascular risk factors by race 
 
When the black patients were compared with the non-black patients with respect to cardiovascular risk 
factors, the black patients were older and had significantly lower total cholesterol and triglyceride levels 
compared with the non-black patients. Mean cholesterol was 3.61 ± 0. 10mmol/L in blacks and 4.00 ± 
0.14 mmol/L in non-blacks, p= 0.030; mean triglyceride of 1.04 ± 0.08mmol/L in black patients and 1.74 
± 0.17 mmol/L in non-blacks p <0.001 (table 3.19).  
 
The serum lipoprotein was significantly higher in the black patients compared with the non-black 
patients.  Mean lipoprotein level (a) was 49.25 ± 5.04 mg/dl in the blacks versus 30.05 ± 6.57 mg/dl in 
the non-black patients p = 0.031. Black patients had significantly higher adiponectin levels when 
compared with the non-black patients (23.55 ± 1.14 µg/mL versus 19.15 ± 1.77 g/mL p=0.037). 
 
 Systolic blood pressure, diastolic blood pressure, HDL-cholesterol, LDL cholesterol, plasma 
homocysteine level was similar in both groups. The non-black patients had slightly higher Hs-CRP levels 
but this difference was not significant table 3.19.  The black patients did less exercise compared with the 
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non-black patients. Prevalence of smoking was higher among the non-black patients (26.9%) compared 
with black patients (18%) but this difference was not statistically significant X 2 =0.29 p= 0.592. 
 
In a sub analysis comparing CIMT by race in all the groups, the black subjects (patients and controls) had 
higher CIMT compared with the non-black subjects but this difference was not significant. Mean CIMT 
in black patients was 0.66 ± 0.17mm vs. 0.63 ± 0.14mm in the non-black patients table 3.19; 0.64mm ± 
0.13 in black controls vs. 0.59 ± 0.17mm in non-black controls table 3.20.  
 
The prevalence of atherosclerotic plaques was slightly higher in the non-black patients (42.3%) than in 
the black patients (36.2%) although not significant table 3.19. There was no difference in occurrence of 
LVH in both groups.  
 
Among the control groups, the black controls had significantly higher systolic BP (p=0.042) than the non-
black subjects but no significant difference in the diastolic BP. The black controls had significantly lower 
total cholesterol, HDL cholesterol and homocysteine levels (p = 0.003, p = 0.006, p = 0.035 respectively) 
but had higher lipoprotein (a) p = 0.056 (Table 3.20). More black controls (25.7%) had LVH than whites 
(7.14%), this difference was of borderline significance X2 3.72 p = 0.054. Prevalence of plaques was 
similar in both groups.  
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Table 3.19 Comparison of CVD risk factors in black and non-black haemodialyisis patients 
 
Risk factors Black Patients Non-black patients t value p value 
  Mean ± SEM or % Mean ± SEM or % or X2  
  N = 58 N = 26   
Gender M/F 33/25 (56.9%) 11/15 (42.31%) 1.53 NS 
Age (years) 41.6± 1.25 36.6± 2.27 2.07 0.042 
Current smokers 11 (18.97%) 7 (26.92%) 0.29 NS 
Exercise 13 (22.41%) 11 (42.31%) 3.48 0.062 
BMI (kg/m2 24.73 ± 0.55 25.48 ± 0.58 − 1.28 NS 
Systolic BP (mmHg) 148.9 ± 2.36 143.0 ± 3.56 1.37 NS 
Diastolic BP (mmHg) 85.7 ± 1.70 80.1 ± 2.63 1.81 NS 
Pulse pressure (mmHg) 63.19 ± 1.53 62.96 ± 2.17 0.08 NS 
MAP (mmHg) 106.74 ± 1.80 101.06 ± 2.80 1.67 NS 
Total Cholesterol (mmol/L) 3.61 ± 0.10 4.00 ± 0.14 −2.21 0.03 
Triglyceride (mmol/L) 1.04 ± 0.08 1.74 ± 0.17 − 4.32 <0.001 
HDL-Cholesterol (mmol/L 1.21 ± 0.04 1.10 ± 0.07 1.31 NS 
LDL- Cholesterol (mmol/L) 1.93 ± 0.09 2.09 ± 0.13 − 1.01 NS 
Carotid IMT (mm) 0.66± 0.02 0.63 ± 0.03 0.68 NS 
Hs-CRP (mg/L) 7.26 ± 1.29 9.85 ± 3.13 −0.92 NS 
Homocysteine mol/L 20.20 ± 0.72 20.26 ± 1.58 −0.04 NS 
Adiponectin (mol/L) 23.55 ± 1.14 19.15 ± 1.77 2.12 0.037 
Lipoprotein(a) (mg/dl) 49.25 ± 5.04 30.05 ± 6.57 2.20 0.031 
LVH 49 (84.48%) 20 (76.92%) 0.70 NS 
Plaques 21 (36.21%) 11 (42.31%) 0.28 NS 
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Table 3.20 CVD characteristics in black and non-black controls 
Risk factors Black controls Non-black controls t value p value 
  
Mean ± SEM or 
% Mean ± SEM or % or X2  
  N =35 N = 28   
Gender M/F 18/17 (51.43%) 12/16 (42.88%) 0.46 NS 
Current smokers 5 (14.29%) 7 (25%) 1.16 NS 
Exercise 12 (34.29%) 18 (64.29%) 5.61 0.018 
Age (years) 41.8± 1.65 37.5 ± 2.19 1.61 NS 
BMI (kg/m2 25.98 ± 0.85 24.84 ± 0.74 0.984 NS 
Systolic BP (mmHg) 123 ± 2.05 116.1 ± 2.66 2.076 0.042 
Diastolic BP (mmHg) 76.3 ± 1.78 71.8 ± 1.68 1.807 NS 
Pulse pressure (mmHg) 46.97 ± 1.61 44.32 ± 2.07 1.026 NS 
MAP (mmHg) 91.94 ± 1.72 86.56 ± 1.81 2.143 0.036 
Total Cholesterol (mmol/L) 4.55 ± 1.72 5.49 ± 0.22 −3.046 0.003 
Triglyceride (mmol/L) 1.58 ±0.18 1.55 ± 0.19 0.137 NS 
HDL-Cholesterol (mmol/L 1.16 ± 0.04 1.44 ± 0.09 − 2.854 0.006 
LDL- Cholesterol (mmol/L) 2.71 ± 0.20 3.24 ± 0.20 − 1.832 NS 
Carotid IMT (mm) 0.64± 0.02 0.59 ± 0.03 1.315 NS 
Hs-CRP (mg/L) 2.30 ± 0.49 2.23 ± 0.47 0.112 NS 
Homocysteine mol/L 8.26 ± 0.46 10.28 ± 0.88 −2.160 0.035 
Adiponectin (mol/L) 9.09 ± 0.97 10.99 ± 0.91 −1.401 NS 
Lipoprotein(a) (mg/dl) 50.21 ± 6.45 31.96 ± 6.71 0.192 0.056 
LVH 9 (25.7%) 2 (7.14%) 3.723 0.054 
Plaques 3 (8.57%) 2 (7.14%) 0.043 NS 
 
 
3.8 Cardiovascular risk factors based on previous kidney transplant status 
Table 3.21 shows the comparison of cardiovascular risk factors in haemodialysis patients who have had a 
failed transplant and have returned to dialysis. The only significant findings were a higher systolic and 
diastolic blood pressure among patients who have never been transplanted. The patients who have had a 
previous failed transplant had significantly higher LDL cholesterol levels compared with those who did 
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not (2.16 ± 0.14mmol/L versus 1.90 ± 0.09mmol/L, t = 7.87 p <0.000). CIMT, LVMI and prevalence of 
plaques were similar in both groups.  
 
 
Table 3.21 Comparison of CVD risk factors among patients with and 
without previous failed kidney transplant 
CVD risk factors 
Previous kidney 
transplant 
No kidney 
transplant t-value/X2 p value 
  Mean ± SEM or % Mean ± SEM or %     
  N = 27 N = 57     
CIMT (mm) 0.62 ± 0.02 0.67 ± 0.02 – 1.12 NS 
LVMI gm/m2 194.5 ± 13.1 194.1 ± 9.27 0.02 NS 
Plaques 13 (48.2%) 19 (33.3%) 1.68 NS 
Total cholesterol 
(mmol/L) 3.89 ± 0.15 3.65 ± 0.10 1.32 NS 
Triglyceride (mmol/L) 1.48 ± 0.18 1.15 ± 0.09 1.92 0.058 
HDL cholesterol 
(mmol/L) 1.05 ± 0.04 1.24 ± 0.05 – 0.74 NS 
LDL cholesterol 
(mmol/L) 2.16 ± 0.14 1.90 ± 0.09 7.87 <0.001 
Systolic BP (mmHg) 139.5 ± 3.07 150.6 ± 2.40 – 2.72 0.008 
Diastolic BP (mmHg) 79.6± 2.30 86 ± 1.78 – 2.09 0.04 
Hs-CRP (mg/L) 9.18 ± 2.72 7.53 ± 1.45 0.59 NS 
Lipoprotein (a) (mg/dl) 37.12 ± 6.76 46.24 ± 5.16 – 1.03 NS 
Homocysteine (mol/L 21.44 ± 1.40 19.76 ± 0.77 1.14 NS 
Adiponectin (mol/L) 20.83 ± 1.67 22.83 ± 1.21 – 0.95 NS 
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3.9 CVD risk factors in black patients; comparison of essential hypertensive black 
patients with non-essential hypertensive black patients 
 
The black patients were divided into two groups based on aetiology of ESRF. There were 37 patients 
with essential hypertension as the cause of ESRD and 21 patients with other causes of ESRF (non-
essential hypertension. Table 3.22 shows a comparison of the CVD risk factors in the groups. The 
patients with essential hypertension were older ( mean age of 43.8 ± 1.4years vs 37.8 ± 2.2yrs), had 
significantly higher total cholesterol, LDL-cholesterol and higher homocysteine levels compared with 
non-essential hypertensive group. The essential hypertensive group also had significantly lower 
adiponectin levels. The prevalence of plaques was significantly higher in the essential hypertensive group 
(46% vs 19.1% uncorrected X2 = 4.12, p = 0.042) however when this was corrected for the small 
numbers, there was no significant difference. Hs-CRP, LVMI and BMI were similar in both groups.  
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Table 3.22    Comparing CVD risk factors by aetiology in black patients  
  
   
  
CVD risk factors 
Essential 
hypertension Non-essential hypertension t value p value 
  n = 37 n = 21 or X 2   
  Mean ± SEM or % Mean ± SEM or %     
age (years) 43.8 ± 1.43 37.8 ± 2.17 2.37 0.021 
BMI (kg/m2) 25.10 ± 0.85 24.09 ± 1.19 0.7 NS 
Total cholesterol (mmol/L) 3.79 ± 0.4 3.30 ± 0.10 2.42 0.019 
Triglyceride (mmol/L) 1.06 ± 0.10 0.99 ± 0.14 0.45 NS 
HDL-cholesterol (mmol/L) 1.25 ± 0.06 1.15 ± 0.05 1.06 NS 
LDL-cholesterol (mmol/L) 2.06 ± 0.12 1.70 ± 0.10 1.98 0.053 
CIMT (mm) 0.66 ± 0.03 0.66 ± 0.02 0.03 NS 
Adiponectin (mol/L) 21.49 ±1.51 27.18 ± 1.38 -2.51 0.015 
Lipoprotein (a) (mg/dl) 44.44 ± 5.45 57.73 ± 10.02 -1.27 NS 
Homocysteine (mol/L) 21.51 ± 0.85 18.21 ± 1.19 2.28 0.026 
Hs-CRP (mg/L) 7.16 ± 1.78 7.42 ± 1.73 -0.09 NS 
LVMI (kg/m2) 192.82 ± 11.98 24.09 ± 1.19 -0.59 NS 
Plaques ** 17 ( 46) 4 ( 19.1) 4.12 0.042 
 
    
** Yates corrected X 2 value = 3.11, p = 0.078    
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CHAPTER 4 
 
DISCUSSION 
 
Cardiovascular disease is a leading cause of death in haemodialyisis patients. One of the reasons for this 
high CVD mortality in haemodialyisis patients is due to a high prevalence of both traditional and non-
traditional risk factors for CVD present in this patient population. There are three distinct types of CVD 
that are highly prevalent in patients with CKD, all of which lead to poor outcomes. These include 
alterations in cardiac geometry (LVH), atherosclerosis and arteriosclerosis. This study was carried out to 
evaluate the prevalence of traditional and some non-traditional risk factors for atherosclerosis in our 
haemodialyisis patients and to examine the relationship between these risk factors and the presence of 
sub-clinical atherosclerosis. In this study, common carotid intima-media thickness and occurrence of 
plaques were measured as surrogate markers of sub-clinical atherosclerosis, while LVMI was used to 
determine cardiac geometry. The cohort in this study includes patients with diverse causes of renal 
disease except diabetic nephropathy. Diabetic patients were excluded because diabetes accelerates 
atherosclerosis. 
 
4.1 Demographic data 
There was a preponderance of black patients in this study; this is similar to reports from the HEMO Study 
[8] but differs from the CHOICE Study [21] and the USRDS data [4] in which there was a predominance 
of white patients. This difference is due to the different population demographics. Our general population 
is predominantly black, while in the US the whites are the predominant racial group.  The gender 
distribution was similar to that reported by these studies [4, 21], however differs from the HEMO study in 
which there was a slight female preponderance. The demographic data of the HEMO study appears to be 
different from other reported studies from the US because of selection bias. There was a preponderance 
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of urban dialysis units in the HEMO Study. Our patients were much younger than the patients reported in 
other studies [4, 8, 21, 129, 136] but similar to the study subjects reported by Salvage et al [62]. In South 
Africa [42], patients who are older than 60 years, patients with advanced cardiovascular disease, and 
diabetic patients with cardiovascular disease are not accepted onto the chronic dialysis programme 
because of limited resources. This would explain the relatively younger population in our study compared 
to the other studies. The predominant cause of CKD in the CHOICE Study [21] and USRDS [4, 39] data 
was diabetes while in our study we found hypertension to be the commonest cause of CKD. Again this 
may be due to a predominance of black subjects in our study and also the exclusion of diabetics from our 
study. Hypertensive nephrosclerosis is the commonest cause of CKD amongst the blacks [134] whereas 
in the white and Indian population it is diabetes mellitus [39]. 
 
4.2 Traditional risk factors 
4.2.1 Hypertension 
We found a high prevalence of hypertension in our study population. This is in keeping with reports from 
other studies in which the prevalence ranged between 75 and 100% depending on the target population, 
cause of renal disease and residual renal function [20, 21].  
 
Hypertension is more prevalent among the blacks and also in patients with glomerular diseases than 
interstitial diseases [127, 134]. In the CHOICE study [21] and according to the USRDS data [4], the 
prevalence of hypertension was 96% and 74% respectively. The high prevalence of hypertension in our 
population could be due to the predominance of black patients. The HD patients had significantly higher 
systolic and diastolic pressures compared with controls. This result is similar to that reported in the 
CHOICE study [21], however differs from the report by Salvage et al [62], in which they found no 
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difference in blood pressure measurements between the dialysis patients and controls. The problem with 
this study is the very small number of patients and controls; there were only 24 subjects in each group. 
 
4.2.2 Serum Lipids 
The haemodialyisis patients had lower total cholesterol, triglyceride and LDL levels. This is not 
surprising, since the concept of reverse epidemiology has been addressed recently [135]. Numerous 
studies have shown that in contrast to the general population, where indices of over-nutrition are 
associated with increased risk of cardiovascular disease, markers of malnutrition like low BMI, low 
serum albumin and low cholesterol levels are associated with increased morbidity and mortality [35, 36].  
The finding of lower serum cholesterol in the dialysis patients is not surprising for the following reasons: 
many are on dietary restrictions and some may also be malnourished although this appears not to be the 
case in our patients because the mean BMI of our patients was similar to that of the controls. The low 
cholesterol could be due to higher number of black patients in our study population. Studies carried out in 
the general population in South Africa have shown that the black population has lower serum cholesterol, 
LDL-cholesterol levels compared with other races [127, 138]. Although lately with increased 
urbanization and the attendant changes in life style and dietary habit, a gradual transition towards 
increased lipids has been observed in the black South Africans. Oosthuizen et al [138] reported higher 
serum total cholesterol and LDL-cholesterol in their subjects living in the urban and suburban township 
compared with rural dwellers. However they noted that these values were still within the recommended 
levels. This finding was confirmed in our study where the non-black patients had higher cholesterol, TG 
and HDL-cholesterol compared with the black patients.  Third, cholesterol could be lowered in our 
patients because of inflammation. Our patients had significantly higher Hs-CRP compared with the 
controls. 
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4.2.3 Left ventricular hypertrophy 
Echocardiographic abnormalities are common among HD dialysis patients and are associated with poor 
outcomes. These have been characterized into LVH, dilated cardiomyopathy and LV dysfunction by 
Parfrey [12]. Left ventricular hypertrophy includes concentric LVH and eccentric LVH (left ventricular 
dilatation plus hypertrophy). In this study we found a high prevalence of concentric LVH in our HD 
patients compared with controls. Only 12% of our HD patients had normal cardiac size. In a Canadian 
prospective cohort study of 432 patients who had echocardiography done within one year of starting 
dialysis, only 16% had normal cardiac function and dimensions, 42% had concentric LVH, 23% had 
eccentric LVH, 4% isolated LV dilatation and 16% had systolic dysfunction [14].  
 
Our HD patients had a higher prevalence of concentric LVH and diastolic dysfunction compared with the 
Canadian cohort [14]. LV dilatation, systolic dysfunction and percentage of patients with normal 
echocardiograms were similar in both groups. Stewart and colleagues [132] reported a higher prevalence 
of concentric LVH in their HD patients and also a significantly higher LVMI in their patients compared 
with controls.  Concentric LVH is associated with pressure overload, as in hypertension, arteriosclerosis 
or occasionally, aortic stenosis [1, 5, 12]. The higher prevalence of concentric LVH in our patients could 
be due to a higher prevalence of hypertension in our population compared with the Canadian cohort. 
Concentric LVH results in increased ventricular stiffness or diastolic dysfunction [5], hence the higher 
prevalence of diastolic dysfunction in our study population. Eccentric LVH is characterized by an 
increase in wall thickness that is proportional to the increase in left ventricular (LV) diameter [1, 5, 12]. 
Risk factors for eccentric LVH include volume overload secondary to salt and water retention, anaemia 
and arteriovenous fistulae [1, 5, 12]. Eccentric LVH leads to systolic dysfunction. It is surprising that 
despite the low haemoglobin levels reported in our study population, the prevalence of eccentric LVH 
was low.   
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LV mass index is strongly associated with cardiovascular mortality in the general population; this 
association is also found in dialysis patients [14]. The LVMI was significantly higher in our dialysis 
patients compared with controls. LVMI was predictably determined by male gender, diastolic BP, 
presence of CKD, smoking, plaque occurrence and adiponectin levels. Stewart et al [132] reported an 
association between LVMI with age, gender, BMI, blood pressure and CKD status. In our study, male 
gender was associated with significantly higher LVMI in keeping with their findings. Also the presence 
of ESRD was associated with a higher LVMI confirming results from previous studies showing an 
inverse relationship between prevalence of LVH and GFR. In a study by Levin and colleagues [13], the 
prevalence of LVH as measured by echocardiography was 45%, 31%, and 27% in patients with creatinine 
clearances  of < 25, 25 to 50, and >50ml/L respectively. 
 
4.3 Carotid artery plaques 
In our study, we found an increased plaque prevalence and plaque score which is consistent with the 
previous reports on carotid atherosclerosis in CRF [56, 62, 136, 133). Approximately 38% of the study 
population had sub- atherosclerosis as determined by the presence of plaques in the carotid arteries. 
Salvage et al [62] reported a prevalence of 71% in their patients while Hoys et al reported prevalence of 
64% [136]. Most of the patients had more than one plaque; this is in contrast to the control subjects who 
had plaques at only one location. Similar results have been reported by several authors [56, 63, 136, 139]. 
Foley et al [1] reported prevalence of CAD to be 40% in haemodialysis (HD) patients. This prevalence is 
higher than that in the general population which has been reported to be 5-12% depending on age and 
gender [1]. The prevalence of plaques in our HD population is higher than that reported in the general 
population (134) but much lower than reports from studies carried out in the white population [62, 136, 
139]. This confirms that patients with ESRD are in the highest risk group for CVD irrespective of their 
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race or gender. Risk factors associated with plaques in our patients include age, systolic blood pressure, 
male gender, serum phosphate, calcium phosphate product and smoking.  This finding is similar to 
reports by Salvage [62], Hoys [136] and Leskinen [139]. The association of plaques with age is not 
surprising since CAD is a disease of middle age and the elderly. Our findings also support the hypothesis 
that apart from the known traditional risk factors, some uraemia-related risk factors may also play a part 
in ASCVD in ESRD patients. Our study showed that plaque occurrence was related to serum phosphate 
and calcium phosphate product. Calcification of plaques was more common in HD patients than in the 
control group in our study. This result is in agreement with previous findings of carotid atherosclerosis in 
CRF [62]. Increased coronary artery calcification in CKD has been shown in a study using electron-beam 
computed tomography (EBCT) [92]. Thus, arterial calcification is another characteristic feature of the 
arterial disease in CKD and our study confirms this. In view of the increased vascular calcification, it is 
hypothesized that atherosclerosis in CKD patients is different from the general population and is more 
related to deposits of calcified products in the arterial wall. The following predisposing factors specific to 
CKD may contribute to the development of vascular calcification in patients with CKD: secondary 
hyperparathyroidism, disordered calcium and phosphorus homeostasis, and the use of vitamin D and 
high-dose calcium preparations [29]. Alterations in calcium/phosphorus metabolism are directly related 
to decline in kidney function. As the level of kidney function declines, phosphate levels increase and 
calcium levels decrease and parathyroid hormone (PTH) levels increase.   Block et al [89] have shown 
that an elevated serum phosphate and a calcium / phosphate product in excess of 4.5-5 mmol/l (72  when 
expressed in mg/dl) is associated with an increased risk of mortality in patients on haemodialysis. Serum 
phosphate has been shown to be associated with increased IMT of the carotid artery [89]. In our study we 
did not find a relationship between serum phosphate IMT; rather the relationship was with plaque 
occurrence. Hyperphosphataemia has been shown to be associated with increased blood pressure, 
hyperdynamic circulation, increased cardiac work and high arterial tensile stress [29]. Other factors 
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associated with calcification include longer duration of dialysis [15]. In our study, patients who had 
plaques had been on dialysis for a much longer duration. This is similar to other published studies in the 
literature [62, 139]. The relationship between presence of plaques and duration on dialysis will suggest 
that haemodialysis may contribute to accelerated atherosclerosis. The possible mechanism by which 
abnormal calcium/phosphate product increases cardiovascular risk is via PTH. PTH is a growth factor for 
smooth muscle cells and may contribute to sclerosis of the major peripheral vessels causing increased 
after-load and subsequent LV dysfunction [29]. As expected the IMT measurements were significantly 
higher among the patients who had plaques compared with those without plaques. The significance of 
increased plaque burden has been shown to exist in the general population. In the study by Ebrahim et al 
[140] plaque status explained prevalent cardiovascular disease rather than IMT.  
 
Carotid IMT and plaque burden may prove to be useful markers of atherosclerosis in CKD, because they 
are associated with risk factors for atherosclerosis in the present study. Our results suggest that increased 
plaque burden is more characteristic of atherosclerosis in CKD because when the CIMT measurements in 
the patients were compared with controls there was no significant difference; however adding plaque 
occurrence and plaque score improved the diagnostic yield.  
 
4.4 Carotid-intima media thickness 
Atherosclerotic changes in the carotid artery mirror generalized atherosclerosis in the other arterial 
districts including the coronary tree. Carotid intima-media thickness (CIMT) is usually measured by high 
resolution B-mode ultrasonography which is a non invasive, cheap, simple and reproducible method used 
in early diagnosis of coronary artery disease.  Several studies in the general population have shown that 
increased CIMT was associated with increased risk of cardiovascular events like fatal and non fatal MI 
and strokes [120, 121].  
 99
In our study the CIMT in the haemodialysis patients was higher than in controls although this was not 
statistically significant. Similar results were reported by Salvage et al [62] and Konings et al [141]. 
However, Kawagishi et al [90] and Hoys et al [136] in their studies reported significantly higher CIMT in 
HD patients compared with age matched controls. The large number of patients in these studies compared 
with small numbers studied by Salvage [62] and Konings may account for this difference. Although we 
studied 84 patients, this number still falls below that of Kawagishi [90] and Hoys [136]. The mean 
difference in CIMT values was small hence very large study population is required to detect this 
difference. The other possible reasons may be due to differences in the methodology of the carotid artery 
ultrasound examination or in the selection of the control group.  
 
In some studies, the extent of plaques may have an effect on the IMT measurement, since the exclusion 
of the measurement at the site of a plaque has not been consistently described. There is also variation in 
the descriptions of CIMT and plaques in previous studies; some studies used IMT measurement of 1mm 
[62] others have used measurements > 1.2mm [139]. In addition some studies [141] have included plaque 
measurements as part of the carotid intima media thickness. Furthermore, there is high variation in the 
site of the IMT measurement: bifurcation, carotid bulb, common carotid artery, internal carotid artery, 
and a combination of the above. The IMT measurement of the common carotid artery alone has been 
considered to be more reliable and reproducible than measurements from external or internal carotid 
arteries [124]. However, the IMT measurement of the common carotid artery may not be equally 
associated with prevalent cardiovascular disease as an IMT measurement of the bifurcation or the carotid 
bulb [119, 124]. In our study we tried to take measurements of the far wall and near wall in all three 
segments where possible, but had problems because the near wall could not be seen distinctly in some of 
our patients. Some of them still had temporary catheters in the internal jugular vein which made 
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examination difficult and others had suffered previous injury to the carotid arteries in the process of 
temporary catheter insertion, hence we resolved to use the mean of the far wall of the common carotid 
which has good reproducibility rather the mean of all measurements. It is however argued that 
atherosclerotic changes occur more frequently in the bifurcation and the internal carotid arteries than in 
the common carotid arteries because of the turbulence of blood flow at these sites. Our study confirms 
this as most of the plaques were seen in these regions and we found a significant difference in the IMT 
measurements taken at the bifurcation between our cases and controls.  
 
From this we propose that CIMT measurements could be useful diagnostic tools in HD patients if 
measurements are taken at the different carotid segments (common carotid, internal carotid and 
birfurcation) and also assessment of plaque burden is added to it. In our study we found that black 
subjects (patients and controls) had higher CIMT compared with white subjects. Several studies [142, 
143] have shown that the black population has a higher carotid IMT compared with the whites. A genetic 
inheritance pattern is postulated to be responsible for this differences.The selection of the control group 
could also affect the differences between the groups. In our study, the control group represents the 
healthy general population or subjects with similar cardiovascular risk factor profiles with the exception 
of renal disease. Except for previously known chronic diseases, our control group was not selected based 
on other cardiovascular risk factors. In the study by Kawagishi [90], the control group, were subjects 
without major coronary risk factors and this could have exaggerated the differences between their 
patients and controls. The confounding influence of risk factors associated with obesity and smoking was 
diminished in our study because the controls were matched for body mass index, and prevalence of 
smoking was similar in both groups.  
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CIMT has also been shown to be directly associated with most of the risk factors for atherosclerosis 
[119]. In our study population, CIMT was associated with Hs-CRP, total cholesterol, LDL cholesterol, 
age, and a family history of chronic kidney disease. This is consistent with previous reports that 
demonstrated significant correlation between CIMT and age both in the general population [119] and in 
HD patients [62, 90, 136]. Kawagishi et al [90] found a relationship between carotid and femoral IMT 
and age. In our study we found a relationship between Hs-CRP and CIMT. Zoccalli et al [129] reported a 
significant relationship between CIMT and Hs-CRP on univariate analysis, but this relationship lost 
statistical strength on multivariate analysis. We found a relationship between CIMT and LDL-cholesterol 
and this was similar to the findings of Hoy et al [136] but differs from the findings of Kawagishi et al 
[90]. This finding confirms the finding that abnormally elevated LDL-cholesterol contributes to the 
pathogenesis of atherosclerosis. The lack of association of lipids in the study by Kawagishi [90] could be 
due to selection bias of their control group. The controls were matched with the HD patients for age, 
gender, BMI and total cholesterol. This may not be reflective of the true distribution of cholesterol in the 
general population in their setting. Cholesterol had an inverse relationship with CIMT in our study. This 
is not surprising because although hypercholesterolaemia is associated with increased risk of CVD in the 
general population, in haemodialysis patients (with the exception of diabetic ESRD patients), low serum 
cholesterol is associated with a high mortality [34, 35].  The possible explanations for this reverse 
causality are: first, cholesterol may simply be a marker of inflammation or malnutrition both of which are 
powerful predictors of mortality in dialysis patients [34, 35, 36]. Cytokines like tumour necrosis factor  
(TNF ), interleukin 2 (IL-2) have been reported to have inhibitory effects on lipoprotein lipase activity 
[30]. Bologa et al reported that high IL-6 levels predicted low serum cholesterol levels, suggesting that 
cholesterol may be suppressed in response to inflammation. [36]. Hs-CRP which is also a marker of 
inflammation was found to be increased in our patients; thus inflammation could partly explain the low 
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cholesterol level in our HD patients. Second, since most patients on dialysis have dyslipidaemia, it may 
not be a discriminating factor.  
 
Third, the total cholesterol-HDL cholesterol ratio is a better indicator of atherogenic risk than total 
cholesterol [29]. Analysis of risk factors in HD patients alone showed CIMT to be associated with Hs-
CRP and family history of CKD. This confirms that inflammation plays a very important role in the 
atherosclerosis of CKD.  
 
We found a significant relationship between family history of CKD and CIMT. Chronic kidney disease 
has recently been included among the strongest predictors of cardiovascular risk [106]. It is therefore not 
surprising that a family history of CKD is associated with increased CIMT; possible explanation is that 
CKD is associated with a high prevalence of both traditional and non-traditional risk factors for CVD; 
risk factors like hypertension, LVH, dyslipidaemia, microalbuminuria, endothelial dysfunction, and 
oxidant stress. Some of these risk factors like hypertension; dyslipidaemias are known to have some 
complex inheritance patterns.  
 
We found no relationship between CIMT and duration on dialysis, calcium phosphate product, phosphate 
and PTH on regression analysis. This finding is similar to that of Hoy [136] et al but differs from that 
reported by Kawagishi [90] and Salvage [62]. Kawagishi et al [90] reported an independent relationship 
between CIMT and serum phosphorus level, while Salvage et al [62] reported a relationship with calcium 
phosphate product. London et al did show that IMT was strongly associated with left ventricular mass 
index [122]. Benedetto et al [123] in their study of 138 patients who were receiving chronic dialysis 
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showed that IMT was associated with concentric LVH and was also an independent predictor of 
cardiovascular death [123]. We did not find any relationship between LVMI and CIMT.   
 
4.5 Non-traditional risk factors 
4.5.1 Hs-CRP 
One of the major findings in this study is that HD patients had significantly higher Hs-CRP levels 
compared with controls. This finding is in keeping with results from other studies [53, 54, 56, 57]. Iseki 
et al [54] looked at baseline CRP levels in 163 HD patients. They divided the patients into two groups 
based on normal and abnormal CRP levels. Those patients with higher CRP levels had significantly lower 
albumin levels and a higher mortality rate. Our  patients with increased CRP levels had lower serum 
albumin levels. CRP is an acute phase reactant whose serum levels tend to reflect on-going inflammation. 
Albumin is a negative acute phase reactant. In the presence of on-going inflammation, proinflammatory 
cytokines induce an acute phase response in the liver resulting in the increased degradation of albumin. 
Stenvinkel [56] also reported a higher CIMT in patients with low serum albumin. His study was carried 
out on patients with advanced chronic renal prior to starting dialysis. Our patients with higher Hs-CRP 
levels also had unfavourable lipid profiles compared with those with normal CRP. They had a higher total 
cholesterol and LDL-cholesterol levels. The prevalence of plaques was also higher among this group of 
patients. These findings are in keeping with results from other studies [56] and also demonstrate that 
atherosclerosis, in addition to being a disease of lipid accumulation, also represent an inflammatory 
process [56, 57].  
 
The Cardiovascular Risk Extended Evaluation in Dialysis (CREED) study [57] did show that CRP was an 
independent predictor of the number of atherosclerotic plaques in the carotid artery of 112 chronic HD 
patients. Stenvinkel et al [56] also showed a significantly increased carotid intima media thickness of pre-
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dialysis patients with elevated CRP levels. Generalized linear model regression analysis in HD patients 
did show a strong relationship between CIMT and Hs-CRP levels. Our patients with high Hs- CRP levels 
also had lower haemoglobin levels. Anaemia is a known risk factor for eccentric LVH. Hs-CRP was 
found to be associated with plasma homocysteine, another risk factor for CVD. These findings suggest 
that Hs-CRP may be an important factor for CVD risk assessment in view of its association with other 
CVD risk factors. Several studies, both in the general population and haemodialysis patients, have 
pointed to the strong predictive value of Hs-CRP. In the Women Health Study [51], baseline levels of 
CRP were significantly higher among women who subsequently developed CV events compared with 
those who did not. In the MONICA (monitoring trends and determinants in cardiovascular disease) 
Study, men who subsequently developed coronary heart disease had higher baseline CRP levels 
compared with those who did not. [50]. All these factors are in support of the role of inflammation in 
atherosclerosis and that Hs- CRP is a sensitive indicator for atherosclerosis. Zimmermann et al [53], in a 
prospective cohort study of 288 HD patients showed that all-cause and CV mortality was higher in 
patients with elevated CRP, being 31% and 16% respectively. Patients in the highest quartile of CRP had 
a 4.6 fold and 5.5 fold higher risks of all cause and CV mortality compared with patients in the lowest 
quartile.  Yeun et al [35] have also identified CRP as the most powerful predictor of all-cause and CV 
mortality in 91 HD patients who were followed up for 34months. Patients with CRP levels in the highest 
quartile had the lowest survival compared with those in the lowest quartile. CRP levels have also been 
found to be associated with various classic markers of CVD such as Lp (a), fibrinogen and low HDL in 
ESRD populations [53].  Because of the cross sectional nature of our study, it will be difficult to make 
any statements about the predictive value of Hs-CRP for future CV events.  Hs-CRP was significantly 
associated with CIMT on regression analysis therefore the addition of Hs-CRP testing to the routine lipid 
tests will improve the predictive value of this test for CVD. Ridker et al [58] demonstrated that the 
combination of increased Hs-CRP (> 2,11mg/L) and increased total cholesterol is associated with a 5-fold 
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increased risk of coronary events compared with a 1.5-fold and 2.3-fold increase respectively if only one 
parameter was elevated.  These data lend support to the hypothesis that inflammation plays a role in the 
pathogenesis of atherosclerosis in these patients. 
 
4.5.2 Lipoprotein (a) 
Numerous studies have shown that patients with ESRD treated by haemodialysis, peritoneal dialysis and 
patients with proteinuria have elevated plasma Lp (a) levels. In this study, the mean serum lipoprotein (a) 
levels were similar in both patients and controls and also among patients with and without plaques. This 
finding is similar to the results of Stenvinkel et al [56] in which there was no difference in the serum 
Lp(a) levels among patients with low versus high CRP levels and among patients with plaques and 
without plaques. The black subjects had significantly higher Lp (a) levels compared with the non-black 
subjects in keeping with findings in the literature. Even though black patients have much higher Lp(a) 
levels compared with white subjects, the heterogeneity of apo (a) iso form sizes could account for 
differences in prevalence of CAD in the two populations [144]. Lipoprotein (a) is a strong risk factor for 
vascular disease in the general populations [78, 94] as well as in HD patients [93]. Studies have shown 
that it is the apolipoprotein (a) [apo(a)] gene locus that determines the risk for CVD through its allelic 
control of Lp (a). Subjects who express the low molecular weight (LMW) apo (a) phenotype show on 
average markedly higher Lp (a) concentrations than those with higher molecular weight apo (a) 
phenotypes and these have been shown to be associated with increased cardiovascular risk [29, 93]. 
Delport et al [78] carried out a study in 91 male Caucasians with vascular disease in Pretoria; they 
reported an increased risk in patients with high-molecular apo (a) isoforms especially in the presence of 
hyperhomocysteinaemia. The lack of correlation between Lp (a) and the surrogate markers of 
atherosclerosis in our study could be attributed to the fact that we did not measure the apo (a) iso forms.  
Kronenberg et al [93], in a cross sectional study involving 167 patients found that the LMW phenotypes 
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of apo (a) and higher serum Lp (a) levels were associated with carotid plaques as investigated by 
ultrasound. They demonstrated that haemodialysis patients with the LMW phenotypes of apo (a) had 
significantly more carotid sites affected by atherosclerotic plaques than those with other phenotypes. 
 
4.5.3 Adiponectin 
Adiponectin (ADPN), a recently discovered collagen-like protein, is secreted exclusively by adipocytes 
and circulates in the blood. Interest in adiponectin derives from its potential protective role for the 
cardiovascular system. Adiponectin has anti-atherogenic and anti -inflammatory properties [113]. ADPN 
is inversely related to creatinine clearance and serum levels are markedly increased in patients with 
ESRD [114, 115]. This was confirmed in our study. Our haemodialysis patients had significantly higher 
serum ADPN levels compared with controls and even among the HD patients, those who were 
completely anuric had the highest adiponectin levels. Zoccali and colleagues [115] reported that HD 
patients had ADPN levels about 2.5 times that of controls, while Huang et al [145] reported that patients 
on peritoneal dialysis (PD) and haemodialysis had significantly higher ADPN levels compared with 
controls. ADPN concentrations seem to be gender-dependent, being higher among women than men. In 
our study women had higher adiponectin levels than the men and this was particularly significant among 
the controls. However, what is not known is whether this increase is just due to accumulation or whether 
it represents a counter-regulatory response to several metabolic and haemodynamic risk factors of renal 
insufficiency.  Adiponectin has been linked to several metabolic risk factors like glucose, TG, insulin, 
and HDL cholesterol in uraemic patients and these are all consistently in line with the hypothesis that 
adiponectin is a protective factor [115]. Adiponectin stimulates fatty acid oxidation, decreases plasma 
triglycerides, and improves glucose metabolism by increasing glucose sensitivity [113]. Our study 
confirms the association of adiponectin with lipid metabolism; adiponectin level was inversely related to 
serum triglyceride and LDL levels. Among HD patients, these factors remained significant in addition; 
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adiponectin was related to LV dysfunction and serum cholesterol. Huang et al [145] did not find any 
relationship between left ventricular ejection fraction, LVM and ADPN levels. There are many reasons 
for the observed differences between Huang’s report and ours. There are methodological differences with 
regards to echocardigraphic examination in their study. First the LVM was corrected for body weight in 
their study not body surface area as in our study. Second, the cut-off level of ejection used in their study 
was much higher than the recommended level of <50% for determining systolic dysfunction [130]. Third 
LVH was defined as posterior wall thickness > 1.2cm and there was no distinction into the various types 
of LVH. Fourth, the study was carried out in PD patients. The mechanism underlying the association of 
ADPN with LV dysfunction is not clear, further studies are needed for clarification. Adiponectin was 
positively associated with cholesterol in our study. Most of our dialysis patients had low to normal 
cholesterol levels. In HD patients, low cholesterol is not only a marker of nutrition but also a marker of 
inflammation. The observed low cholesterol in our HD patients could be a marker of inflammation and 
inflammatory processes may play a role in the increased plasma levels of ADPN; although in our study 
we did not find any association between ADPN and Hs-CRP levels. One limitation of this study is that 
we did not measure insulin resistance and this could have effects on the association of cholesterol with 
ADPN. Plasma adiponectin concentrations are reduced in patients with obesity, type 2 diabetes mellitus 
and coronary artery disease [116]. ADPN in patients with ESRD is increased compared with healthy 
subjects, but within the uraemic milieu, low adiponectin is still a marker of high risk because it predicts a 
higher rate CV event [115]. Our study did not show any difference in the serum adiponectin levels 
between patients with carotid plaques and those without plaques. Zoccali et al [115], reported that 
adiponectin levels were increased in both HD patients with low incidence of cardiovascular events (20.8 
± 6.8 µg/mL) and those with high CV events (9.3 ± 2.7µg/ mL) compared with healthy subjects (5.9 ± 
2.6µg/ mL) [115]. Although it is speculated that ADPN is a protective factor for CVD in uraemic 
patients, however there are some questions that need clarification. What is the level of ADPN that 
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prevents CVD in uraemic patients since levels are higher in ESRD compared with controls irrespective of 
CVD status? The exact metabolism and role of ADPN in ESRD also needs further clarification.  Zoccali 
and colleagues [115] hypothesized that in ESRD, the cardioprotective role of ADPN may be 
downregulated, perhaps at the receptor level, thus resetting the relationship between ADPN, 
cardiovascular damage and clinical complications at a higher plasma concentration. This hypothesis must 
be fully tested in vitro and in vivo experiments, to better elucidate the role of this cytokine in human 
diseases. 
 
4.5.4 Homocysteine 
Homocysteine is an intermediate amino acid formed during the metabolism of methionine, a sulphur-
containing essential amino acid and is cleared by the kidneys. Hyperhomocysteinaemia has been 
identified as an independent risk factor for cardiovascular morbidity and mortality in the general 
population [75, 77, 78,] and in ESRD patients on dialysis [79, 80]. High homocysteine levels were 
reported in subjects with IHD and stroke in the general population [77, 78]. Delport et al [78] reported 
that hyperhomocysteinaemia was associated with a 7.20 fold increased risk for vascular disease among 
Caucasian South African males. In our study, homocysteine levels were significantly higher in patients 
compared with controls. This finding is similar to reports from previous studies [80]. Risk factors 
associated with plasma homocysteine levels in our study include Hs-CRP, age, and total cholesterol. 
Among HD patients, homocysteine was independently associated with age, Hs-CRP and inversely related 
to serum adiponectin levels.  The relationship between plasma homocysteine levels and CVD in HD 
patients remains controversial; some studies found that plasma homocysteine was an independent CV 
morbidity and mortality predictor in uremic patients [80, 146] while another study did not [79].   
Robinson et al [80] reported that high total plasma homocysteine concentration is an independent risk 
factor for atherosclerotic complications of end-stage renal disease. On the other hand, Suliman et al [79] 
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found a negative relationship between CVD and plasma homocysteine levels, but the prevalence of 
hypoalbuminemia, malnutrition and inflammation was high in their patients and more prevalent in those 
without CVD.  In our study the association of homocysteine with other risk factors for CVD like 
inflammation (Hs-CRP), increasing age hypercholesterolaemia and the inverse relationship with ADPN,  
support the fact that homocysteine itself is an important risk factor for CVD in ESRD. The mechanisms 
by which homocysteine might contribute to atherogenesis include induction of endothelial dysfunction, 
promotion of platelet aggregation and enhanced coagulability, increased smooth muscle cell proliferation, 
cytotoxicity and stimulation of LDL oxidation [75, 76 ]. 
 
4.6 CVD risk factors based on previous kidney transplantation 
It is well known that cyclosporine and steroids used as immunosuppressive therapy in kidney transplant 
patients do cause hypertension and atherosclerotic vascular changes [147].  
 
We compared the CVD risk factors in patients who have had a previous kidney transplant with those who 
have never been transplanted.  The significant differences were higher LDL-cholesterol and triglycerides 
in patients who received kidney transplant. This is not surprising as steroids and calcineurin inhibitors are 
known to cause dyslipidaemia [147]. Patients who had previously been transplanted had significantly 
lower blood pressure compared with those who had not been transplanted, CIMT, LVMI and plaque 
occurrence was similar in both groups. This suggests that prior kidney transplantation does not contribute 
significantly to the vascular changes seen in ESRF patients. 
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4.7  Cardiovascular risk factors by aetiology 
Hypertension is the most common cause ESRF in the black population [127].  Hypertension is a known 
risk factor for CVD and it is suggested that the presence of hypertension could contribute to accelerated 
atherosclerosis in CRF and these changes occur well before the commencement of dialysis [1, 3, 12]. We 
analyzed CVD risk factors by aetiology especially in our black patients since hypertension is more 
prevalent in these patients. Our results suggest that hypertension could contribute to accelerated 
atherosclerosis in these patients as evidenced by significantly higher levels of some CVD risk factors and 
higher prevalence of plaques in the essential hypertensive group.  
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CHAPTER 5 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 Conclusions 
 The findings from this study, demonstrate that:  
 
1. Prevalence of sub-clinical atherosclerosis as determined by increased CIMT and carotid plaques 
was higher in HD patients than the controls, in keeping with previous studies and also confirming 
the statement by the NKF that patients with CKD are in the highest risk for CVD. No evidence of 
any differences in the prevalence of sub-clinical atherosclerosis (plaque occurrence) between the 
racial groups was found.  
2. HD patients have a prevalence of traditional (hypertension, LVH, physical inactivity) and non-
traditional risk factors (hyperhomocysteinaemia, inflammation) for atherosclerosis, in keeping 
with reports in the literature on this subject.  
3. Some traditional risk factors like lipids appear to have opposite effects in ESRD patients (reverse 
epidemiology) 
4. Inflammation appears to play an important role in the pathogenesis of atherosclerosis in ESRD, as 
demonstrated by the association of Hs-CRP to CIMT a surrogate marker of sub-clinical 
atherosclerosis.  
5. Some racial differences in risk factors like smoking, exercise, lipids, blood pressure, adiponectin 
and Lp(a), LVH were noted, with, the black race having lower serum cholesterol, triglycerides, 
LDL-cholesterol compared with the non-black race. The black subjects in this study were older, 
had higher Lp (a) and adiponectin levels, higher LVMI and prevalence of LVH.  More non-black 
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subjects currently smoked cigarettes and exercised compared with black subjects. There was no 
significant difference in CIMT between the different racial groups.  
6. CIMT showed significant correlation with some major risk factors for atherosclerosis like age, 
Hs-CRP,  LDL cholesterol and family history of CKD 
7. Plaque occurrence showed significant correlation with some major risk factors for atherosclerosis 
like age, systolic BP, male gender, smoking, serum phosphate and calcium phosphate product. 
8. HD patients had higher ADPN levels than controls but the exact role of this adipocyte cytokine in 
ESRD needs to be defined.  
 
5.2     Recommendations for clinical practice 
1. Ultrasound assessment of the carotid artery is a useful tool for the early diagnosis of 
atherosclerosis especially if measurements of IMT are done in all carotid segments and plaque 
occurrence is also incorporated. It is simple, highly reproducible and cheap and therefore 
recommended as a screening tool in high risk subjects. 
2. The addition of Hs-CRP to routine screening of HD patients could help identify those at risk of 
CVD 
3. Patients with ESRD are considered to be in the highest risk group for CVD. It is therefore 
recommended that this patient population should be carefully assessed and treated for CV risk 
factors early in the course of the disease. 
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5.3   Recommendations for future work 
The cross-sectional nature of this study is a limitation; a longitudinal study will provide more substantial 
data.  
1. A longitudinal study will help determine the relationship between these non-traditional risk 
factors and CVD outcomes in our environment. 
2. It is desirable that a similar study be carried out involving patients with early CKD, patients on 
peritoneal dialysis and kidney transplant patients to determine if there are differences in 
prevalence of these risk factors and atherosclerosis in these conditions and whether treatment 
modality influences their occurrence. 
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Appendix A 
 
 
Test principle for cholesterol,  HDL-Cholesterol and triglyceride 
 
Enzymatic colorimetric test for cholesterol 
 
Sample plus addition of R1 (cholesterol reagent) start of reaction: 
Cholesterol is determined enzymatically using cholesterol esterase and cholesterol oxidase. 
cholesterol 
Cholesterol esters + H2O   cholesterol + RCOOH 
esterase 
 
Cholesterol esters are cleaved by the action of cholesterol esterase to yield free cholesterol and 
fatty acids. 
 
Cholesterol 
Cholesterol + O2     cholest-4-en-3-one + H2O2 
Oxidase 
 
Cholesterol is converted by oxygen with the aid of cholesterol oxidase to cholest-4-en-3-one and 
hydrogen peroxide. 
Peroxidase 
2 H2O2 + 4-aminophenazone + phenol                  4-(p-benzoquinone-monoimino)   –  phenazone 
+ 4 H2O 
 
Hydroen peroxide created forms a red dyestuff by reacting with 4-aminophenazone and phenol 
under the catalytic action of peroxidase.  The color intensity is directly proportional to the 
concentration of cholesterol and can be determined spectrophotometrically. 
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Test principle for HDL 
 
HDL was determined directly by the use of magnetically responsive particles such as polyanion-metal 
combinations and the use of Polyethyleneglycol (PEG) with anti-apoprotein B and anti-apoprotein 
CIII antibodies. The automated method for direct determination of HDL-cholesterol in serum uses 
PEG-modified enzymes and dextran sulphate. When the cholesterol esterase and cholesterol oxidase 
enzymes are modified by PEG, they show selective catalytic activities toward lipoprotein fractions, 
with the reactivity increasing in the order: LDL, VLDL  chylomicrons < HDL.  Homogeneous 
enzymatic colorimetric test. 
Sample and addition of R1 (buffer). 
In the presence of magnesium sulphate, dextran sulphate selectively forms water-soluble 
complexes with LDL, VLDL and chylomicrons which are resistant to PEG-modified enzymes. 
Addition of R2 (PEG-modified enzymes/4-amino-antipyrine/buffer) and start of reaction: 
The cholesterol concentration of HDL-cholesterol is determined enzymatically by cholesterol 
esterase and cholesterol oxidase coupled with PEG to the amino groups (approx.40%). 
PEG-cholesterol 
HDL-cholesterol esters + H2O 
Esterase         Cholesterol + RCOOH 
 
Cholesterol esters are broken down quantitatively into free cholesterol and fatty acids by 
cholesterol esterase. 
PEG-cholesterol 
HDL-cholesterol + O2           4-cholestenone + H2O2 
Oxidase 
 
In the presence of oxygen, cholesterol is oxidized by cholesterol oxidase to 
     4-cholestenone and hydrogen peroxide. 
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                                                                                         Peroxidase 
2H2O2 + 4-amino-antipyrine + HSDA* + H *+  H2O 
                                                                                               purple-blue pigment + 5H2O 
HSDA=N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline 
 
In the presence of peroxidase, the hydrogen peroxide generated reacts with 4-amino-antipyrine 
and HSDA to form a purple-blue dye.  The color intensity of this dye is directly proportional to 
the cholesterol concentration and is measured spectrophotometrically. 
 
 
Test principle for triglyceride 
 
Enzymatic colorimetric test 
 
Sample and addition of R1 (buffer/4-chlorophenol/enzymes) and start of reaction: 
      LPL 
triglycerides + 3 H2O              glycerol + 3 RCOOH 
         GK 
glycerol + ATP  glycerol-3-phosphate + ADP 
         Mg2 
GPO 
glycerol-3-phosphate + O2            dihydroxyacetone phosphate 
+ H2O2 
peroxidase 
H2O2 + 4-aminophenazone + 4-chlorophenol 
• 4-(p-benzoquinone-monoimino)-phenazone + 2 H2O + HC 
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Appendix B 
 
Assay principle for PTH 
 
 The ADVIA Centaur Intact PTH assay is a two-site sandwich immunoassay which uses directed 
chemiluminometric technology which uses constant amounts of two anti-human PTH antibodies in 
the Lite reagent. The first antibody is a polyclonal goat anti-human PTH antibody labeled with 
acridinium ester. The second is a biotinylated polyclonal goat anti-human PTH (39–84) antibody. 
Streptavidin in the solid Phase is covalently coupled to the paramagnetic latex particles. 
 
The system automatically performs the following steps: 
dispenses 200µL of sample into a cuvette 
dispenses 50µL of Lite Reagent and incubates for 5.0 minutes at 37°C 
dispenses 200µL of Solid Phase and incubates for 2.5 minutes at 37°C 

separates, aspirates, and washes the cuvettes with reagent water13 
dispenses 300 µL each of Acid Reagent and Base Reagent to initiate the chemiluminescent 
reaction 
reports results according to the selected option, as described in the system operating instructions 
or in the online help system 
A direct relationship exists between the amount of PTH present in the patient sample and the 
amount of relative light units (RLUs) detected by the system.  
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Appendix C 
 
Pat No Age sex Race SUBJECT FHx MI FHx HTN FHx DM FHx CKD height weight HT SQ BMI smoking Quantity 
1 24 1 1 1 0 1 0 0 1.66 63 2.76 22.86 2 0 
2 28 1 1 1 0 0 0 0 1.48 33 2.19 15.07 1 1 
3 50 1 1 1 0 1 1 0 1.75 59.6 3.06 19.46 2 0 
4 31 1 1 1 0 0 0 0 1.65 55 2.72 20.20 2 0 
5 19 1 1 1 0 0 0 0 1.62 56.4 2.62 21.49 2 0 
6 45 1 1 1 0 0 0 0 1.77 91.3 3.13 29.14 0 0 
7 52 1 1 1 0 1 0 0 1.67 70.5 2.79 25.28 0 0 
8 47 1 1 1 0 1 0 0 1.71 66.3 2.92 22.67 0 0 
9 41 1 1 1 0 1 0 0 1.77 77.9 3.13 24.87 2 0 
10 50 1 1 1 0 0 0 0 1.59 57 2.53 22.55 2 0 
11 26 1 1 1 0 1 0 1 1.65 56.9 2.72 20.90 0 0 
12 28 1 1 1 1 1 0 0 1.59 51 2.53 20.17 0 0 
13 39 1 1 1 0 0 0 0 1.62 56 2.62 21.34 1 1 
14 19 1 1 1 0 1 1 0 1.73 56.5 2.99 18.88 2 1 
15 41 1 1 1 0 0 0 0 1.69 47.2 2.86 16.53 2 1 
16 46 1 1 1 0 0 0 0 1.76 62.7 3.10 20.24 0 0 
17 37 1 1 1 0 1 0 1 1.71 73 2.92 24.96 2 1 
18 42 1 1 1 0 1 0 0 1.74 80 3.03 26.42 1 1 
19 43 1 1 1 0 1 0 0 1.72 75.7 2.96 25.59 2 0 
20 43 1 1 1 0 0 0 0 1.62 57.7 2.62 21.99 2 0 
21 50 1 1 1 0 1 1 0 1.72 76 2.96 25.69 1 1 
22 47 1 1 1 0 0 0 0 1.68 64.3 2.82 22.78 2 0 
23 46 1 1 1 0 1 0 0 1.83 82 3.35 24.49 1 1 
24 42 1 1 1 0 1 0 1 1.66 60.3 2.76 21.88 1 1 
25 26 1 1 1 0 0 1 0 1.5 47.2 2.25 20.98 1 1 
26 45 1 1 1 0 0 0 0 1.69 59.8 2.86 20.94 1 1 
27 34 1 1 1 0 1 0 0 1.78 57 3.17 17.99 1 1 
28 52 1 1 1 0 0 0 0 1.61 60 2.59 23.15 0 0 
29 55 1 1 1 0 1 0 0 1.7 84.5 2.89 29.24 2 2 
30 55 1 1 1 0 0 1 0 1.62 67.9 2.62 25.87 2 1 
31 53 1 1 1 0 1 1 1 1.67 77.9 2.79 27.93 2 1 
32 53 1 1 1 0 1 0 0 1.71 72.2 2.92 24.69 2 1 
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33 47 1 1 1 0 0 0 0 1.62 69 2.62 26.29 2 0 
34 37 2 1 1 0 0 0 0 1.57 54.1 2.46 21.95 0 0 
35 39 2 1 1 0 1 0 0 1.61 63 2.59 24.30 0 0 
36 40 2 1 1 0 0 0 0 1.62 69.4 2.62 26.44 0 0 
37 40 2 1 1 0 0 0 0 1.62 78.2 2.62 29.80 0 0 
38 38 2 1 1 0 1 1 0 1.52 63.5 2.31 27.48 0 0 
39 45 2 1 1 1 0 0 0 1.5 53 2.25 23.56 0 0 
40 49 2 1 1 0 0 0 0 1.54 93.6 2.37 39.47 0 0 
41 47 2 1 1 0 1 1 0 1.65 106 2.72 38.93 0 0 
42 44 2 1 1 0 1 1 0 1.64 66.7 2.69 24.80 0 0 
43 28 2 1 1 0 1 0 0 1.5 50.4 2.25 22.40 0 0 
44 40 2 1 1 0 0 0 0 1.5 52.8 2.25 23.47 0 0 
45 37 2 1 1 0 0 0 0 1.55 53.5 2.40 22.27 1 1 
46 43 2 1 1 0 0 0 0 1.64 59 2.69 21.94 0 0 
47 49 2 1 1 0 1 0 0 1.52 90 2.31 38.95 2 1 
48 36 2 1 1 0 0 0 0 1.49 58 2.22 26.12 0 0 
49 35 2 1 1 0 1 1 0 1.54 88 2.37 37.11 1 1 
50 48 2 1 1 0 1 0 0 1.59 88 2.53 34.81 0 0 
51 37 2 1 1 0 0 0 0 1.49 56.4 2.22 25.40 0 0 
52 20 2 1 1 0 0 0 0 1.66 52 2.76 18.87 0 0 
53 51 2 1 1 0 1 0 0 1.64 63.4 2.69 23.57 0 0 
54 53 2 1 1 0 0 0 0 1.66 70.3 2.76 25.51 0 0 
55 57 2 1 1 0 1 0 0 1.55 68.5 2.40 28.51 0 0 
56 49 2 1 1 0 0 0 0 1.55 71 2.40 29.55 2 0 
57 47 2 1 1 1 1 1 0 1.64 48.5 2.69 18.03 0 0 
58 48 2 1 1 0 1 0 1 1.56 69.8 2.43 28.68 0 0 
59 25 1 2 1 1 1 1 0 1.57 51.7 2.46 20.97 0 0 
60 29 1 2 1 0 0 0 0 1.8 105.5 3.24 32.56 2 0 
61 23 1 2 1 0 0 1 0 1.57 60.5 2.46 24.54 2 0 
62 58 1 2 1 0 0 0 0 1.67 75.3 2.79 27.00 2 5 
63 31 1 2 1 0 1 0 0 1.79 87 3.20 27.15 1 1 
64 22 1 2 1 0 1 0 0 1.73 56.4 2.99 18.84 1 1 
65 52 1 2 1 1 1 0 0 1.76 70.1 3.10 22.63 2 0 
66 54 1 2 1 0 0 0 0 1.72 70 2.96 23.66 1 3 
67 39 1 2 1 0 0 0 0 1.67 62 2.79 22.23 1 1 
68 42 1 2 1 1 0 0 0 1.63 59 2.66 22.21 1 1 
69 41 1 2 1 0 1 1 0 1.78 82.5 3.17 26.04 0 0 
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70 32 2 2 1 0 1 0 0 1.55 58.4 2.40 24.31 0 0 
71 27 2 2 1 0 0 0 0 1.66 55.4 2.76 20.10 1 1 
72 32 2 2 1 0 1 1 0 1.66 100.3 2.76 36.40 0 0 
73 32 2 2 1 1 1 0 0 1.58 48 2.50 19.23 0 0 
74 37 2 2 1 1 0 0 0 1.57 52.5 2.46 21.30 0 0 
75 35 2 2 1 1 1 1 0 1.58 37 2.50 14.82 2 1 
76 23 2 2 1 0 0 0 0 1.55 48 2.40 19.98 0 0 
77 28 2 2 1 1 0 1 0 1.55 60.5 2.40 25.18 1 1 
78 43 2 2 1 0 0 0 0 1.48 52.4 2.19 23.92 0 0 
79 20 2 2 1 0 0 0 0 1.5 50 2.25 22.22 2 1 
80 26 2 2 1 0 0 0 0 1.68 50 2.82 17.72 0 0 
81 54 2 2 1 0 0 0 0 1.64 67.8 2.69 25.21 0 0 
82 51 2 2 1 0 1 0 0 1.65 78 2.72 28.65 0 0 
83 54 2 2 1 1 1 1 0 1.45 57 2.10 27.11 0 0 
84 42 2 2 1 0 0 0 0 1.65 68.7 2.72 25.23 0 0 
 
Exercise Ex FREQ SBP  DBP Pulse P PP/3 MAP total chol 
Triglyceride 
(mmol/L) HDL LDL LCCA RCCA s CCA 
CIMT 
(mm) 
0 0 118 67 51 17.00 84.0 2.9 0.6 1 1.5 0.5 0.7 1.2 0.6 
1 3 141 92 49 16.33 108.3 2.9 0.6 1 1.6 0.6 0.6 1.2 0.6 
0 0 138 87 51 17.00 104.0 3.8 0.8 1.3 2.2 0.9 0.8 1.7 0.85 
0 0 133 60 73 24.33 84.3 4.5 0.8 1.1 3 0.7 0.8 1.5 0.75 
0 0 152 88 64 21.33 109.3 3.5 0.5 1 2.3 0.5 0.5 1 0.5 
0 0 118 71 47 15.67 86.7 4.8 0.5 0.9 3.7 0.5 0.6 1.1 0.55 
1 3 114 61 53 17.67 78.7 3.4 1.4 1 1.8 0.6 0.7 1.3 0.65 
0 0 141 70 71 23.67 93.7 4 1.4 1 2.4 0.4 0.7 1.1 0.55 
0 0 148 93 55 18.33 111.3 4.5 0.6 1.5 2.7 0.6 0.5 1.1 0.55 
0 0 169 98 71 23.67 121.7 3.6 0.9 1.4 1.9 0.6 0.7 1.3 0.65 
1 3 145 86 59 19.67 105.7 3.7 1.7 1 1.9 0.6 0.7 1.3 0.65 
0 0 160 95 65 21.67 116.7 3.4 0.6 1.5 1.6 0.9 0.6 1.5 0.75 
0 0 178 106 72 24.00 130.0 2.6 0.2 1.5 1 0.6 0.6 1.2 0.6 
1 2 159 99 60 20.00 119.0 2.4 0.8 1 1 0.6 0.6 1.2 0.6 
1 3 153 82 71 23.67 105.7 4.1 1.3 1.9 1.6 0.9 0.7 1.6 0.8 
0 0 143 91 52 17.33 108.3 3.5 3.2 1 1 0.9 0.7 1.6 0.8 
1 2 150 100 50 16.67 116.7 4.3 2.5 1 2.2 0.8 0.7 1.5 0.75 
0 0 152 95 57 19.00 114.0 3.8 1.3 1.1 2.1 0.6 0.4 1 0.5 
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1 3 141 92 49 16.33 108.3 3 0.6 1.1 1.6 0.6 0.7 1.3 0.65 
1 2 150 77 73 24.33 101.3 3.6 1.3 1 2 0.8 0.7 1.5 0.75 
0 0 137 87 50 16.67 103.7 3.1 0.6 1.2 1.6 0.7 0.7 1.4 0.7 
0 0 158 86 72 24.00 110.0 4 0.4 1.3 2.6 0.8 0.7 1.5 0.75 
0 0 186 100 86 28.67 128.7 2.1 0.6 0.7 1.1 0.8 0.8 1.6 0.8 
0 0 138 84 54 18.00 102.0 2.2 1.1 1.4 0.3 0.6 0.9 1.5 0.75 
1 3 155 101 54 18.00 119.0 3 0.9 0.9 1.7 0.7 0.8 1.5 0.75 
0 0 150 85 65 21.67 106.7 3.7 0.9 1.2 2.1 0.7 0.6 1.3 0.65 
0 0 163 109 54 18.00 127.0 3 0.5 0.5 2.3 0.7 0.7 1.4 0.7 
0 0 148 76 72 24.00 100.0 4 0.4 1.4 2.4 0.6 0.7 1.3 0.65 
0 0 170 91 79 26.33 117.3 2.9 0.9 1.3 1.3 0.5 0.9 1.4 0.7 
0 0 155 79 76 25.33 104.3 3.2 0.8 1 1.8 0.6 0.6 1.2 0.6 
0 0 145 77 68 22.67 99.7 4.3 1.9 1.3 2.1 0.7 0.5 1.2 0.6 
0 0 165 77 88 29.33 106.3 3.3 0.6 1.3 1.7 0.7 0.8 1.5 0.75 
0 0 184 115 69 23.00 138.0 3.1 0.7 0.7 2.1 0.6 0.6 1.2 0.6 
0 0 123 58 65 21.7 79.7 4 0.9 2.6 1 0.3 0.4 0.7 0.35 
0 0 130 89 41 13.7 102.7 3.8 1.4 1.3 1.8 0.5 0.7 1.2 0.6 
1 3 130 76 54 18.0 94.0 4 1.2 1.5 2 0.4 0.6 1 0.5 
0 0 140 80 60 20.0 100.0 3.1 1.3 1.1 1.5 0.7 0.7 1.4 0.7 
0 0 147 78 69 23.0 101.0 2.5 0.7 1.2 1 0.7 0.7 1.4 0.7 
0 0 145 90 55 18.3 108.3 3.2 1.1 1.1 1.6 0.6 0.5 1.1 0.55 
0 0 141 70 71 23.7 93.7 3.9 1.5 1.1 2.1 0.8 0.8 1.6 0.8 
0 0 115 63 52 17.3 80.3 4.9 3.2 1.2 2.2 0.5 0.6 1.1 0.55 
1 2 140 93 47 15.7 108.7 3.1 0.8 1.1 1.6 0.6 0.6 1.2 0.6 
0 0 147 82 65 21.7 103.7 4 0.4 1.6 2.2 0.4 0.6 1 0.5 
0 0 160 90 70 23.3 113.3 3.1 1.2 1.1 1.5 0.5 0.6 1.1 0.55 
0 0 129 82 47 15.7 97.7 4.5 1.7 1.3 2.5 0.5 0.5 1 0.5 
1 2 168 89 79 26.3 115.3 3.4 1 1.1 1.8 0.7 0.7 1.4 0.7 
0 0 142 81 61 20.3 101.3 4.7 1.9 0.9 3 0.9 0.8 1.7 0.85 
0 0 188 114 74 24.7 138.7 3 0.4 1.3 1.5 0.7 0.6 1.3 0.65 
1 3 140 85 55 18.3 103.3 3 1.1 0.7 1.8 0.5 0.5 1 0.5 
0 0 127 76 51 17.0 93.0 3.4 0.8 0.7 2.3 0.7 0.6 1.3 0.65 
0 0 142 93 49 16.3 109.3 3.6 0.8 1.3 1.9 0.7 0.9 1.6 0.8 
0 0 149 78 71 23.7 101.7 3.8 1.3 1.6 1.6 0.5 0.6 1.1 0.55 
0 0 143 75 68 22.7 97.7 3.8 1 1.4 2.1 0.6 0.6 1.2 0.6 
0 0 170 100 70 23.3 123.3 3.4 0.9 1.3 1.7 0.5 0.6 1.1 0.55 
0 0 140 78 62 20.7 98.7 6.1 0.8 2.1 3.6 0.6 0.6 1.2 0.6 
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0 0 162 82 80 26.7 108.7 5.9 1.4 1.2 4.1 0.7 0.7 1.4 0.7 
0 0 199 110 89 29.7 139.7 3.1 0.5 1.5 1.4 0.4 0.6 1 0.5 
0 0 160 80 80 26.7 106.7 3.8 1 1.3 2 1.8 1.5 3.3 1.65 
1 3 157 88 69 23.00 111.00 3.7 3.1 0.8 1.5 0.6 0.6 1.2 0.6 
0 0 168 100 68 22.67 122.67 4.1 1.9 0.7 2.5 0.5 0.6 1.1 0.55 
0 0 130 70 60 20.00 90.00 3.8 0.7 1.2 2.2 0.7 0.5 1.2 0.6 
0 0 167 94 73 24.33 118.33 4 2.5 1 1.8 0.7 0.7 1.4 0.7 
0 0 165 90 75 25.00 115.00 3.8 2 0.7 2.2 0.7 0.7 1.4 0.7 
0 0 142 80 62 20.67 100.67 3.8 0.9 1.1 2.3 0.7 0.7 1.4 0.7 
1 2 144 80 64 21.33 101.33 2.5 1.9 0.8 0.9 0.7 0.6 1.3 0.65 
0 0 162 74 88 29.33 103.33 3.3 0.6 1.9 1.1 1.7 0.7 2.4 1.2 
1 3 156 81 75 25.00 106.00 4.7 3.2 0.9 2.3 0.7 0.7 1.4 0.7 
1 3 122 65 57 19.00 84.00 5.7 1.2 1 4.1 0.6 0.8 1.4 0.7 
0 0 130 80 50 16.67 96.67 3.5 3.8 0.6 1.2 0.6 0.7 1.3 0.65 
1 3 117 52 65 21.67 73.67 5.2 2.9 0.9 3 0.6 0.5 1.1 0.55 
1 3 166 110 56 18.67 128.67 4.3 0.8 1.2 2.8 0.5 0.5 1 0.5 
1 2 130 65 65 21.67 86.67 3.3 1.9 0.8 1.7 0.7 0.6 1.3 0.65 
0 0 144 88 56 18.67 106.67 4.4 2.2 1.3 2 0.6 0.6 1.2 0.6 
1 2 114 69 45 15.00 84.00 3.9 1.6 1 2.1 0.7 0.6 1.3 0.65 
0 0 155 92 63 21.00 113.00 4.8 2.1 1.8 2 0.6 0.6 1.2 0.6 
0 0 142 80 62 20.67 100.67 3.7 0.9 1 2.3 0.4 0.4 0.8 0.4 
1 2 122 72 50 16.67 88.67 2.3 1.5 0.8 0.8 0.7 0.5 1.2 0.6 
0 0 110 62 48 16.00 78.00 4.1 1.2 1.1 2.4 0.5 0.6 1.1 0.55 
0 0 120 80 40 13.33 93.33 4.3 1.1 1.3 2.5 0.6 0.6 1.2 0.6 
0 0 163 100 63 21.00 121.00 3.9 0.9 1.3 2.2 0.6 0.6 1.2 0.6 
0 0 144 65 79 26.33 91.33 3.9 0.9 1.4 2.1 0.6 0.8 1.4 0.7 
1 2 147 73 74 24.67 97.67 4.5 2.1 1.2 2.3 0.6 0.6 1.2 0.6 
1 3 144 83 61 20.33 103.33 4.3 1.6 1.2 2.3 0.6 0.4 1 0.5 
0 0 158 89 69 23.00 112.00 4.3 1.7 1.7 1.8 0.6 0.7 1.3 0.65 
 
LBIF LICA RBIF RICA PLAQUE Plq No 
PLQ 
Score Plq type nwLCCA nwLBIF nwLICA nwRCCA nwRBIF nwRICA 
0.5 0.6 0.4 0.6 0 0 0   0.6 0 0 0.6 0 0 
0.5 0.5 0.7 0.6 0 0 0   0.7 0 0 0.7 0 0 
0.8 0.6 0.8 0.7 0 0 0   0.6 0 0 0.7 0 0 
0.6 0.7 0.7 0.7 0 0 0   0.7 0 0 0.7 0 0 
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0.5 0.5 0.6 0.5 0 0 0   0.5 0 0 0.5 0 0 
0.5 0.7 0.6 0.5 0 0 0   0.5 0 0 0.6 0 0 
0.8 0.7 0.9 0.7 0 0 0   0.7 0.8 0.7 0.9 0.6 0.5 
1 0.8 0.5 0.3 0 0 0   0.7 0 0 0.5 0 0.5 
0.8 0.4 1.5 0.7 0 0 0   0.6 0 0 0.6 0 0 
0.7 0.7 0.7 0.4 0 0 0   0.7 0 0 0.5 0 0 
0.4 0.4 0.5 0.4 0 0 0   0.5 0.4 0.4 0.6 0.5 0.5 
0.9 0.6 0.7 0.6 0 0 0   0.7 0.9 0.6 0.6 0.7 0.6 
0.9 0.5 0.7 0.6 0 0 0   0.6 0.6 0.5 0.6 0.6 0.6 
0.7 0.6 0.5 0.5 0 0 0   0.7 0.5 0.5 0.5 0.5 0.6 
1.1 0.4 0.6 0.5 0 0 0   0.6 1.1 0.5 0.7 0.4 0.7 
1.3 0.6 1.1 0.6 0 0 0   1.5 0 0.6 1.1 0 1.3 
1.3 0.9 0.7 0.7 0 0 0   0.7 0.5 0 0.8 0 0.9 
0.8 0.7 0.9 0.9 1 1 1.3 C 0.6 0 0.7 0.6 0 0 
0.7 0.5 0.7 0.6 1 1 1.4 C 0.6 0 0 0.6 0 0 
1.4 0.6 0.9 0.9 1 2 3.1 M 1.1 0 0 0.9 0 0 
0.6 0.6 0.8 0.7 1 1 1.1 S 0.7 0 0 0.6 0 0 
0.9 0.7 1.1 0.8 1 3 6.7 C 0.7 0 0 0.7 0 0 
0.9 0.8 1.2 0.8 1 2 3.5 C 0.7 1 0.6 0.8 1.1 0.6 
1.3 0.6 1.5 0.5 1 2 3.7 C 0.9 0 0 0.9 0 1.5 
0.8 0.9 1.5 1.3 1 2 2.9 C 0.8 0.7 1 1 1.5 1 
0.5 0.4 0.5 0.5 1 3 4.1 C 0.6 0.6 0.4 0.6 0.4 0.5 
0.7 0.4 0.4 0.8 1 1 1.3 C 0.6 0.7 0.4 0.6 0.9 0.7 
1 0.5 0.7 0.4 1 2 2.2 C 0.6 0.7 0.5 0.5 0.4 0.6 
2.5 0.6 0.6 0.7 1 3 6.2 C 0.7 0 0 0.5 0 0.8 
0.9 1.7 1.7 0.6 1 6 8.7 C 0.6 0 0 0.7 0 0 
0.7 0.8 0.6 0.9 1 1 2.2 C 1.3 1.4 0.7 0.7 0.9 0.6 
1 0.7 1.1 0.8 1 2 4.9 C 0.9 0 0.8 0.9 0.6 1 
1.7 1.1 0.5 0.6 1 4 7.8 C 0.6 1 1.1 0.5 0 1.1 
0.5 0.5 0.6 0.5 0 0 0   0.4 0.6 0.5 0.5 0.6 0.5 
0.6 0.4 0.6 0.6 0 0 0   0.4 0 0 0.6 0 0 
0.6 0.5 0.6 0.6 0 0 0   0.7 0 0 0.6 0 0.4 
0.7 0.6 0.6 0.6 0 0 0   0.8 0 0 0.8 0 0 
0.9 0.7 0.8 0.7 0 0 0   0.7 0 0 0.7 0 0 
0.6 0.5 0.6 0.6 0 0 0   0.6 0 0 0.5 0 0 
0.6 0.7 0.8 0.6 0 0 0   0.7 0 0 0.7 0 0 
0.8 0.5 0.6 0.5 0 0 0   0.5 0 0 0.7 0 0 
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2.3 1 0.8 0.8 0 0 0   0.6 0 0 0.6 0 0 
0.5 0.5 0.6 0.4 0 0 0   0.4 0 0 0.6 0 0 
0 0 0.7 0.4 0 0 0   0.5 0.8 0 0.5 0.7 0 
0.8 0.5 0.5 0.4 0 0 0   0.5 0.8 0.4 0.5 0.7 0.6 
0.7 0.5 1 0.8 0 0 0   0.7 0.7 0.5 0.7 0.7 0.5 
0.7 0.6 0.7 0.6 0 0 0   0.9 0.8 0.6 0.8 0.6 0.5 
0.6 0.5 0.5 0.4 0 0 0   0.7 0.8 0.5 0.6 0.5 0.4 
0.6 0.5 0.6 0.5 0 0 0   0.6 0.7 0.5 0.5 0.5 0.6 
0.9 0.5 1.1 0.4 0 0 0   0.7 0 0 0.6 0 0 
1 0.5 1.7 0.7 0 0 0   0.4 0.7 0.5 0.5 0.7 0.7 
0.6 0.6 0.5 0.5 0 0 0   0.6 0.5 0.5 0.6 0.5 0.5 
0.8 0.5 0.7 0.5 0 0 0   0.8 0 0 0.5 1.1 0 
0.8 0.6 0.7 0.5 1 3 4.8 C 0.7 0 0 0.5 0 0 
0.6 0.4 0.5 0.4 1 4 7.6 M 0.6 1 0.4 0.6 0.6 0.5 
1 0.5 1.5 0.6 1 2 3.7 C 0.7 0.7 0.5 0.7 0.7 0.6 
0.5 0.4 0.6 0.4 1 2 4.8 C 0.5 0 0.4 0.4 0.9 0.4 
1.2 0 2 0.6 1 3 5 C 0.7 0 0 0.6 0 0 
0.6 0.4 0.8 0.7 0 0 0   0.5 0.5 0 0.6 0.7 0 
0.6 0.5 0.5 0.7 0 0 0   0.6 0.4 0.4 0.6 0.4 0.6 
0.4 0.4 0.5 0.6 0 0 0   0.6 0.4 0.4 0.5 0.6 0.6 
0.8 0.5 0.6 0.6 0 0 0   0.7 0.6 0.5 0.7 0.6 0.6 
0.5 0.5 0.7 0.5 0 0 0   0.5 0 0 0.7 0 0 
1.1 0.9 0.9 0.5 1 1 1.5 S 0.7 1.1 1.1 0.7 1 0.7 
1 0.7 1 0.7 1 6 14.8 C 0.7 2 0.6 0.9 0.9 0.7 
0.7 0.9 0.9 0.8 1 7 18.8 C 0.8 0.7 0.7 0.9 0.9 0 
0.6 0.4 0.6 0.4 1 3 4 C 0.4 0 0 0.5 1 0 
0.8 0.6 0.8 0.8 1 4 8.2 C 0.6 0.8 0.8 0.7 0.8 0.8 
0.9 0.7 0.9 0.6 1 3 8 C 0.7 1 0.5 0.9 1.3 0.6 
0.4 0.6 0.7 0.5 0 0 0   0.7 0 0 0.6 0 0 
0.6 0.5 0.5 0.5 0 0 0   0.6 0.6 0.6 0.5 0.6 0.6 
0.6 0.6 0.7 0.9 0 0 0   0.7 0.6 0 0.6 0.7 0 
0.6 0.5 0.6 0.6 0 0 0   0.6 0.9 0.6 0.6 0.8 0.6 
0.5 0.6 0.7 0.6 0 0 0   0.7 0 0 0.5 0 0 
0.5 0.5 0.7 0.6 0 0 0   0.7 0 0 0.7 0 0 
0.7 0.4 0.5 0.5 0 0 0   0.5 0.6 0.5 0.6 0.5 0.5 
0.4 0.5 0.6 0.6 0 0 0   0.6 0.8 0.4 0.6 0.9 0.5 
0.6 0.6 0.7 0.4 0 0 0   0.5 0 0.8 0.6 0.8 0.3 
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0.6 0.5 0.6 0.4 0 0 0   0.6 0.6 0 0.6 0.6 0 
0.8 0.6 0.8 0.5 1 1 1.1 S 0.7 0.8 0 0.7 0.5 0 
1 0.4 0.7 1 1 2 4.1 C 0.8 0.8 1.1 0.8 0.9 0.8 
0.7 0.6 0.5 1.1 1 2 3.6 C 0.5 1.2 0.6 0.7 1 0.7 
0.6 0.7 0.7 0.5 1 4 7 C 0.6 0.5 0 0.5 0.7 0 
0.6 0.6 0.6 0.8 1 1 1.9 C 0.6 0.8 0.6 0.6 0.6 0.8 
 
 
Syst dysf dias dysf EF  FS LVH LVEDD IVSd PWd sum  Sum^3 LVID^3     LVM 
0 1 64.92 35.63 1 4.94 1.32 0.9 7.16 367.06 120.55 246.51 256.37 242.77 
0 1 67.1 36.8 1 4.21 1.6 1.18 6.99 341.53 74.62 266.91 277.59 263.99 
0 0 55 29 0 4.03 0.75 1.15 5.93 208.53 65.45 143.08 148.80 135.20 
0 0 65.5 36 0 4.88 1.41 1.27 7.56 432.08 116.21 315.87 328.50 314.90 
0 1 57.7 30.4 1 4.93 1.66 1.27 7.86 485.59 119.82 365.76 380.40 366.80 
1 1 43 26 1 5.45 1.86 1.19 8.5 614.13 161.88 452.25 470.34 456.74 
0 1 52 28.8 1 5.8 1 1 7.8 474.55 195.11 279.44 290.62 277.02 
0 1 63.1 34.2 1 4.65 1.48 1.26 7.39 403.58 100.54 303.04 315.16 301.56 
0 1 66 37 1 5.62 0.96 1.48 8.06 523.61 177.50 346.10 359.95 346.35 
1 0 43 21 1 4.66 1.27 1.67 7.6 438.98 101.19 337.78 351.29 337.69 
0 0 66.8 37 1 4.94 1.2 1.28 7.42 408.52 120.55 287.96 299.48 285.88 
0 1 72.4 41.5 1 4.65 2.08 1.72 8.45 603.35 100.54 502.81 522.92 509.32 
0 1 68 34 1 4.3 1.5 1.68 7.48 418.51 79.51 339.00 352.56 338.96 
1 0 40 20 1 6.31 1.26 1.19 8.76 672.22 251.24 420.98 437.82 424.22 
0 0 55 23 2 4.4 1.1 1.03 6.53 278.45 85.18 193.26 200.99 187.39 
1 1 48 24 1 4.65 1.48 1.25 7.38 401.95 100.54 301.40 313.46 299.86 
1 0 46 23.7 1 5.6 1 1.09 7.69 454.76 175.62 279.14 290.31 276.71 
0 1 62.06 34.21 2 6.47 1.77 1.51 9.75 926.86 270.84 656.02 682.26 668.66 
0 1 54.87 28.4 1 5.01 1.48 1.15 7.64 445.94 125.75 320.19 333.00 319.40 
0 1 71.6 40.7 1 4.6 1.27 1.04 6.91 329.94 97.34 232.60 241.91 228.31 
0 1 75.5 44.68 1 5 1.7 1.7 8.4 592.70 125.00 467.70 486.41 472.81 
1 1 48 24.3 1 6.2 1.76 1.49 9.45 843.91 238.33 605.58 629.80 616.20 
0 1 61.61 33.65 1 5.9 2.36 2.13 10.39 1121.62 205.38 916.24 952.89 939.29 
0 1 78.6 47.3 1 4.85 1.53 1.6 7.98 508.17 114.08 394.09 409.85 396.25 
0 1 68 38 1 4.26 1.32 2.13 7.71 458.31 77.31 381.01 396.25 382.65 
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1 0 46 23 3 6.4 1.4 1.2 9 729.00 262.14 466.86 485.53 471.93 
0 1 59 27 1 5.84 1.4 1.5 8.74 667.63 199.18 468.45 487.19 473.59 
0 1 50 25 1 4.43 1.62 1.59 7.64 445.94 86.94 359.01 373.37 359.77 
0 1 62 33.7 1 4.88 1.7 1.13 7.71 458.31 116.21 342.10 355.78 342.18 
0 0 66 36 0 4.9 1.2 0.8 6.9 328.51 117.65 210.86 219.29 205.69 
0 0 58 31 0 5.2 1.7 1.2 8.1 531.44 140.61 390.83 406.47 392.87 
0 1 76 45 1 4.24 1.5 1.26 7 343.00 76.23 266.77 277.45 263.85 
1 0 32 15 3 6.5 1 1 8.5 614.13 274.63 339.50 353.08 339.48 
0 0 66 36 0 3.88 1.08 1.01 5.97 212.78 58.41 154.37 160.54 146.94 
0 0 71.7 41.2 3 5.28 1.12 0.88 7.28 385.83 147.20 238.63 248.18 234.58 
0 0 68.49 38.37 1 4.88 1.34 1.25 7.47 416.83 116.21 300.62 312.64 299.04 
0 1 59 31.25 1 4.54 1.42 1.36 7.32 392.22 93.58 298.65 310.59 296.99 
0 1 54 28 1 4.31 1.27 1.21 6.79 313.05 80.06 232.98 242.30 228.70 
0 1 58 30.5 1 4.52 1.3 1.39 7.21 374.81 92.35 282.46 293.76 280.16 
0 0 72.4 41.4 1 4.54 1.63 1.29 7.46 415.16 93.58 321.58 334.45 320.85 
0 1 64.13 34.3 1 3.8 1.51 1.39 6.7 300.76 54.87 245.89 255.73 242.13 
0 1 67.33 36.99 1 4.14 1.59 1.08 6.81 315.82 70.96 244.86 254.66 241.06 
1 0 40 20 1 3.73 1.51 1.16 6.4 262.14 51.90 210.25 218.66 205.06 
0 1 71 41.1 1 5.19 1.19 1.08 7.46 415.16 139.80 275.36 286.38 272.78 
0 1 70 39 1 4.49 1.55 1.38 7.42 408.52 90.52 318.00 330.72 317.12 
1 0 47.9 32 1 5.77 1.53 1.24 8.54 622.84 192.10 430.74 447.97 434.37 
0 1 74 38 1 4.82 1.64 1.38 7.84 481.89 111.98 369.91 384.71 371.11 
0 1 52 26.1 1 5 1.1 1.24 7.34 395.45 125.00 270.45 281.26 267.66 
0 0 66.3 36.1 0 4.07 0.96 1.3 6.33 253.64 67.42 186.22 193.67 180.07 
0 1 54.7 27.8 1 4.32 1.21 1.18 6.71 302.11 80.62 221.49 230.35 216.75 
1 0 36 18 1 4.9 1.21 1.18 7.29 387.42 117.65 269.77 280.56 266.96 
0 0 52 26 1 3.79 1.3 1.22 6.31 251.24 54.44 196.80 204.67 191.07 
0 1 76 45 1 5 1.2 1.2 7.4 405.22 125.00 280.22 291.43 277.83 
0 1 79.1 47.5 1 4.32 2.38 1.61 8.31 573.86 80.62 493.23 512.96 499.36 
0 1 60 32.5 1 4.78 1.98 1.42 8.18 547.34 109.22 438.13 455.65 442.05 
0 1 73 42 1 5.2 1.75 1.2 8.15 541.34 140.61 400.74 416.76 403.16 
0 1 76 36 1 4.88 1.31 1.43 7.62 442.45 116.21 326.24 339.29 325.69 
0 0 76.8 45.7 1 4.98 1.64 1.48 8.1 531.44 123.51 407.94 424.25 410.65 
0 0 62.8 34.1 0 5.04 1.11 0.89 7.04 348.91 128.02 220.89 229.73 216.13 
0 1 58.5 31.3 1 5.43 0.79 1.99 8.21 553.39 160.10 393.28 409.02 395.42 
0 1 72.1 41.9 1 5.94 1.09 1.34 8.37 586.38 209.58 376.79 391.86 378.26 
0 1 76 44.8 1 4.94 1.43 1.1 7.47 416.83 120.55 296.28 308.13 294.53 
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0 1 54.2 28.3 1 5.22 1.9 1.63 8.75 669.92 142.24 527.69 548.79 535.19 
0 0 63.8 34.7 1 4.7 1.68 1.39 7.77 469.10 103.82 365.27 379.89 366.29 
0 1 66.5 36.9 1 5.09 2.27 1.44 8.8 681.47 131.87 549.60 571.58 557.98 
1 1 48 24 1 6 1.4 0.98 8.38 588.48 216.00 372.48 387.38 373.78 
0 1 63.2 34.2 1 4.9 1.48 1.4 7.78 470.91 117.65 353.26 367.39 353.79 
1 1 35 17 3 6.09 0.99 1.1 8.18 547.34 225.87 321.48 334.34 320.74 
0 1 58 32 1 6.9 1.04 1.27 9.21 781.23 328.51 452.72 470.83 457.23 
0 1 65.9 36 0 4.26 1.11 1.05 6.42 264.61 77.31 187.30 194.79 181.19 
0 1 54.4 28.4 1 5.39 1.99 1.53 8.91 707.35 156.59 550.76 572.79 559.19 
0 0 57 28.9 1 4.71 1.28 1.1 7.09 356.40 104.49 251.91 261.99 248.39 
1 1 44.3 22.2 1 4.09 1.37 1.39 6.85 321.42 68.42 253.00 263.12 249.52 
0 0 69.1 38.2 0 3.9 0.89 0.82 5.61 176.56 59.32 117.24 121.93 108.33 
0 1 71.7 39.4 1 2.8 1.57 0.89 5.26 145.53 21.95 123.58 128.52 114.92 
0 1 74.4 42.1 1 3.23 1.36 1.08 5.67 182.28 33.70 148.59 154.53 140.93 
0 0 63 34 1 4.61 1.43 1 7.04 348.91 97.97 250.94 260.98 247.38 
0 1 78.2 45.5 0 3.12 1.02 1.48 5.62 177.50 30.37 147.13 153.02 139.42 
0 1 60.3 32 1 4.41 1.31 1.16 6.88 325.66 85.77 239.89 249.49 235.89 
1 1 48.6 24.4 2 5.09 1.64 1.3 8.03 517.78 131.87 385.91 401.35 387.75 
1 0 36 17.5 3 5.85 1.4 1.4 8.65 647.21 200.20 447.01 464.89 451.29 
0 0 80 49.1 2 5.41 1.55 1.15 8.11 533.41 158.34 375.07 390.07 376.47 
0 1 73.3 41.9 1 4.2 1.39 1.26 6.85 321.42 74.09 247.33 257.22 243.62 
1 0 50 25 2 6.5 1.3 1.32 9.12 758.55 274.63 483.93 503.28 489.68 
 
HT Ht wt wt x Ht   BSA LVMI  RWT VALVES Hs CRP  LP(a)  HCY ADPN Ca Phos Ca x PO4 PTH HB 
1.66 166 63 10458.00 2.91 1.70 142.44 0.36 0 5 35.2 7 21.85      
1.48 148 33 4884.00 1.36 1.16 226.65 0.56 2 4 118 12.85 32.55      
1.75 175 59.6 10430.00 2.90 1.70 79.43 0.57 0 2 101.6 22.92 24.67      
1.65 165 55 9075.00 2.52 1.59 198.34 0.52 0 2 77.6 27.11 18.83      
1.62 162 56.4 9136.80 2.54 1.59 230.24 0.52 0 2 167.6 17.12 32.55      
1.77 177 91.3 16160.10 4.49 2.12 215.57 0.44 0 7 13.6 29.33 10.33      
1.67 167 70.5 11773.50 3.27 1.81 153.18 0.34 0 5 37.7 22.89 32.55      
1.71 171 66.3 11337.30 3.15 1.77 169.93 0.54 2 6 44.2 26.47 6.97      
1.77 177 77.9 13788.30 3.83 1.96 176.97 0.53 0 1 8.5 15.64 28.16      
1.59 159 57 9063.00 2.52 1.59 212.83 0.72 0 3 50.6 14.03 15.59      
1.65 165 56.9 9388.50 2.61 1.61 177.03 0.52 0 8 71.3 9.2 13.7      
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1.59 159 51 8109.00 2.25 1.50 339.36 0.74 2 7 56.4 22.55 32.55      
1.62 162 56 9072.00 2.52 1.59 213.53 0.78 2 2 6.4 15.6 25.16      
1.73 173 56.5 9774.50 2.72 1.65 257.45 0.38 1; 2 3 26.2 9.44 32.55      
1.69 169 47.2 7976.80 2.22 1.49 125.89 0.47 0 0.1 40.9 18.67 20.26      
1.76 176 62.7 11035.20 3.07 1.75 171.27 0.54 1,3 4.8 112 20.83 30.68      
1.71 171 73 12483.00 3.47 1.86 148.60 0.39 0 1.7 14.4 29.04 8.77      
1.74 174 80 13920.00 3.87 1.97 340.05 0.47 0 16 38.8 21.68 12.82      
1.72 172 75.7 13020.40 3.62 1.90 167.95 0.46 0 5 30.8 27.83 11.5      
1.62 162 57.7 9347.40 2.60 1.61 141.69 0.45 0 6 32.5 20.91 16.66      
1.72 172 76 13072.00 3.63 1.91 248.12 0.68 0 2 25.6 16.75 9.34      
1.68 168 64.3 10802.40 3.00 1.73 355.73 0.48 0 10 135.2 22.72 32.55      
1.83 183 82 15006.00 4.17 2.04 460.07 0.72 0 3 26.2 20.63 32.55      
1.66 166 60.3 10009.80 2.78 1.67 237.63 0.66 0 1 56.5 17.59 16.43      
1.5 150 47.2 7080.00 1.97 1.40 272.85 1.00 0 14 15.4 14.69 24.21      
1.69 169 59.8 10106.20 2.81 1.68 281.67 0.38 1 20 119.3 15.73 32.55      
1.78 178 57 10146.00 2.82 1.68 282.10 0.51 0 2 81.1 21.01 28.2      
1.61 161 60 9660.00 2.68 1.64 219.63 0.72 0 8.9 51.3 20.95 30.68      
1.7 170 84.5 14365.00 3.99 2.00 171.30 0.46 0 3 57.8 21.94 32.55      
1.62 162 67.9 10999.80 3.06 1.75 117.67 0.33 1 25.6 11.5 26.92 23.77      
1.67 167 77.9 13009.30 3.61 1.90 206.67 0.46 0 2 18.1 20.59 10.14      
1.71 171 72.2 12346.20 3.43 1.85 142.47 0.59 0 4.8 28.1 20.65 30.68      
1.62 162 69 11178.00 3.11 1.76 192.66 0.31 1,2 8 26.3 15.76 30.68      
1.57 157 54.1 8493.70 2.36 1.54 95.66 0.52 0 7 142.6 23.6 30.68      
1.61 161 63 10143.00 2.82 1.68 139.75 0.33 2 1 32.9 23.44 15.34      
1.62 162 69.4 11242.80 3.12 1.77 169.22 0.51 0 6 58.2 22.11 30.68      
1.62 162 78.2 12668.40 3.52 1.88 158.32 0.60 0 3 60.6 27.04 14.04      
1.52 152 63.5 9652.00 2.68 1.64 139.67 0.56 0 1 3.6 11.4 20.2      
1.5 150 53 7950.00 2.21 1.49 188.53 0.62 0 31 21.5 13.71 29.64      
1.54 154 93.6 14414.40 4.00 2.00 160.34 0.57 0 22 69.1 21.9 22.43      
1.65 165 106 17490.00 4.86 2.20 109.85 0.73 0 3 22.2 28.1 24.4      
1.64 164 66.7 10938.80 3.04 1.74 138.29 0.52 2 3 1.7 26.71 15.29      
1.5 150 50.4 7560.00 2.10 1.45 141.50 0.62 2 11 93.9 15.03 30.68      
1.5 150 52.8 7920.00 2.20 1.48 183.91 0.42 0 3 13.5 23.96 8.35      
1.55 155 53.5 8292.50 2.30 1.52 208.94 0.61 0 1.2 48.1 18.77 27.19      
1.64 164 59 9676.00 2.69 1.64 264.95 0.43 1 5 46.5 14.61 30.68      
1.52 152 90 13680.00 3.80 1.95 190.37 0.57 0 8 54.1 28.06 15.98      
1.49 149 58 8642.00 2.40 1.55 172.76 0.50 0 3 31.5 21.66 30.68      
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1.54 154 88 13552.00 3.76 1.94 92.81 0.64 0 1 75.5 16.63 0.09      
1.59 159 88 13992.00 3.89 1.97 109.94 0.55 0 1 26.5 24.3 30.68      
1.49 149 56.4 8403.60 2.33 1.53 174.73 0.48 0 52 23.6 18.87 30.68      
1.66 166 52 8632.00 2.40 1.55 123.39 0.64 0 0.1 69.9 21.62 22.34      
1.64 164 63.4 10397.60 2.89 1.70 163.48 0.48 1 4 5.2 16.85 30.68      
1.66 166 70.3 11669.80 3.24 1.80 277.36 0.75 2 4 32.5 12.59 31.31      
1.55 155 68.5 10617.50 2.95 1.72 257.40 0.59 1 7 10.7 25.97 30.68      
1.55 155 71 11005.00 3.06 1.75 230.59 0.46 0 3.9 102.3 19.44 24      
1.64 164 48.5 7954.00 2.21 1.49 219.11 0.59 1 3 71.5 28.26 30.68      
1.56 156 69.8 10888.80 3.02 1.74 236.12 0.59 1,2 41.8 2 26.74 25.55      
1.57 157 51.7 8116.90 2.25 1.50 143.93 0.35 2 1 24.5 20.13 7.57      
1.8 180 105.5 18990.00 5.28 2.30 172.16 0.73 0 75 4.1 40.93 8.1      
1.57 157 60.5 9498.50 2.64 1.62 232.87 0.45 0 4.1 47.3 13.81 23.15      
1.67 167 75.3 12575.10 3.49 1.87 157.59 0.45 0 11 1.7 10.9 18.44      
1.79 179 87 15573.00 4.33 2.08 257.32 0.62 3,4 6 7.7 21.01 10.98      
1.73 173 56.4 9757.20 2.71 1.65 222.49 0.59 0 11 5.2 19.65 10.77      
1.76 176 70.1 12337.60 3.43 1.85 301.41 0.57 1,2,3 3 13.3 17.83 32.55      
1.72 172 70 12040.00 3.34 1.83 204.39 0.33 0 4 24.9 23.8 23.34      
1.67 167 62 10354.00 2.88 1.70 208.62 0.57 0 8 24.3 15.66 12.82      
1.63 163 59 9617.00 2.67 1.63 196.24 0.36 0 6 88.8 13.72 22.23      
1.78 178 82.5 14685.00 4.08 2.02 226.39 0.37 0 5 47.8 20.19 7.33      
1.55 155 58.4 9052.00 2.51 1.59 114.27 0.49 0 5 29.1 14.86 16.93      
1.66 166 55.4 9196.40 2.55 1.60 349.86 0.57 3 6 98.5 36.55 30.68      
1.66 166 100.3 16649.80 4.62 2.15 115.50 0.47 0 8 26.3 25.34 9.51      
1.58 158 48 7584.00 2.11 1.45 171.91 0.68 0 7 76.6 20.58 23.15      
1.57 157 52.5 8242.50 2.29 1.51 71.59 0.42 0 2 6.3 23.61 10.37      
1.58 158 37 5846.00 1.62 1.27 90.18 0.64 0 3 3.2 13.13 32.55      
1.55 155 48 7440.00 2.07 1.44 98.03 0.67 0 1 128.2 16.9 32.55      
1.55 155 60.5 9377.50 2.60 1.61 153.27 0.43 2 4 2.3 22.81 17.86      
1.48 148 52.4 7755.20 2.15 1.47 94.99 0.95 0 1 15.5 17.48 22.56      
1.5 150 50 7500.00 2.08 1.44 163.43 0.53 2 8 7.5 14.42 19.53      
1.68 168 50 8400.00 2.33 1.53 253.84 0.51 0 8 5.8 10.69 5.36      
1.64 164 67.8 11119.20 3.09 1.76 256.79 0.48 1 4 12.6 20.04 30.68      
1.65 165 78 12870.00 3.58 1.89 199.11 0.43 1,2,3,4 10 3.2 40.56 13.57      
1.45 145 57 8265.00 2.30 1.52 160.79 0.60 1,2,3 7 39.5 15.1 32.55      
1.65 165 68.7 11335.50 3.15 1.77 275.96 0.41 1,3 48 37.2 17.11 22.82      
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Appendix D 
 
Controls age  sex Race SUBJECT FHx MI FHx HTN FHx DM FHx CKD height weight HT SQ BMI Controls Smoking 
1 30 2 2 2 0 0 0 0 1.68 67.0 2.82 23.74 1 1 
2 38 2 2 2 0 1 1 0 1.59 52.8 2.53 20.89 2 0 
3 30 2 2 2 0 0 0 0 1.70 75.6 2.89 26.16 3 2 
4 42 2 2 2 1 0 0 0 1.63 57.0 2.66 21.45 4 2 
5 32 2 2 2 0 0 1 0 1.56 70.2 2.43 28.85 5 0 
6 27 2 2 2 0 0 0 0 1.63 58.0 2.66 21.83 6 0 
7 56 2 2 2 0 0 0 0 1.65 69.6 2.72 25.56 7 0 
8 41 2 2 2 0 0 0 0 1.50 52.0 2.25 23.11 8 0 
9 36 2 2 2 0 0 0 0 1.64 64.5 2.69 23.98 9 0 
10 22 2 2 2 0 0 0 0 1.64 53.5 2.69 19.89 10 0 
11 26 2 2 2 1 0 1 0 1.68 64.4 2.82 22.82 11 0 
12 29 2 2 2 0 0 0 0 1.72 58.0 2.96 19.61 12 0 
13 51 2 2 2 1 1 0 0 1.57 64.5 2.46 26.17 13 0 
14 22 2 2 2 1 1 1 0 1.56 45.2 2.43 18.57 14 2 
15 23 1 2 2 0 0 0 0 1.75 66.0 3.06 21.55 15 0 
16 26 1 2 2 1 1 0 0 1.64 78.0 2.69 29.00 16 0 
17 39 1 2 2 1 1 1 0 1.67 60.0 2.79 21.51 17 1 
18 30 1 2 2 1 1 0 0 1.68 80.0 2.82 28.34 18 2 
19 54 1 2 2 0 0 0 0 1.72 94.0 2.96 31.77 19 0 
20 53 1 2 2 0 0 0 0 1.73 82.5 2.99 27.57 20 1 
21 23 1 2 2 1 1 1 1 1.75 71.5 3.06 23.35 21 1 
22 27 1 2 2 0 0 0 1 1.71 72.0 2.92 24.62 22 2 
23 54 1 2 2 0 0 0 1 1.77 82.0 3.13 26.17 23 2 
24 40 1 2 2 0 0 0 0 1.65 65.7 2.72 24.13 24 1 
25 46 1 2 2 1 0 1 0 1.84 97.2 3.39 28.71 25 1 
26 34 2 1 2 0 1 0 0 1.49 68.3 2.22 30.76 26 0 
27 38 2 1 2 0 0 0 0 1.66 47.0 2.76 17.06 27 0 
28 44 2 1 2 0 1 0 0 1.59 81.2 2.53 32.12 28 0 
29 47 2 1 2 1 1 1 1 1.58 87.1 2.50 34.89 29 0 
30 45 2 1 2 0 0 0 0 1.65 92.0 2.72 33.79 30 0 
31 49 2 1 2 0 1 0 0 1.65 61.6 2.72 22.63 31 0 
32 36 2 1 2 0 0 0 0 1.72 61.2 2.96 20.69 32 0 
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33 40 2 1 2 0 1 1 0 1.62 67.0 2.62 25.53 33 0 
34 27 2 1 2 0 1 0 0 1.54 59.2 2.37 24.96 34 0 
35 56 2 1 2 0 1 0 0 1.62 68.0 2.62 25.91 35 0 
36 49 2 1 2 0 1 1 0 1.60 78.5 2.56 30.66 36 0 
37 39 2 1 2 0 0 0 0 1.57 47.4 2.46 19.23 37 0 
38 49 2 1 2 0 1 0 0 1.58 86.0 2.50 34.45 38 0 
39 21 2 1 2 0 1 0 0 1.65 48.5 2.72 17.81 39 0 
40 40 1 1 2 0 0 0 0 1.72 68.2 2.96 23.05 40 2 
41 31 1 1 2 1 1 0 1 1.70 60.2 2.89 20.83 41 0 
42 41 1 1 2 1 0 1 0 1.79 85.5 3.20 26.68 42 0 
43 49 1 1 2 0 0 0 0 1.70 70.0 2.89 24.22 43 1 
44 22 1 1 2 0 1 0 0 1.64 60.6 2.69 22.53 44 0 
45 20 1 1 2 0 0 1 0 1.73 72.5 2.99 24.22 45 0 
46 28 1 1 2 0 0 0 0 1.80 84.0 3.24 25.93 46 0 
47 51 1 1 2 1 1 0 1 1.61 67.5 2.59 26.04 47 0 
48 43 1 1 2 0 1 0 0 1.83 85.0 3.35 25.38 48 0 
49 51 1 1 2 0 0 0 0 1.64 72.0 2.69 26.77 49 2 
50 46 1 1 2 0 0 0 0 1.64 77.9 2.69 28.96 50 2 
51 45 1 1 2 0 0 0 0 1.60 53.5 2.56 20.90 51 1 
52 50 1 1 2 0 0 0 1 1.77 55.6 3.13 17.75 52 1 
53 46 1 1 2 0 1 0 1 1.62 62.7 2.62 23.89 53 0 
54 58 2 1 2 0 1 1 0 1.68 103.0 2.82 36.49 54 0 
55 51 2 2 2 0 0 0 0 1.65 84.1 2.72 30.89 55 2 
56 43 2 1 2 0 1 0 0 1.50 72.8 2.25 32.36 56 0 
57 39 2 1 2 0 1 0 0 1.49 62.4 2.22 28.11 57 0 
58 39 1 1 2 0 0 0 0 1.78 93.3 3.17 29.45 58 0 
59 52 2 2 2 0 0 0 1 1.52 50.0 2.31 21.64 59 1 
60 55 1 1 2 0 0 0 0 1.60 67.3 2.56 26.29 60 0 
61 51 1 1 2 0 0 0 0 1.60 67.2 2.56 26.25 61 1 
62 42 1 1 2 0 0 0 0 1.75 70.0 3.06 22.86 62 1 
63 50 1 2 2 0 1 1 0 1.83 113.0 3.35 33.74 63 0 
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Quantity exercise Ex FREQ SBP  DBP Pulse P PP/3 MAP total chol Controls TG HDL LDL LCCA RCCA 
1 1 1 126 66 60 20.00 86.00 4.8 1 1.1 1.5 2.8 0.5 0.5 
0 1 1 90 60 30 10.00 70.00 6.7 2 1.3 1.1 4.9 0.6 0.4 
0 0 0 123 74 49 16.33 90.33 6.2 3 1.0 1.4 4.3 0.4 0.5 
0 0 0 128 72 56 18.67 90.67 5.4 4 1.4 1.9 2.9 0.6 0.7 
0 1 3 117 74 43 14.33 88.33 5.3 5 0.9 1.0 3.9 0.7 0.5 
0 0 0 110 60 50 16.67 76.67 4.5 6 0.8 1.6 2.5 0.6 0.6 
0 0 0 122 80 42 14.00 94.00 5.5 7 1.2 1.9 3.0 0.5 0.6 
0 1 3 100 56 44 14.67 70.67 6.6 8 1.4 1.4 4.5 0.4 0.5 
0 1 3 90 70 20 6.67 76.67 4.7 9 1.5 1.6 2.4 0.5 0.6 
0 1 2 100 60 40 13.33 73.33 5.4 10 1.3 2.3 2.5 0.5 0.5 
0 0 0 100 70 30 10.00 80.00 4.6 11 1.0 1.5 2.6 0.5 0.5 
0 1 2 110 76 34 11.33 87.33 4.6 12 0.9 1.4 2.7 0.6 0.5 
0 0 0 120 70 50 16.67 86.67 5.9 13 1.3 1.7 3.6 0.7 0.7 
1 0 0 90 60 30 10.00 70.00 3.8 14 0.6 1.4 2.1 0.4 0.5 
0 1 3 110 70 40 13.33 83.33 5.7 15 2.1 1.2 3.5 0.5 0.4 
0 1 2 128 65 63 21.00 86.00 5.6 16 1.3 1.3 3.8 0.5 0.4 
1 1 3 110 70 40 13.33 83.33 4.6 17 1.8 1.1 2.7 0.5 0.5 
0 1 2 131 76 55 18.33 94.33 4.9 18 1.1 1.0 3.4 0.5 0.5 
0 0 0 134 80 54 18.00 98.00 6.4 19 3.4 1.3 3.5 0.7 0.7 
1 1 3 130 80 50 16.67 96.67 5 20 2.3 3.1 0.8 0.6 0.5 
1 1 1 127 65 62 20.67 85.67 6.6 21 3.1 1.3 3.9 0.4 0.5 
2 1 3 120 80 40 13.33 93.33 7.3 22 2.0 1.1 5.3 0.5 0.5 
1 1 3 130 80 50 16.67 96.67 6.2 23 0.9 1.4 4.4 0.7 0.8 
2 0 0 120 70 50 16.67 86.67 3.6 24 1.1 1.1 2.0 0.5 0.6 
2 1 3 130 90 40 13.33 103.33 6.4 25 1.4 1.1 4.7 1.2 1.4 
0 0 0 128 81 47 15.67 96.67 4.6 26 1.4 1.0 3.0 0.6 0.5 
0 0 0 100 60 40 13.33 73.33 3.7 27 0.8 1.7 1.7 0.4 0.5 
0 0 0 133 81 52 17.33 98.33 3.6 28 1.1 1.6 1.5 0.7 0.7 
0 0 0 136 91 45 15.00 106.00 4.9 29 3.8 1.0 2.2 0.7 0.6 
0 0 0 140 88 52 17.33 105.33 4.7 30 1.4 1.4 2.7 0.8 0.8 
0 1 3 122 71 51 17.00 88.00 4.3 31 1.0 1.2 2.6 0.6 0.6 
0 0 0 100 70 30 10.00 80.00 3.5 32 1.0 0.9 2.1 0.5 0.7 
0 0 0 120 80 40 13.33 93.33 6.3 33 1.5 1.4 4.2 0.6 0.6 
 133
0 1 1 112 61 51 17.00 78.00 5.5 34 1.1 0.9 4.1 0.5 0.6 
0 0 0 134 76 58 19.33 95.33 6.7 35 2.1 1.4 4.3 0.6 0.8 
0 1 1 111 67 44 14.67 81.67 4.6 36 1.3 1.1 2.9 0.6 0.8 
0 0 0 97 73 24 8.00 81.00 2.8 37 1.1 1.5 0.8 0.5 0.5 
0 0 0 128 78 50 16.67 94.67 5.4 38 1.2 2.1 2.7 0.6 0.6 
0 0 0 128 74 54 18.00 92.00 4.7 39 0.8 1.3 3.0 0.5 0.5 
1 1 3 120 70 50 16.67 86.67 3.7 40 6.1 0.6 0* 0.7 0.7 
0 0 0 132 67 65 21.67 88.67 4.9 41 1.0 1.1 3.3 0.5 0.5 
0 0 0 136 90 46 15.33 105.33 5.1 42 1.1 1.2 3.4 0.7 0.8 
1 1 1 120 80 50 16.67 96.67 4.2 43 3.6 1.1 1.4 0.5 0.5 
0 1 1 135 76 59 19.67 95.67 5.7 44 0.9 1.2 4.2 0.5 0.6 
0 0 0 118 57 61 20.33 77.33 2.8 45 1.5 1.1 1.0 0.4 0.5 
0 1 3 120 80 40 13.33 93.33 4.3 46 1.4 1.4 2.3 0.5 0.5 
0 0 0 110 70 40 13.33 83.33 4 47 0.9 1.1 2.4 0.8 0.9 
0 1 1 120 75 45 15.00 90.00 3.8 48 1.5 0.9 2.2 0.6 0.5 
1 1 3 130 90 40 13.33 103.33 4.9 49 1.2 1.1 3.2 0.8 0.7 
0 0 0 120 90 30 10.00 100.00 2.6 50 1.2 0.3 0.7 0.5 0.5 
2 1 1 120 80 40 13.33 93.33 2.8 51 0.7 1.1 1.4 0.6 0.7 
1 0 0 114 65 49 16.33 81.33 4.7 52 1.3 0.9 3.2 0.8 1.2 
0 0 0 130 92 38 12.67 104.67 3.2 53 0.9 0.9 1.9 0.7 0.6 
0 0 0 137 80 57 19.00 99.00 4.1 54 0.9 1.0 2.7 0.8 0.9 
0 1 2 135 81 54 18.00 99.00 9 55 5.3 0.9 0* 0.7 0.5 
0 0 0 128 75 53 17.67 92.67 8.8 56 2.4 1.1 6.5 0.6 0.6 
0 0 0 150 100 50 16.67 116.67 4.3 57 0.7 1.0 3.0 0.6 0.6 
0 1 1 110 80 30 10.00 90.00 5.8 58 2.7 1.1 3.5 0.7 0.7 
1 0 0 100 65 35 11.67 76.67 4.4 59 0.9 1.7 2.3 0.8 0.8 
0 1 3 135 82 53 17.67 99.67 4.6 60 2.8 1.1 2.3 0.9 0.8 
1 0 0 120 60 60 20.00 80.00 4.6 61 1.4 1.7 2.3 0.7 0.6 
1 0 0 110 60 50 16.67 76.67 5.2 62 1.6 1.0 3.5 0.7 0.5 
0 1 2 120 90 30 10.00 100.00 3.9 63 0.9 1.0 2.4 0.8 0.7 
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s CCA CIMT  LBIF LICA RBIF RICA PLAQUE Plq No 
PLQ 
Score Plq type nwLCCA nwLBIF nwLICA nwRCCA nwRBIF 
1.0 0.50 0.6 0.4 0.5 0.5 0 0 0 0 0.4 0.4 0.4 0.5 0.4 
1.0 0.50 0.5 0.5 0.9 0.4 0 0 0 0 0.6 0.5 0.4 0.5 0.5 
0.9 0.45 0.6 0.6 0.7 0.7 0 0 0 0 0.6 0.6 0.6 0.7 0.5 
1.3 0.65 0.8 0.5 0.8 0.4 0 0 0 0 0.8 0.8 0.8 0.9 0.9 
1.2 0.60 0.5 0.5 0.5 0.5 0 0 0 0 0.7 0.4 0.5 0.7 0.6 
1.2 0.60 0.6 0.5 0.5 0.5 0 0 0 0 0.5 0.5 0.5 0.6 0.7 
1.1 0.55 0.9 0.7 0.6 0.6 0 0 0 0 0.8 0.0 0.0 0.7 0.0 
0.9 0.45 0.5 0.5 0.5 0.5 0 0 0 0 0.5 0.6 0.6 0.4 0.5 
1.1 0.55 0.7 0.5 0.6 0.6 0 0 0 0 0.5 0.7 0.5 0.5 0.6 
1.0 0.50 0.5 0.4 0.6 0.5 0 0 0 0 0.5 0.5 0.4 0.6 0.6 
1.0 0.50 0.6 0.6 0.6 0.5 0 0 0 0 0.5 0.8 0.6 0.5 0.8 
1.1 0.55 0.7 0.5 0.5 0.6 0 0 0 0 0.5 0.4 0.6 0.4 0.5 
1.4 0.70 0.6 0.5 0.7 0.6 0 0 0 0 0.7 0.6 0.6 0.7 0.5 
0.9 0.45 0.6 0.5 0.5 0.5 0 0 0 0 0.4 0.5 0.5 0.6 0.5 
0.9 0.45 0.4 0.5 0.6 0.5 0 0 0 0 0.5 0.4 0.5 0.4 0.6 
0.9 0.45 0.7 0.7 0.7 0.7 0 0 0 0 0.7 0.6 0.7 0.4 0.7 
1.0 0.50 0.5 0.6 0.6 0.5 0 0 0 0 0.5 0.4 0.5 0.5 0.5 
1.0 0.50 0.6 0.6 0.8 0.8 0 0 0 0 0.5 0.6 0.6 0.7 0.8 
1.4 0.70 0.8 0.9 0.7 0.6 0 0 0 0 0.8 0.8 0.7 0.8 0.9 
1.1 0.55 0.7 0.4 0.6 0.4 0 0 0 0 0.6 0.5 0.0 0.5 0.6 
0.9 0.45 0.4 0.5 0.4 0.4 0 0 0 0 0.4 0.4 0.5 0.5 0.6 
1.0 0.50 0.7 0.5 0.8 0.6 0 0 0 0 0.6 0.7 0.5 0.7 0.9 
1.5 0.75 1.1 0.7 0.8 0.7 0 0 0 0 0.7 0.0 0.0 0.7 1.1 
1.1 0.55 0.8 0.4 0.6 0.6 0 0 0 0 0.5 0.7 0.5 0.4 0.6 
2.6 1.30 0.8 0.5 1 0.5 0 0 0 0 0.6 0.8 0.6 1.5 1.0 
1.1 0.55 0.6 0.6 0.6 0.5 0 0 0 0 0.7 0.5 0.6 0.7 0.6 
0.9 0.45 0.5 0.7 0.6 0.4 0 0 0 0 0.4 0.6 0.7 0.6 0.4 
1.4 0.70 0.8 0.5 0.5 0.5 0 0 0 0 0.7 0.7 0.5 0.8 0.5 
1.3 0.65 0.8 1 0.8 0.7 0 0 0 0 0.8 1.1 0.9 0.8 0.7 
1.6 0.80 1 0.9 1.1 0.8 0 0 0 0 1.1 1.0 0.5 0.8 0.5 
1.2 0.60 0.5 0.5 0.8 0.4 0 0 0 0 0.4 0.0 0.0 0.5 0.0 
1.2 0.60 0.8 0.5 0.7 0.5 0 0 0 0 0.5 0.7 0.7 0.8 0.7 
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1.2 0.60 0.8 0.7 0.7 0.7 0 0 0 0 0.6 0.8 0.6 0.7 0.8 
1.1 0.55 0.7 0.6 0.7 0.6 0 0 0 0 0.5 0.0 0.6 0.4 0.7 
1.4 0.70 0.5 0.4 0.8 0.4 0 0 0 0 0.6 0.5 0.4 0.5 0.0 
1.4 0.70 0.5 0.5 0.7 0.6 0 0 0 0 0.7 0.5 0.5 0.8 0.8 
1.0 0.50 0.4 0.4 0.6 0.7 0 0 0 0 0.5 0.6 0.4 0.5 0.5 
1.2 0.60 0.6 0.6 0.6 0.5 0 0 0 0 0.6 0.6 0.6 0.6 0.6 
1.0 0.50 0.5 0.5 0.6 0.6 0 0 0 0 0.4 0.6 0.4 0.5 0.6 
1.4 0.70 0.7 0.7 1 0.7 0 0 0 0 0.7 0.0 0.5 0.4 0.0 
1.0 0.50 0.5 0.5 0.6 0.6 0 0 0 0 0.5 0.6 0.5 0.5 0.7 
1.5 0.75 0.8 0.7 0.8 0.5 0 0 0 0 0.6 0.5 0.8 0.7 0.7 
1.0 0.50 0.5 0.7 0.7 0.6 0 0 0 0 0.6 0.5 0.7 0.8 0.7 
1.1 0.55 0.4 0.6 0.7 0.6 0 0 0 0 0.3 0.6 0.6 0.3 0.4 
0.9 0.45 0.4 0.3 0.4 0.4 0 0 0 0 0.6 0.4 0.5 0.5 0.4 
1.0 0.50 0.6 0.6 0.5 0.5 0 0 0 0 0.4 0.7 0.6 0.5 0.5 
1.7 0.85 1.2 0.6 0.7 0.5 0 0 0 0 1.0 0.6 0.6 0.8 0.4 
1.1 0.55 0.8 0.6 0.7 0.7 0 0 0 0 0.6 0.8 0.0 0.4 0.7 
1.5 0.75 0.8 0.5 0.8 0.6 0 0 0 0 0.6 0.7 0.0 0.5 0.7 
1.0 0.50 0.5 0.5 0.6 0.6 0 0 0 0 0.6 0.6 0.5 0.6 0.6 
1.3 0.65 0.9 0.6 0.8 0.6 0 0 0 0 0.7 0.0 0.0 0.6 0.8 
2.0 1.00 0.9 1.2 0.8 0 0 0 0 0 0.8 0.0 0.0 0.6 0.0 
1.3 0.65 0.6 0.7 0.6 0.6 0 0 0 0 0.6 0.0 0.7 0.5 0.5 
1.7 0.85 1.4 0.8 0.5 0.8 0 0 0 0 0.7 1.1 0.8 0.9 1.1 
1.2 0.60 0.6 0.7 0.6 0.6 0 0 0 0 0.7 0.7 0.7 0.7 0.6 
1.2 0.60 0.7 0.6 0.9 0.7 0 0 0 0 0.8 0.7 0.6 0.7 0.6 
1.2 0.60 0.5 0.5 0.6 0.6 0 0 0 0 0.5 0.5 0.5 0.4 0.6 
1.4 0.70 0 0 0 0.5 0 0 0 0 0.8 0.0 0.0 0.8 1.3 
1.6 0.80 0.8 1.4 1.5 1.2 1 1 2 S 0.8 2.0 1.4 0.9 1.4 
1.7 0.85 0.9 0.8 1 0.6 1 1 1.3 S 0.9 1.3 0.8 1.0 1.9 
1.3 0.65 0.5 1 0.8 0.7 1 1 1.2 S 0.7 0.5 0.3 0.7 0.5 
1.2 0.60 0.8 0.5 0.6 0.6 1 1 1.1 S 0.6 0.0 0.0 0.4 0.0 
1.5 0.75 1 1 0.8 0.7 1 1 1.5 S 0.8 1.0 1.2 0.6 1.2 
 
 
 
 136
nwRICA Syst dysf dias dysf EF  FS Controls LVH LVEDD IVSd PWd sum  Sum^3 LVID^3     LVM 
0.4 0 0 65.0 35.1 1 0 3.82 0.92 0.84 5.58 173.74 55.74 118.00 122.72 109.12 
0.5 0 0 59.2 31.3 2 0 4.60 0.66 0.72 5.98 213.85 97.34 116.51 121.17 107.57 
0.5 0 0 69.0 39.6 3 0 4.00 1.00 1.00 6.00 216.00 64.00 152.00 158.08 144.48 
0.5 0 0 73.6 41.7 4 0 3.57 0.95 0.67 5.19 139.80 45.50 94.30 98.07 84.47 
0.5 0 0 65.4 35.7 5 0 4.48 0.92 0.77 6.17 234.89 89.92 144.97 150.77 137.17 
0.5 0 0 68.0 38.2 6 0 3.37 0.90 0.83 5.10 132.65 38.27 94.38 98.15 84.55 
0.0 0 0 60.9 32.0 7 0 3.78 0.99 0.70 5.47 163.67 54.01 109.66 114.04 100.44 
0.5 0 0 66.0 36.0 8 0 4.54 0.85 0.73 6.12 229.22 93.58 135.64 141.07 127.47 
0.6 0 0 63.5 34.2 9 0 4.31 1.08 0.91 6.30 250.05 80.06 169.98 176.78 163.18 
0.5 0 0 70.5 39.2 10 0 3.67 0.84 0.79 5.30 148.88 49.43 99.45 103.42 89.82 
0.6 0 0 64.2 34.7 11 0 4.26 0.96 0.91 6.13 230.35 77.31 153.04 159.16 145.56 
0.5 0 0 65.0 34.8 12 0 4.02 0.92 0.88 5.82 197.14 64.96 132.17 137.46 123.86 
0.6 0 0 65.5 36.0 13 0 4.86 0.79 1.05 6.70 300.76 114.79 185.97 193.41 179.81 
0.5 0 0 67.0 36.0 14 0 3.51 0.92 0.86 5.29 148.04 43.24 104.79 108.98 95.38 
0.4 0 0 72.0 40.5 15 0 3.98 0.98 0.85 5.81 196.12 63.04 133.08 138.40 124.80 
0.6 0 0 63.2 34.2 16 0 4.24 1.00 0.96 6.20 238.33 76.23 162.10 168.59 154.99 
0.4 0 0 58.8 30.8 17 0 4.15 1.28 1.09 6.52 277.17 71.47 205.69 213.92 200.32 
0.8 0 0 63.2 34.2 18 0 4.71 1.08 0.85 6.64 292.75 104.49 188.27 195.80 182.20 
0.8 0 0 79.7 48.0 19 1 4.26 1.22 1.10 6.58 284.89 77.31 207.58 215.88 202.28 
0.0 0 0 67.0 37.0 20 0 4.93 1.01 0.86 6.80 314.43 119.82 194.61 202.39 188.79 
0.4 0 0 65.4 35.7 21 0 4.47 1.12 0.74 6.33 253.64 89.31 164.32 170.89 157.29 
0.6 0 0 62.3 33.3 22 0 4.32 0.94 0.72 5.98 213.85 80.62 133.23 138.55 124.95 
0.0 0 1 73.9 42.5 23 1 4.14 1.36 1.19 6.69 299.42 70.96 228.46 237.60 224.00 
0.5 0 0 70.0 40.5 24 0 4.45 1.20 1.02 6.67 296.74 88.12 208.62 216.96 203.36 
0.5 0 0 73.5 43.0 25 0 5.67 1.25 0.85 7.77 469.10 182.28 286.81 298.29 284.69 
0.5 0 0 60.6 31.9 26 0 3.91 1.08 0.68 5.67 182.28 59.78 122.51 127.41 113.81 
0.4 0 0 51.8 26.4 27 0 4.60 1.40 0.77 6.77 310.29 97.34 212.95 221.47 207.87 
0.5 0 0 67.2 37.1 28 0 4.52 1.14 0.74 6.40 262.14 92.35 169.80 176.59 162.99 
0.8 0 0 75.0 44.0 29 1 4.99 1.15 1.15 7.29 387.42 124.25 263.17 273.70 260.10 
1.1 0 0 78.0 47.0 30 0 4.66 0.98 0.98 6.62 290.12 101.19 188.92 196.48 182.88 
0.0 0 0 67.6 37.7 31 0 4.82 0.96 1.13 6.91 329.94 111.98 217.96 226.68 213.08 
0.5 0 0 72.6 41.3 32 0 4.26 0.96 0.85 6.07 223.65 77.31 146.34 152.19 138.59 
0.7 0 0 75.0 43.2 33 0 4.02 0.91 0.88 5.81 196.12 64.96 131.16 136.40 122.80 
0.6 0 0 60.0 29.0 34 0 4.21 0.88 0.78 5.87 202.26 74.62 127.64 132.75 119.15 
0.4 0 1 63.4 33.3 35 1 4.62 1.18 1.22 7.02 345.95 98.61 247.34 257.23 243.63 
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0.6 0 0 70.7 40.2 36 0 4.60 1.02 0.88 6.50 274.63 97.34 177.29 184.38 170.78 
0.6 0 0 58.0 30.0 37 0 4.73 0.88 0.55 6.16 233.74 105.82 127.92 133.04 119.44 
0.5 0 0 60.2 32.2 38 0 4.99 0.85 0.85 6.69 299.42 124.25 175.17 182.17 168.57 
0.5 0 0 61.6 32.2 39 0 3.35 0.91 0.85 5.11 133.43 37.60 95.84 99.67 86.07 
0.0 0 0 61.2 32.6 40 0 4.42 1.14 0.94 6.50 274.63 86.35 188.27 195.81 182.21 
0.6 0 0 64.7 35.0 41 0 4.17 0.91 0.83 5.91 206.43 72.51 133.91 139.27 125.67 
0.5 0 0 79.7 48.0 42 0 4.15 1.18 1.10 6.43 265.85 71.47 194.37 202.15 188.55 
0.6 0 0 70.3 40.0 43 0 5.43 1.11 0.63 7.17 368.60 160.10 208.50 216.84 203.24 
0.6 0 0 65.4 42.0 44 1 3.86 0.96 1.36 6.18 236.03 57.51 178.52 185.66 172.06 
0.4 0 0 68.0 34.5 45 0 3.90 1.01 0.86 5.77 192.10 59.32 132.78 138.09 124.49 
0.5 0 0 70.7 40.0 46 0 4.60 1.12 0.88 6.60 287.50 97.34 190.16 197.77 184.17 
0.5 0 0 60.8 32.6 47 0 4.88 1.08 0.74 6.70 300.76 116.21 184.55 191.93 178.33 
0.4 0 0 68.7 38.2 48 0 4.31 1.04 1.03 6.38 259.69 80.06 179.63 186.82 173.22 
0.0 0 0 68.0 38.0 49 1 4.72 1.20 0.88 6.80 314.43 105.15 209.28 217.65 204.05 
0.0 0 0 65.0 36.0 50 0 4.54 1.00 1.01 6.55 281.01 93.58 187.43 194.93 181.33 
0.0 0 0 61.9 33.3 51 1 4.74 1.33 1.12 7.19 371.69 106.50 265.20 275.81 262.21 
0.0 0 0 57.9 30.3 52 0 4.31 1.11 0.69 6.11 228.10 80.06 148.04 153.96 140.36 
0.0 0 1 65.5 35.5 53 1 4.04 1.44 0.90 6.38 259.69 65.94 193.75 201.51 187.91 
0.0 0 1 83.8 52.2 54 1 4.90 1.40 1.20 7.50 421.88 117.65 304.23 316.40 302.80 
0.6 0   74.8 43.3 55 0 4.36 0.99 0.95 6.30 250.05 82.88 167.17 173.85 160.25 
0.7 0 1 79.0 46.0 56 0 2.75 1.43 1.04 5.22 142.24 20.80 121.44 126.30 112.70 
0.6 0 1 69.3 38.1 57 1 3.57 1.25 1.19 6.01 217.08 45.50 171.58 178.45 164.85 
0.0 0 1 69.7 39.3 58 1 4.88 1.30 1.42 7.60 438.98 116.21 322.76 335.67 322.07 
1.2 0 0 76.0 46.0 59 0 4.26 1.04 0.98 6.28 247.67 77.31 170.36 177.18 163.58 
1.0 0 0 80.7 48.7 60 0 3.88 1.05 0.98 5.91 206.43 58.41 148.01 153.93 140.33 
0.4 0 0 65.0 35.2 61 0 4.42 1.07 0.99 6.48 272.10 86.35 185.75 193.18 179.58 
0.0 0 0 60.0 30.0 62 0 4.10 1.04 0.92 6.06 222.55 68.92 153.62 159.77 146.17 
0.7 0   64.0 34.6 63 0 4.26 1.93 1.30 7.49 420.19 77.31 342.88 356.60 343.00 
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HT Ht Controls wt wt XHt   BSA LVMI  RWT VALVES Hs CRP LP(a)  
Homocysteine 
(µmol/L) ADPN 
1.68 168 1 67.0 11256.0 3.13 1.77 61.71 0.44 0 1.0 5.3 10.05 21.40 
1.59 159 2 52.8 8395.2 2.33 1.53 70.44 0.31 0 1.0 47.9 7.58 9.80 
1.70 170 3 75.6 12852.0 3.57 1.89 76.47 0.50 0 1.0 140.5 13.08 14.71 
1.63 163 4 57.0 9291.0 2.58 1.61 52.58 0.38 2 0.1 112.5 5.98 18.07 
1.56 156 5 70.2 10951.2 3.04 1.74 78.65 0.34 0 3.0 19.2 7.74 7.61 
1.63 163 6 58.0 9454.0 2.63 1.62 52.18 0.49 0 1.0 54.3 13.37 9.03 
1.65 165 7 69.6 11484.0 3.19 1.79 56.24 0.37 0 2.0 17.8 9.14 15.56 
1.50 150 8 52.0 7800.0 2.17 1.47 86.60 0.32 0 2.0 42.8 11.27 10.61 
1.64 164 9 64.5 10578.0 2.94 1.71 95.20 0.42 0 1.0 2.9 9.51 18.21 
1.64 164 10 53.5 8774.0 2.44 1.56 57.54 0.43 0 10.0 43.5 11.68 15.52 
1.68 168 11 64.4 10819.2 3.01 1.73 83.96 0.43 2 4.0 5.4 6.70 9.13 
1.72 172 12 58.0 9976.0 2.77 1.66 74.41 0.44 0 1.0 43.8 10.01 7.57 
1.57 157 13 64.5 10126.5 2.81 1.68 107.21 0.43 1 1.0 45.8 10.95 9.08 
1.56 156 14 45.2 7051.2 1.96 1.40 68.15 0.49 0 1.0 38.3 7.94 10.68 
1.75 175 15 66.0 11550.0 3.21 1.79 69.68 0.43 0 1.0 18.0 7.32 12.75 
1.64 164 16 78.0 12792.0 3.55 1.89 82.22 0.45 0 1.0 10.7 7.17 6.86 
1.67 167 17 60.0 10020.0 2.78 1.67 120.07 0.53 0 0.1 38.2 8.80 8.83 
1.68 168 18 80.0 13440.0 3.73 1.93 94.30 0.36 0 1.0 2.2 9.10 12.23 
1.72 172 19 94.0 16168.0 4.49 2.12 95.45 0.52 0 8.0 10.0 17.29 10.97 
1.73 173 20 82.5 14272.5 3.96 1.99 94.82 0.35 0 8.0 1.4 29.26 10.54 
1.75 175 21 71.5 12512.5 3.48 1.86 84.37 0.33 0 1.0 18.3 7.34 10.93 
1.71 171 22 72.0 12312.0 3.42 1.85 67.57 0.33 1,2 0.1 104.4 10.75 7.71 
1.77 177 23 82.0 14514.0 4.03 2.01 111.56 0.57 2 1.0 1.8 16.26 7.80 
1.65 165 24 65.7 10840.5 3.01 1.74 117.19 0.46 0 2.0 22.7 8.61 4.01 
1.84 184 25 97.2 17884.8 4.97 2.23 127.72 0.30 0 4.0 1.7 7.37 5.32 
1.49 149 26 68.3 10176.7 2.83 1.68 67.69 0.35 2 0.1 15.4 7.47 8.18 
1.66 166 27 47.0 7802.0 2.17 1.47 141.20 0.33 0 0.1 4.0 5.68 6.15 
1.59 159 28 81.2 12910.8 3.59 1.89 86.07 0.33 0 1.0 62.7 6.90 5.02 
1.58 158 29 87.1 13761.8 3.82 1.96 133.03 0.46 0 1.0 97.4 5.42 10.06 
1.65 165 30 92.0 15180.0 4.22 2.05 89.06 0.42 1,2 1.0 16.8 8.58 4.63 
1.65 165 31 61.6 10164.0 2.82 1.68 126.81 0.47 0 0.1 76.2 6.68 20.59 
1.72 172 32 61.2 10526.4 2.92 1.71 81.05 0.40 0 1.0 39.3 6.39 3.88 
1.62 162 33 67.0 10854.0 3.02 1.74 70.72 0.44 0 4.0 80.8 7.62 6.05 
1.54 154 34 59.2 9116.8 2.53 1.59 74.87 0.37 0 1.0 113.5 8.43 17.25 
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1.62 162 35 68.0 11016.0 3.06 1.75 139.27 0.53 1, 2 3.0 72.9 19.34 16.01 
1.60 160 36 78.5 12560.0 3.49 1.87 91.43 0.38 0 1.0 38.4 8.49 10.03 
1.57 157 37 47.4 7441.8 2.07 1.44 83.07 0.23 0 0.1 21.6 8.09 9.36 
1.58 158 38 86.0 13588.0 3.77 1.94 86.77 0.34 0 9.0 16.5 7.75 10.60 
1.65 165 39 48.5 8002.5 2.22 1.49 57.73 0.51 0 1.0 25.3 5.39 6.11 
1.72 172 40 68.2 11730.4 3.26 1.81 100.94 0.43 0 0.1 44.3 8.10 2.71 
1.70 170 41 60.2 10234.0 2.84 1.69 74.53 0.40 0 0.1 95.3 12.58 20.45 
1.79 179 42 85.5 15304.5 4.25 2.06 91.45 0.53 0 1.0 9.4 12.97 10.39 
1.70 170 43 70.0 11900.0 3.31 1.82 111.79 0.23 0 6.0 16.0 8.07 3.69 
1.64 164 44 60.6 9938.4 2.76 1.66 103.55 0.70 0 1.0 113.4 9.19 7.58 
1.73 173 45 72.5 12542.5 3.48 1.87 66.70 0.44 0 1.0 47.0 10.97 10.31 
1.80 180 46 84.0 15120.0 4.20 2.05 89.86 0.38 2 5.0 3.1 6.93 4.88 
1.61 161 47 67.5 10867.5 3.02 1.74 102.64 0.30 0 1.0 60.1 8.16 10.39 
1.83 183 48 85.0 15555.0 4.32 2.08 83.33 0.48 2 1.0 68.1 6.60 0.85 
1.64 164 49 72.0 11808.0 3.28 1.81 112.67 0.37 0 2.0 25.5 9.03 25.69 
1.64 164 50 77.9 12775.6 3.55 1.88 96.26 0.44 0 1.0 15.2 6.78 3.98 
1.60 160 51 53.5 8560.0 2.38 1.54 170.04 0.47 0 8.0 51.6 6.05 16.35 
1.77 177 52 55.6 9841.2 2.73 1.65 84.89 0.32 0 1.0 153.3 8.04 9.57 
1.62 162 53 62.7 10157.4 2.82 1.68 111.87 0.45 0 1.0 15.7 6.08 2.23 
1.68 168 54 103.0 17304.0 4.81 2.19 138.11 0.49 0 8.0 126.5 7.83 10.35 
1.65 165 55 84.1 13876.5 3.85 1.96 81.62 0.44 3 3.0 9.2 9.21 13.03 
1.50 150 56 72.8 10920.0 3.03 1.74 64.71 0.76 0 3.0 41.6 8.17 8.50 
1.49 149 57 62.4 9297.6 2.58 1.61 102.58 0.67 1,2 12.0 21.5 4.80 5.65 
1.78 178 58 93.3 16607.4 4.61 2.15 149.95 0.58 0 1.0 67.3 11.45 13.53 
1.52 152 59 50.0 7600.0 2.11 1.45 112.58 0.46 0 1.0 2.1 7.71 19.50 
1.60 160 60 67.3 10768.0 2.99 1.73 81.14 0.51 0 2.0 54.3 6.14 7.17 
1.60 160 61 67.2 10752.0 2.99 1.73 103.91 0.45 0 1.0 29.6 10.40 6.19 
1.75 175 62 70.0 12250.0 3.40 1.84 79.24 0.45 0 1.0 17.9 8.42 3.87 
1.83 183 63 113.0 20679.0 5.74 2.40 143.11 0.61 0 2.0 34.1 6.70 0.14 
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APPENDIX E 
 
Code for data entry 
 
Sex:     
Male     = 1     
Female     = 2 
Smoking:     
Current smoker    = 1    
Former      = 2 
Non smoker      = 3 
Exercise           
Yes      = 1            
No                = 0 
Exercise frequency    
>3times/week     = 3 
1-3 times/week    = 2 
<1 /week    = 1 
Never      = 0 
Antihypertensive         
yes     = 1 
No      = 0 
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Family history    
Yes      = 1     
No      = 0 
Aetiology    
Hypertension     = 1 
Glomerulonephritis    = 2 
APKD      = 3 
Lupus nephritis    = 4 
Unknown    = 5 
Reflux nephropathy    = 6 
Miscellaneous    = 7 
Echo report 
Concentric LVH    = 1 
Eccentric LVH   = 2 
LV dilation    = 3 
Systolic dysfunction           
Yes = 1                    
 No      = 0 
Diastolic dysfunction  
Yes      = 1 
 No     = 0 
Valvular abnormality 
Mitral regurgitation    = 1 
Tricuspid regurgitation   = 2 
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Aortic regurgitation     = 3 
Aortic stenosis    = 4 
 
Vascular access  
Arteriovenous fistula   = 1 
Temporary catheter   = 2 
Perm cath    = 3 
Graft     = 4 
Race 
Non-blacks (i.e. Whites and Indians) = 2 
Blacks     = 1 
Subjects 
Controls    = 2 
Patients    = 1         
Family history 
Fhx MI    family history of myocardial infarction 
Fhx HTN    family history of hypertension 
Fhx DM    family history of diabetes 
Fhx CKDd    family history of CKD 
LCCA     far wall left common carotid  
RCCA     far wall right common carotid  
SCCA     sum of the right and left common carotid 
LBIF     far wall left bifurcation 
RBIF     far wall right bifurcation 
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LICA     left internal carotid artery 
RICA     right internal carotid 
nwLCCA    near wall left common carotid  
nwRCCA    near wall right common carotid  
nwLICA    near wall left internal carotid  
nwRICA    near wall right internal carotid artery 
nwRBIF    near wall right bifurcation 
nwLBIF    near wall left bifurcation 
PLQ Score    plaque score 
syst dysf    systolic dysfunction 
diast dysf    diastolic dysfunction 
HT SQ     height squared 
HD dur    haemodialysis duration 
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